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Abstract
Inappropriate or prolonged inflammation contributes to the pathogenesis of 
many diseases including atherosclerosis, rheumatoid arthritis, sepsis, heart 
disease and cancer. It is widely accepted that the A2A adenosine receptor 
(A2aAR) is a critical non-redundant suppressor of inflammatory responses in 
vivo. Therefore understanding the mechanisms behind the suppression of 
inflammation would be beneficial in providing future drug targets for chronic 
inflammatory diseases. While the receptor is known to elevate intracellular 
cAMP levels, the molecular mechanisms underlying its inhibitory effects on 
defined pro-inflammatory signalling pathways remains obscure.
We have demonstrated that adenovirus-mediated human A2aAR gene 
transfer into approximately 75% of virally-infected human umbilical vein 
endothelial cells (HUVECs) results in an expression level of 0.3-0.4 pmol/mg 
membrane protein as determined by ^^®I-ZM241385 antagonist radioligand 
binding studies. A2AAR-expression results in a constitutive suppression of 
TN Fa-mediated induction of NFkB target genes such as cyclooxygenase-2  
(COX-2) and the adhesion molecule E-selectin. To assess the functional 
significance of this phenomenon, the effects of A2aAR gene transfer in 
HUVECs on the accumulation of three important gene products known to be 
controlled at least in part by NFkB, namely COX-2, E-selectin and vascular 
cell adhesion molecule -1 (VCAM-1) was determined. Characterisation of 
TNFa-mediated COX-2 induction revealed that while sustained induction 
(24hr) was solely dependent on the activation of p38 MAP kinase, earlier 
time-points at which induction was first detectable (8 hr) were also sensitive 
to inhibition of the NFkB pathway. At this time-point, A2aAR gene transfer 
alone was sufficient to reduce TNFa-mediated COX-2 induction compared 
with controls, whilst no effect of the A2aAR was detectable at 24hr. 
Surprisingly, addition of the A2AAR-selective agonist CGS21680 to A2aAR- 
expressing HUVECs actually reversed the effect observed with receptor 
expression alone. Time-course experiments in control cells using elevated 
concentrations of the adenylyl cyclase activator forskolin demonstrated that
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cAMP elevation was sufficient to promote the transient induction of COX-2 
even in the absence of TNFa. However, in the presence of TNFa, exposure 
to different concentrations of forskolin exerted a biphasic effect, suppressing 
COX-2 induction at low concentrations while enhancing it at higher 
concentrations. These data suggest that the effects of A2aAR expression 
with or without agonist on TNFa-mediated COX-2 induction can be 
accounted for completely by changes in cAMP. Comparative analysis with 
E-selectin revealed that induction of this gene was more straightforward, 
being sensitive to NFicB-inhibition alone with no contribution of any other 
signalling pathway being detectable. Moreover, while induction was 
suppressed by A2aAR gene transfer, the suppression was more pronounced 
in the presence of CGS21680 and correlated with an ability of cAMP- 
elevating stimuli to block TNFa-mediated E-selection in control cells. 
Interestingly TNFa-mediated VCAM-1 induction was unaffected by either 
A2aAR gene transfer or pre-treatment of control cells with cAMP-elevating 
agents. Taken as a whole, these data argue that the ability of the A2aAR to 
modulate the expression patterns of defined xB-sensitive target genes in 
HUVECs can be explained completely by the ability of the receptor to 
positively couple to adenylyl cyclase and elevate intracellular cAMP. They 
also suggest that the net effects of A2aAR gene transfer on specific kB- 
regulated genes will vary depending on the nature of their control by cAMP 
elevation.
Consistent with a suppression of NFkB signalling, A2aAR expression 
specifically reduced the DNA binding capacity of p50/p65 heterodimers in 
response to TNFa stimulation. Subcellular fractionation studies 
demonstrated that this was the result of a dramatically reduced ability of 
TNFa to promote the time-dependent accumulation of p65 in the nuclei of 
A2AAR-expressing cells compared with controls. Interestingly, the ability of 
TNFa to promote the IKK-dependent phosphorylation and subsequent 
degradation of k B a  and kBs was unaffected. Thus, A2aAR expression was 
either reducing nuclear importin-mediated nuclear import of p50/p65 
heterodimers and/or accelerating the CRM-1-driven export of p50/p65/kBa
XIX
complexes from the nucleus back into the cytoplasm. However, pre­
treatment with a concentration of LMB that was effective in blocking CRM-1 
mediated nuclear export of MEK-1 did not alter the Inhibitory effect of A2aAR 
gene transfer on TNFa-stimulated nuclear accumulation of p65. This 
suggests that the A2aAR was selectively blocking nuclear import rather than 
accelerating nuclear export. This inhibitory effect of A2aAR gene transfer did 
not appear to be due to a global inhibition of all nuclear import processes, as 
TNFa-stimulated p38 MAP kinase-mediated phosphorylation of the 
transcription factor ATF-2 was unaffected.
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Chapter 1 
Introduction
1.1 The Vascular Endothelium
The vascular endothelium lines the entire cardiovascular system and acts as a 
nonthrombogenic and selectively permeable barrier between the blood stream 
and extravascular space. Thus, the endothelium by its anatomical location is an 
enormous organ covering an area up to 7000m^ in adults (RIsau and Flamme, 
1995), and possesses a unique and influential position during normal and 
pathophysiological processes.
1.1.1 The Structure of the Vascular Endothelium
The vascular endothelium forms a one cell thick covering on blood vessel walls 
and has a typical epithelial-like, cobblestone flat morphology. Developmentally, 
these cells are derived from the bone marrow, and in humans, begin to form 
blood vessels at day 21 of embryonic development. The structure of the 
cardiovascular system means that at different positions along the vascular tree, 
endothelial cells (ECs) have to cope with a wide range of physio-chemical 
conditions. In the human body there are a number of different EG phenotypes 
from certain areas of the body which have arisen in response to their specific 
environments. Although all vessels are subjected to laminar shear stress 
(Brooks et al., 2004), large arteries also have to cope with turbulent shear 
stress at branch points and pulsatile stress forces, whereas capillaries have to 
deal with changes in oxygen tension, toxin levels and in certain areas such as 
the skin, temperature fluctuations (Karlsson, 1985). While most endothelia form 
a selectively permeable barrier to the free exchange of blood components with 
the extravascular space, the degree of permeability is dependent on the specific 
EG site. At the blood-brain barrier permeability is minimal due to a high density 
of intercellular tight junctions, whereas some vascular beds have low levels of 
tight junctions, in environments where sampling or filtration occurs, such as 
glomeruli in the kidney and the circumventricular organs of the brain (Goss et 
al., 1986), gaps have been found between adjacent cells.
As well as displaying structural differences, different vascular beds also exhibit 
distinct biochemical and immunological properties. For example, venous ECs 
express more autocoid receptors and are able to induce the expression of 
adhesion molecules at a greater rate (Fisslthaier et al., 1999; Simionescu et ai., 
1982) than arterial ECs which typically generate greater levels of autocoids, 
including prostacyclin and nitric oxide (NO) (Fisslthaier et al., 1999). Despite 
this, ECs also have several common functions in normal physiological states 
including regulating blood flow and local coagulation status, maintenance of a 
local anti-inflammatory state and regulating the cell growth and survival required 
for angiogenesis (Sands and Palmer, 2005).
1.1.2 Endothelial Cell Signalling
The endothelium not only provides a structural barrier between the circulation 
and surrounding tissue, but ECs also secrete mediators that influence vascular 
hemodynamics in the physiologic state. ECs contribute to the regulation of 
blood pressure and blood flow by releasing vasodilators such as nitric oxide 
(NO) and prostacyclin (PGIg), was well as vasoconstrictors including endothelin 
(ET) and platelet-activating factor (PAF). These chemically diverse compounds 
are not stored in intracellular granules. Rather, their major biologic effects are 
regulated by localisation of specific receptors on vascular cells, through their 
rapid metabolism, or at the level of gene transcription. NO is constitutively 
secreted by ECs but its production is modulated by a number of exogenous 
chemical and physical stimuli, whereas the other known mediators (PGE, ET 
and PAF) are synthesised primarily in response to changes in the external 
environment.
1.1.2.1 Nitric Oxide
Nitric oxide (NO) is a heterodiatomic free radical product generated through the 
oxidation of L-arginine to L-citrulline by NO synthetases (Venema et al., 1995). 
Of the three NO synthetases (NOSs), eNOS is constitutively active in ECs but is 
stimulated further by receptor-dependent agonists such as thrombin, adenosine
5’-diphosphate and muscarinic receptor agonists, and/or shear stress, that 
increase intracellular calcium and perturb plasma membrane phospholipid 
asymmetry (Awolesi et al., 1994, Topper et al 1996). EC-derived NO has 
several important effects on the vasculature, including the inhibition of platelet 
adhesion, activation, secretion and aggregation (Desjardins and Balligand, 
2006). In addition NO also inhibits leukocyte adhesion (discussed in detail in 
section 1.2) to the endothelium (Kubes et al., 1991, De Caterina et al., 1995) 
and inhibits smooth muscle migration (Marks et al., 1995) and proliferation 
(Garg and Hassid, 1989). These latter effects have been shown to limit 
neointimal proliferation which occurs after vascular injury, and combined with 
the stimulatory effect of NO on EC migration and proliferation (Fukuo et al 1995) 
suggests that NO helps to sustain vascular reparative mechanisms.
1.1.2.2 Endothelins
Endothelins (ETs), potent vasodilators, are a family of 21-amino acid peptides 
produced by many cell types including ECs (Levin et al., 1996). ET-1 is formed 
from the inactive precursor preproendothelin-1 of ET-1, which is transcribed 
after stimulation by hypoxia, shear stress and ischaemia. ET-1 is released from 
ECs and binds to the abundant GPCR ET-A receptor on vascular smooth 
muscle cells, resulting in an increased intracellular calcium concentration which 
in turn increases vascular smooth muscle cell tone (Simonson and Dunn, 1990). 
NO has been shown to shorten the duration of these effects by accelerating the 
restoration of intracellular calcium to basal levels (Goligorsky et al., 1994). In 
states of endothelial dysfunction, such as atherosclerosis, in which 
concentrations of bioactive NO are reduced, the relatively unopposed actions of 
ET-1 promote vasoconstriction and smooth muscle proliferation (Lopez et al., 
1990)
1.1.2.3 Prostacyclin (PGI2)
Prostacyclin (PGI2) is a vasoactive lipid compound synthesised by stimulated 
ECs and elicits smooth muscle relaxation by activating specific cell-surface Gs-
coupled GPCRs thereby elevating intracellular cyclic adenosine 
monophosphate (cAMP) levels (Mitchell and Warner, 2006). PGb is not present 
in resting human ECs nor stored within the cell. Its synthesis is regulated by 
cyclooxygenase (COX) isoforms and prostaglandin isomerases from 
arachidonic acid (Grosser, 2006, Cines et al., 1998). Once synthesised PGI2 
acts on the IP receptor present on vascular smooth muscle cells, ECs and 
platelets (Coleman et al., 1994, Grosser, 2006), leading to vasodilation, 
reduced platelet aggregation and adhesion and reduced cholesterol uptake 
(Mitchell and Warner, 2006).
1.1.2.4 Reactive Oxygen Species
Oxidative stress is a state in which excess reactive oxygen species (ROS) 
overwhelm endogenous antioxidant systems. ROS have distinct functional 
effects on each cell type in the vasculature and can play both physiological and 
pathophysiological roles (Tanniuama and Griendling, 2003). One of the most 
important ROS in the vasculature is superoxide (O2 ') which is formed by the 
univalent reduction of oxygen (Droge, 2002). Although O2 " can exert effects on 
vascular function, it is also pivotal in generating other reactive species including 
peroxygnitrite and hydrogen peroxide (H2O2) which in turn can react with 
reduced transition metals producing the highly reactive hydroxy radical ( OH) or 
become metabolised by myeloperoxidase to form hypochlorous acid. Virtually 
all types of vascular cells produce O2 " and H2O2 (Griendling et al., 2000).
Many functions of the endothelium are affected by ROS. These include 
impaired endothelial-dependent vasorelaxation due to an inactivation of NO by 
0 2 “ (Cai and Harrison 2000), endothelial apoptosis due to exposure to 0)2 " and 
H2O2 (Dimmeler and Zeiher, 2000), expression of adhesion molecules (Marui et 
al., 1993, Khan et al., 1996) and angiogenesis due to H2O2 induced proliferation 
and migration of ECs (Maulik and Das, 2002) and NAD(P)H oxidase regulation 
of VEGF expression (Ushio-Fukai et al., 2002).
1.1.2.5 Interaction between ECs and Blood Cells
In addition to the regulation of vascular tone, ECs also express cell surface- 
receptors that orchestrate the trafficking of circulating blood cells. These cell- 
associated molecules help direct the migration of leukocytes into specific 
organs under physiologic conditions and accelerate migration towards sites of 
inflammation (discussed in more detail in section 1.2).
1.1.3 The role of the Vascular Endothelium in Inflammation
Inflammation is characterised by the excessive infiltration of leukocytes from the
blood into tissues following cellular injury. This movement is regulated by the 
sequential release of vasoactive and chemotactic mediators. Local vasodilation 
increases regional blood flow to the inflamed area and, together with an 
increase in microvascular permeability, results in the loss of fluid and plasma 
proteins into tissues. Under normal conditions this response is relatively short­
lived and ultimately leads to the restoration of tissue structure and function. 
However prolonged inflammation can cease to be beneficial and contributes to 
the pathogenesis of many disease states such as atherosclerosis and 
rheumatoid arthritis (Karouzakis et al., 2006). Thus, the endothelium has been 
strongly implicated in the pathology of many inflammatory disease states 
including rheumatoid arthritis, atherosclerosis, systemic lupus erythromatosis, 
septic shock and transplant rejection (Anderson et al., 1995; D'Cruz, 1998; 
Gueler et al., 2004; Middleton et al., 2002; Zimmerman et al., 1999) due to the 
translocation of leukocytes into the extravasculature tissue. A brief description 
of the pathogenesis of atherosclerosis and rheumatoid arthritis are detailed 
below.
1.1.3.1 Atherosclerosis
Atherosclerosis is a slowly progressing inflammatory disease of the medium 
and large-sized arteries (Ross, 1999), resulting in the formation of fatty and 
fibrous lesions in the vessel wall. Initiation of atherosclerosis is characterised 
by the formation of modified low-density lipoprotein (mLDL), followed by the
subsequent activation of the endothelial layer, secretion of chemokines and the 
attraction of leukocytes. On migration through the endothelial layer, the 
recruited leukocytes differentiate into macrophages and scavenge the mLDL 
from the vessel wall, resulting in foam cell formation. This process is 
accompanied by inflammatory responses. Later stages involve the proliferation 
and migration of smooth muscle cells (SMCs) resulting in the formation of a 
fibrotic lesion with a fibrous cap of SMCs and an extracellular matrix that 
encloses a lipid-rich necrotic core. These lesions can become increasingly 
complex, with calcification, ulceration at the luminal surface and haemorrhage 
from small vessels that grow into the lesion from the media of the blood vessel 
wall (reviewed in Libby, 2002; Lusis, 2000). Although advanced lesions can 
grow sufficiently large enough to block blood flow, the most common clinical 
complication is an acute occlusion. This is due to the formation of a thrombus 
or blood clot associated with rupture or erosion of the lesion, resulting in 
myocardial infarction or stroke. The nuclear factor kB  (N F k B ) which regulates 
gene expression of many pro-inflammatory markers including selectins and 
adhesion molecules, has been implicated with a role in atherosclerosis 
pathophysiology (de Winther et al., 2005)
1.1.3.2 Rheumatoid Arthritis
Rheumatoid arthritis (RA) is a chronic inflammatory disease associated with the 
destruction of affected joints. The inflamed synovium within the joints consist of 
diverse cell populations including B cells, T cells, macrophages and synovial 
fibroblasts (SF). The presence of these cells lead to the abnormal immune 
phenomena in the joint, namely chronic inflammation and synovial hyperplasia. 
All four populations of cells contribute in their own way to the promotion and 
perpetuation of the disease (Karouzakis et al., 2006). The immune cells interact 
with the SF to maintain inflammation within the joint via the production of pro- 
inflammatory cytokines such as tumour necrosis factor a (TNFa) and 
interleukin-1 (IL-1). TNFa and IL-1 are secreted along with other cytokines by 
macrophages when they are in contact with T cells in the inflamed synovium.
Inhibition of TNFa via monoclonal antibodies such as Infliximab and 
Adaiimumab and soluble receptors have been successfully used in the 
treatment of RA (Main! et al., 1999). In addition B cells also contribute to the 
pathogenesis of the disease by producing rheumatoid factors and 
autoantibodies (Takemura et al., 2001, Edwards et al., 2004).
1.1.4 Strategies to Reduce Inflammation
Various strategies to reduce inflammation have been reported and some are 
currently used clinically to treat chronic inflammatory diseases. These include 
antibodies against pro-inflammatory cytokines and administration of 
glucocorticoids (Adcock et al., 2004; Weaver, 2004).
1.1.4.1 Biological Therapy
Biological therapy selectively targets mediators believed to be involved in the 
pathogenesis of pro-inflammatory diseases such as RA (Arend et al., 1998; 
Taylor, 2001). The actions of these mediators are normally maintained in 
balance by a variety of anti-inflammatory and immunoregulatory cytokines. In 
diseases such as RA, an imbalance occurs favouring the pro-inflammatory 
cytokines, specifically Interleukin-1 (IL-1) and TNFa (Arend, 2001). IL-1 and 
TNFa regulate the expression of cell adhesion molecules and are able to 
increase the expression of various pro-inflammatory mediators including NO 
and prostaglandin E2. There are several of these biological therapies that have 
been evaluated in patients with active RA, including anti-TNFa antibodies 
Infliximab and Adaiimumab, the soluble TNF receptor Etanercept and the IL-1 
receptor agonist Anakinra.
Clinical trials with Infliximab, a chimeric human-murine anti-TNF monoclonal 
antibody, and Adaiimumab, the human anti-TNFa antibody, in patients with 
active RA have been evaluated. In these trials combination treatment of either 
antibody along side methotrexate showed a significant decease in disease
progression when compared to methotrexate treatment alone (Maini et al., 
1999; Weinblatt et al., 2003). Both of these antibodies are used clinically in the 
treatment of RA.
Etanercept, a fusion protein containing the extracellular domain of the TNF 
receptor, has been evaluated as monotherapy and in combination with 
methotrexate in patients with active RA (Bathon et al., 2000; Moreland et al., 
1999) and been recommended for use in RA treatment in both cases (Weaver,
2004).
Anakinra is an exogenous recombinant human IL-1 receptor agonist which 
differs from the non-glycosylated form of natural IL-1 receptor agonist in a 
terminal methionine (Weaver, 2004). Monotherapy and combination therapy 
with methotrexate, clinical trials of anakinra proved to reduce the rate of bone 
erosion of patients compared to methotrexate treatment alone (Bresnihan et al., 
1998; Cohen et al., 2002; Jiang et al., 2000).
1.1.4.2 Glucocorticoids
Glucocorticoids, a class of steroid hormones, are widely used as anti­
inflammatory and immunosuppressives drugs to treat inflammatory conditions, 
such as RA and asthma, and as adjunction therapy for conditions such as 
autoimmune diseases. Glucocorticoids have been shown to bind to cytoplasmic 
glucocorticoid receptors (GRs; GRa has been shown to be the most important) 
that translocate to the nucleus, where they bind to glucocorticoid response 
elements (GREs) in the promoter region of glucocorticoid-sensitive genes. This 
leads to the recruitment and activation of transcription coactivator molecules 
and the activation of genes encoding anti-inflammatory proteins such as 
secretory leukoprotease inhibitor (SLP1), p2-adrenergic receptors and GDI63, a 
cell-surface haemoglobin-complex receptor on macrophages. In spite of this 
ability to induce anti-inflammatory gene transcription, the major anti­
inflammatory effects of glucocorticoids are through the repression of
inflammatory and immune genes. These inhibitory effects appear to be due 
largely to interactions between the activated monomeric GRa and transcription 
factors for inflammatory genes such as NFkB and AP-1 (Adcock et al., 2004; 
Karin, 1998). For example, glucocorticoids have been shown via the inhibition 
of NFkB, to reduce the activation of vascular endothelial cells, their expression 
of ligands for leukocyte adhesion molecules, and atherosclerosis. Monoclonal 
antibodies to vascular endothelial intercellular adhesion molecule-1 inhibited 
hypoxia-induced atherosclerosis in transgenic sickle mice (Okpala, 2006).
1.1.4.3 Other Potential Approaches
In addition to the NFkB pathway, cytokines and TLR agonists are also able to 
activate p38 MAP kinase pathway which control the transcription of AP-1- 
regulated genes. Resent studies have shown that inhibitors of these 
transcription factors are able to block inflammation by preventing the 
transcription of adhesion molecules and other pro-inflammatory genes, as 
outlined below:-
Inhibition of NFkB pathway by IKK inhibitors or the introduction of IKK complex- 
disrupting peptides (NEMO-binding domain peptides) have recently been 
reported. For example, a cell-permeable synthetic peptide corresponding to the 
IKKy a-helical region, which prevents IKKy from interacting with the IKKa/p 
complex, has been shown to block TNFa-induced NFkB activation (May et al., 
2000; Paria et al., 2003), and a recent study of human cytomegalovirus-infected 
human umbilical vein endothelial cells (HUVECs) has shown that treatment with 
a specific IKKp inhibitor, AS602868, also impaired HCMV-induced NFkB activity 
and subsequently prevented up-regulation of inflammatory marker proteins 
including cyclooxygenase-2 (Caposio et al., 2007).
in addition to the induction of cytokines and pro-inflammatory markers, p38 
MAP kinase activity has been shown to have a key role in the pathogenesis of 
Crohn’s disease (Hollenbach et al., 2004). There are many p38 MAP kinase
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inhibitors currently in development and at various stages within clinical trials 
including AMG-548, BIRB-796, SC10-469 and VX-702 (Dominguez et al., 2005; 
Fantini et al., 2006).
1.2 Leukocyte Translocation
Leukocyte translocation into the extravasculature tissue occurs through a 
multistep process in which leukocytes interact with the endothelium in post 
capillary venules and is indicated by the presence of selectins, integrins and 
other pro-inflammatory markers. The three main steps involve initial recognition 
and recruitment of activated leukocytes, firm adhesion between leukocytes and 
the endothelium and finally migration, or diapedesis of leukocytes from the 
blood through to the underlying inflamed area (Figure 1.1). Activation of 
leukocytes and the endothelium is mediated via soluble inflammatory cytokines 
(Sectioni .3 ), such as tumour necrosis factor a  (T N F a )  and interferon y (IF N y) 
which are secreted by the surrounding cells upon recognition of different 
pathogenic stimuli by specific cell-surface receptors. Once activated, initial 
recruitment and rolling of the leukocytes over the endothelium is determined by 
the expression of selectins. For example, studies using knockout mice have 
shown that effective leukocyte recruitment requires the expression of two 
specific selectins (P- and E-selectin; Jung and Ley, 1999; Robinson et al., 
1999). This emphasises the important role selectins play in leukocyte 
trafficking.
1.2.1 Selectins
The selectin family consists of three members E-, P- and L-selectin which all 
mediate rolling of leukocytes along the endothelium (Ley, 2001 ; Vestweber and 
Blanks, 1999). They range in size from 138-212 amino acids and have a 
conserved domain structure, consisting of an N-terminal lectin-like domain, a 
short transmembrane region and a short C-terminal tail (Ley 2003). The 
expression of each selectin is cell-type-specific. Thus, L-selectin is
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Figure 1.1 Leukocyte Translocation
Different adhesion molecules are required for the translocation of leukocytes 
from the blood into the underlying site of injury. The left panel shows the 
selectins and their corresponding high affinity cartx)hydrate ligands which are 
involved in the initial recruitment and rolling of the leukocytes along the 
endothelium (Section 1.2.1). The right panel shows the predominance of cell 
adhesion molecules (CAMs) and integrin interactions involved in the arrest and 
subsequent translocation of leukocytes (Section 1.2.2-1.2.3).
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constitutively expressed on leukocytes, while P-seiectin is stored on a-granules 
of platelets and in Weibel-Palade bodies of endothelial cells and is rapidly 
transferred to the cell surface upon cellular activation. In contrast, E-selectin is 
exclusively expressed on endothelial cells only following exposure to pro- 
inflammatory stimuli (Ulbrich et al., 2003). All selectins bind the tetrasaccharide 
sialyl LewiS(x) ligand which is expressed on inflammatory target cells. An 
important molecule in leukocyte presentation is P-seiectin glycoprotein ligand 
(PSGL). Interaction between PSGL and P-selectin is responsible for a major 
part in leukocyte rolling (Yang et al., 1999). Although it has been suggested 
that E-selectin interacts with PSGL, the identity of the true ligands for E-selectin 
is still unclear (Xia et al., 2002).
The interaction of selectins on leukocytes and the endothelium, in the presence 
of pro-inflammatory mediators, leads to the expression of other types of 
adhesion molecule that mediate the firm adhesion of the leukocyte to the 
endothelium. These are members of the cell adhesion molecule (CAM) family 
and integrin adhesion molecules.
1.2.2 Cell Adhesion Molecules (CAMs)
CAMs are transmembrane glycoproteins that are characterised by the presence 
of several extracellular Ig-like binding domains. Although there are many Ig- 
domain containing proteins, the ones important to leukocyte-endothelium 
interactions are interacellular adhesion molecule-1 and -2  (ICAM-1 and -2), 
vascular cell adhesion molecule-1 (VCAM-1) and platelet-endothelial cell 
adhesion molecule (PECAM). ICAM-1 contains five immunoglobulin (Ig)-like 
domains and is expressed in response to pro-inflammatory signals. Once 
expressed at the surface, ICAM-1 is able to bind to its integrin binding partner 
atp2 which is expressed on infiltrating leukocytes. In contrast, ICAM-2 is 
constitutively expressed by endothelial cells and contains only two ig-like 
domains. These domains share 35% sequence homology with the last two 
ligand binding domains of ICAM-1 (Lehmann et al., 2003) resulting in a degree
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of redundancy between the two ligands. There are other members of the ICAM 
family (ICAM-3-5) of which ICAM-3 is known to be expressed at low levels on 
endothelial cells. However they are not thought to be involved in leukocyte 
interactions (Patey et al., 1996).
VCAM-1 Is predominately expressed on endothelial cells and has two isoforms; 
a full-length protein containing seven Ig-like domains in the N-terminus and a 
smaller protein that does not possess domain 4 which results in reduced affinity 
for integrin. In a similar mechanism to ICAM-1, full-length VCAM-1 is expressed 
in response to pro-inflammatory stimuli and binds a4pi and a4p7 integrins 
expressed on infiltrating leukocytes. VCAM-1 ligand binding is essential for 
lymphocyte migration into inflamed tissue as it stimulates NADPH oxidase- 
dependent production of reactive oxygen species by endothelial cells (Matheny 
et al., 2 0 0 0 ).
PECAM primary transcripts are also subject to alternative splice events which 
results in several isoforms that differ in domain number (Wang et al., 2003). All 
of these are constitutively expressed on endothelial cells, platelets, monocytes, 
neutrophils and specific subsets of T-lymphocytes (Ulbrich et al., 2003). It Is 
thought that the number of isoforms available enables PECAM to interact with 
several substrates including proteoglycans (DeLisser et a!., 1993) and integrins 
(avPsi Buckley et al., 1996).
1.2.3 Integrins
Integrins are non-covalently associated heterodimers containing one a- and p- 
subunits comprising large ligand binding domains and short cytoplasmic 
domains. The binding of integrins to associated ligands expressed on 
infiltrating leukocytes causes changes in the cell cytoskeleton via the 
cytoplasmic domain. 19 a- and 8  p-subunits have been identified in vertebrates 
which are reported to form at least 25 ap heterodimers (Takagi and Springer, 
2 0 0 2 ). Integrins involved in leukocyte-endothelium interactions bind to CAMs.
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These include atp2 integrin which binds to both ICAM-1 and -2  to promote firm 
arrest of the leukocyte on the endothelium, and avPs which binds to PECAM. 
a4Pi and oc4p7 mediate either rolling or firm arrest of lymphocytes and 
monocytes via interaction with VCAM-1. This has led to the a4 integrins being 
identified as governing mononuclear trafficking (Berlin et al., 1995).
1.2.4 Cyclooxygenase-2 (COX-2)
Prostaglandins (PGs) are synthesised in various tissues and cells and are 
considered of importance in the modulation of vascular homeostasis, 
inflammation, pain and angiogenisis (Dormond et al., 2001; Turini and DuBois, 
2002). The major rate-limiting enzyme involved in their synthesis are the 
cyclooxygenases (COXs). The COX proteins are bifunctional enzymes 
containing a cyclooxygenase catalytic centre which adds 2  oxygen atoms to 
arachidonic acid in a bisoxygenation reaction to form the peroxide PGG2, and a 
peroxidase active site which reduces PGG2 to prostaglandin H2 (PGH2) (Smith 
et al., 1996a). PGH2 is a common precursor for the synthesis of biologically 
active prostanoids including prostaglandin E2 (PGE2), prostacyclin (PGI2) and 
thromboxane (TXA2). Of the two COX isoforms, COX-1 is constitutively 
expressed whereas COX-2 is highly induced by pro-inflammatory stimuli such 
as cytokines as well as growth factors such as transforming growth factor 
(TGF)-betal. COX-2 has been shown to be a major source of prostacyclin 
which is produced in response to endogenous and exogenous signals to 
regulate vascular homeostasis in cardiac tissues and vascular endothelial cells 
(Adderley and Fitzgerald, 1999; Hao et al., 2002; Wu, 1998). This regulation is 
due to an alteration of the prostanoid ratio from a pro-thrombotic (high 
TXA2/PGI2) to an anti-thrombotic (high PGI2/TXA2) state (Caughey et ai., 2 0 0 1 ). 
It is important to note that this change in ratio is due to the increased 
concentration of PGI2 concentration due to the induction of COX-2 not a 
decrease in COX-1 dependent TXA2 concentration. Although selective COX-2 
inhibitors have been shown to suppress unwanted inflammation in patients with 
rheumatoid arthritis and osteoarthritis (Crofford et al., 2000) with decreased
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upper gastrointestinal side effects compared with nonsteroidal anti-inflammatory 
drugs (NSAIDs) that non-selectively block the binding to COX receptors 
(Crofford et al., 2000; Simon et al., 1999), up-regulation of COX-2 in the 
vascular endothelium may represent an important protective mechanism 
against vascular injury and insult. This corresponds with the reasons that the 
Merck COX-2 inhibitor Vioxx was taken off the market due to increase incidence 
of myocardial infarction and other cardiovascular related diseases (Mitchell and 
Warner, 2006).
1.3 Cytokines
The endothelium is capable of expressing a broad spectrum of pro-inflammatory 
(TNFa, IL-1, IL-6 ) and anti-inflammatory cytokines (IL-4, IL-10), including 
members of the TNF family, the interferons and the interleukins (Kofler et al.,
2005). Cytokines are small soluble proteins which are secreted by one cell but 
are able to alter the behaviour or properties of itself or other cells. They are 
usually glycoproteins secreted by cells using classical secretory pathways and 
can be grouped into families depending on structure. In the majority of cases, 
expression patterns of different forms of cytokines or members of a cytokine 
family are only partially overlapping. This suggests a specific role for each 
family. This section will look at selected cytokines in greater detail.
1.3.1 Tumour Necrosis Factor a (TNFa)
TNFa is synthesised by macrophages and other cells in response to invasive 
stimuli such as bacterial toxins and inflammatory products. It is a homotrimer 
that is generated by the proteolytic cleavage of transmembrane TNFa by a 
metalloprotease TNFa-converting enzyme (Moss et al., 1997). Although first 
recognised as a soluble factor responsible for the necrosis of tumours in mice, it 
is now known to be part of a wider TNF superfamily, members of which are 
expressed throughout the vasculature. Each TNF family member binds to its 
associated receptor expressed on its target cells which mediates its effects. 
There are two receptors that are selective for TNFa, TNFR1 (75kDa) and
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TNFR2 (55kDa) which are present on practically all cells except erythrocytes. 
These receptors share structural homology in the extracellular TNF-binding 
domains and exhibit similar binding affinity for TNFa, however they induce 
separate cytoplasmic signalling pathways following receptor ligand binding 
(Smith et al., 1990; Thoma et al., 1990).
TNFR1 comprises of an N-terminal TNFa-binding domain, a short 
transmembrane region and a C-terminal intracellular death domain (DD). Upon 
TNFa binding, the receptor clusters with two other receptors to form a trimer 
which causes the release of the protein, silencer of death domains (SODD) 
(Chen and Goeddel, 2002). This exposes the DD of the receptor, allowing it to 
act as a scaffold for other DD-containing proteins including the adaptor protein, 
TN Fa-receptor-associated death domain (TRADD). Once bound TRADD can 
then recruit additional adaptor proteins, receptor-interacting protein (RIP), TNF- 
R-associated factor 2 (TRAF2) and Fas-associated death domain (FADD; 
Figure 1.2). These proteins are then able to recruit key enzymes to TNF-R1 
that are responsible for initiating further downstream signalling events including 
IkB  kinase (IKK; section 1.5) which results in the activation of the nuclear 
transcription factor kB  (N F k B ; section 1.5) (Dempsey et al., 2003).
1.3.2 Interferon y (IFNy)
The potent anti-viral properties of interferons were first identified due to their 
ability to interfere with viral replication (Isaacs and Lindenmann, 1987) since 
then it has been shown that they have several other roles including a role in 
microbial defence (Shtrichman and Samuel, 2001). The interferon family can 
be divided into two classes (I and II) with IFNy being the sole member of the 
type II class. It is synthesised and released from cells of the immune system 
such as natural killer (NK) cells and T lymphocytes in response to other pro- 
inflammatory stimuli such as interleukin-12 (lL-12; Lammas et al., 2000) and 
TNFa. 17kDa in size, IFNy functions as a dimer, binding to the IFNy receptor 
(IFNyR) which is expressed on nearly all cell surfaces (Ramana et al., 2002).
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Figure 1.2 Schematic of TNFa signaiiing
TNFa binding induœs receptor trimérisation leasing to the release of SODD 
allowing the interaction of the receptor death domains. Receptor trimérisation 
generates a scaffold for the recruitment of adaptor proteins such as TRADD, 
TRAF2, RIP, and FADD. Recruitment of TRAF2 and RIP is necessary to 
activate the IKK complex leading to the phosphorylation-dependent 
polyubiquitination and subsequent degradation of IkB. This allows activated 
NFkB to translocate to the nucleus and activate transcription (section 1.4). 
(taken from Chen and Goeddel, 2002)
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The IFNyR consists of two heterologous subunits (a- and j3-). Upon receptor 
activation, Janus activated kinase 1 (JAK1) is recruited to the a- subunit whilst 
JAK2 is recruited to the (3- subunit of the receptor (Shtrichman and Samuel, 
2001). The binding of JAK 1 and 2 activates the JAK dimer which leads to the 
Tyr phosphorylation of signal transducers and activators of transcription (STAT) 
proteins. Once phosphorylated STAT1 undergoes homologous dimérisation 
and translocates to the nucleus where it binds to target genes containing the 
gamma activation sequence (GAS; consensus = TTCN3GAA) initiating 
transcription of genes including iNOS and suppressor of cytokine signailing-1 
(SOCS-1) (Samuel, 2001).
1.3.3 Lipopolysaccharide (LPS)
Although not a member of the cytokine family, LPS is a potent pro-inflammatory 
stimuli. A major component of the outer wall in Gram-negative bacteria, it can 
activate endothelial cells, monocytes and macrophages to stimulate the 
production of many pro-inflammatory cytokines, including TNFa, and IL-1 ,-6 ,-8  
and -12 (Cohen, 2002). In the blood LPS is bound to LPS-binding protein 
(LBP) that transfers it to GDI4, which can be either bound or soluble as 
endothelial and epithelial cells do not have membrane-bound GDI4 but are still 
LPS-responsive (Pugin et al., 1994). The LPS-GD14 complex is then able to 
bind to the Toll-like receptor-4 (TLR-4)-myeloid differentiation protein-2 (MD-2) 
receptor complex thus initiating LPS responsive signaiiing pathways. TLR-4 is 
a member of the wider Toll-like receptor family, which were first characterised in 
Drosphila, and are important in mediating dorsal-ventral polarity in embryonic 
development (Morisato and Anderson, 1994) and in generating the anti-fungal 
response in Drosphila (Lemaitre et al., 1996). There are ten human TLRs which 
all share a common Toll-like/lnterleukin-1 Receptor (TIR) motif which generates 
the downstream signalling from the TLRs. This motif is also common to the IL- 
1 R family of receptors and as a result the downstream signalling events of the 
TLR and IL-1R share a common pathway (Imler and Hoffmann, 2001; Janeway 
and Medzhitov, 2002; Takeda et al., 2003)
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The binding of LPS to TLR-4 initiates the recruitment of a muiti-protein complex 
that is assembled at the cytoplasmic tail of the receptor mediated by the TIR 
domain of the TLR (Figure 1.3; Takeda et al., 2003). Several different proteins 
have been identified as adaptor molecules for TLR-4. Myeloid differentiation 
gene 8 8  (MyD8 8 ) is a TIR containing TLR adaptor protein, which is recruited to 
and binds to the TIR domains of TLR-4 (Medzhitov et al., 1998; Wesche et al.,
1997). It has also been reported that a MyD8 8 -adaptor like protein Mal/TIRAP 
can also bind to the TIR domain of TLR-4 (Fitzgerald et al., 2001; Horng et al.,
2001). Following the recruitment of MyD8 8  to TLR-4, IL-1 receptor associated 
kinase (IRAK) is recruited to the receptor via an interaction between the DD 
present on both proteins, where it becomes phosphorylated by IRAK-4 (Suzuki 
et al., 2002). There are four reported members of the IRAK family, IRAK-1, 
IRAK-2, IRAK-4, IRAK-M all of which contain a conserved DD and kinase 
domain (Li et al., 2002). It has been reported that each kinase interacts with 
TLR-4 through a variety of upstream adapter molecules which may explain the 
non-specific nature of these interactions (Janssens and Beyaert, 2003). IRAK-4 
has been reported to have the most significant interaction as indicated by the 
lack of inflammatory response to LPS or IL-1 in IRAK-4 knockout mice (Suzuki 
et al., 2002). Activated IRAK is then able to interact with TRAF6  leading to the 
downstream activation of NFkB and JNK. Therefore activation of TLR-4 
signalling by LPS leads to the transcription of many pro-inflammatory genes 
including adhesion molecules and COX-2.
1A Nuclear Factor kB (NFkB)
NFkB was first identified in 1986 by Sen and Baltimore, as a constitutively 
active nuclear factor binding to a site in the kappa light-chain Ig enhancer in 
murine B lymphocytes (Sen and Baltimore, 1986). Since then it has been 
identified as a transcription factor existing in an inactive state in the cytoplasm 
of most cells (Liou and Baltimore, 1993).
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Figure 1.3 Schematic of LPS signalling via TLR4
Activation of the TLR-4 receptor complex leads to the recruitment of MyD8 8  via 
the TIR domain. The resulting phosphorylation of IRAK by IRAK-4 enables the 
recruitment of TRAF6  to the complex. Upon its activation, TRAF6  can interact 
with the TAK1/TAB1/TAB2 complex that also contains Uev1A and Ubc13. This 
leads to the polyubiquitination of TRAF6  and TAK1 activating downstream 
signalling to IKK and JNK. (Taken from Takeda and Akira, 2004)
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it is now known that N F k B  plays a central role in controlling gene expression of 
proteins involved in cell survival and pro-inflammatory responses. Activated by 
a range of stimuli including pro-inflammatory cytokines, growth factors, DNA- 
damaging agents and viral proteins (Ghosh et al., 1998), N F k B  regulates a wide 
variety of target genes that include cytokines such as TNFa and IL-6 , 
chemokines (e.g. IL-8 , MCP-1), adhesion molecules (e.g. ICAM, VCAM-1 and 
E.selectin) and inducible effector enzymes such as COX-2 (Tanabe and Tohnai,
2002).
1.4.1 Overview of NFkB Signalling Pathway.
N F k B  is localised in the cytoplasm of unstimulated cells, in an inactive state 
bound to a member of the IkB  family of inhibitory proteins (Ghosh et al., 1998). 
The degradation of this inhibitor upon signal-induced activation has been 
regarded as the conventional model by which N F kB  is activated (Baeuerle and 
Baltimore, 1996). This exposes the nuclear localisation sequence (NLS) of 
N F k B  thereby allowing translocation to the nucleus to activate transcription. 
Many aspects of the signalling pathway that leads to the degradation of IkB  
family members have been described. Briefly, stimuli-specific signalling 
pathways converge on the IkB  kinase (IKK) which is a muiti protein complex 
comprising IKKa/1, lKKp/2 and IKKy/NFKB-essential modulator (NEMO). This 
specifically phosphorylates IkB  at particular residues that prime IkB  for Lys 48- 
polyubiquitination. Polyubiquitination targets IkB  for proteolytic degradation by 
the 26S proteosome unmasking the NLS on N F kB  enabling subsequent nuclear 
translocation and gene transcription (Figure 1.4). In reality the N F k B  signalling 
pathway is far more complex involving multiple protein-protein interactions thus 
the following sections will examine this pathway in greater detail.
1.4.2 IkB Kinase (IKK)
The seminal event in the activation of N F kB  is the phosphorylation of IkB s  
which is mediated by IkB  Kinase (IKK). IKK is a 700-900kDa complex
22
Figure 1.4 Schematic of the ciassicai NFkB signaiiing pathway
The detection of pro-inflammatory mediators at their specific cell surface 
receptors mediates the activation of IKK kinases leading to the phosphorylation 
of the IKK complex. This in turn results in the phosphorylation and 
polyubiquitination of IkB leading to the subsequent degradation. Thus allowing 
the activated NFS to translocate to the nucleus and initiate transcription of its 
target genes.
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comprising several proteins of which the main three subunits are, IKKa (1KK1), 
IKKp (IKK2) and the regulatory subunit NFkB essential modulator (NEMO) also 
known as IKKy (Karin and Delhase, 2000). IKKa and IKKp are catalytic 
subunits sharing 52% overall sequence homology and 65% identity within their 
catalytic domains. In contrast, IKKy has no known kinase activity but contains 
the helix-loop-helix and leucine zipper motifs that are known to be involved in 
protein-protein interactions (see later; Karin and Delhase, 2000).
Gene targeting experiments have clearly demonstrated that the IKKp and y 
subunits of IKK are required for N F k B  activation by all known pro-inflammatory 
stimuli, including LPS, TNF, double-stranded RNA, negative strand RNA 
viruses, IL-1 and antigens (Chu et al., 2000; Li et al., 1999; Makris et al., 2000; 
Tanaka et al., 1999). Ali of these stimuli lead to IKK activation which kinetics 
and magnitude are directly related to those of N F kB  activation, although how 
they all converge to activate a single signalling enzyme still needs to be 
elucidated.
For example in the TNFa signalling pathway, binding of TNFa to TNFR1 
recruits TRADD and TRAF2 causing the subsequent recruitment of the IKK 
complex to the receptor, where RIP1 can activate IKK1 via MEKK (Section 
1.3.1; Devin et al., 2000; Hsu et al., 1996; Kelliher et al., 1998). The activity of 
RIP1 is not due to its protein kinase activity but due to Lys 63 polyubiquitination 
on Lys 377 allowing RIP to bind to IKKy via its Leu zipper region (Chen, 2005; 
Ea et al., 2006). In addition, RIP1 is required for IKK activation by multiple 
pathways including the Toll-like receptors (TLR) and DNA damage pathways 
(Devin et al., 2003; Meylan et al., 2004) suggesting a common convergence 
point for NFkB activation.
The integration of the many upstream signals leads to the phosphorylation of 
conserved serine residues present in the activation loops of IKKa (S I76, S I80)
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and IKKp (S177, S181; Mercurio et al., 1997). Studies have shown that 
although cytokines such as TNFa result in phosphorylation of IKKa and IKKp, 
IKKp is predominantly required for NFkB activation by most pro-inflammatory 
stimuli (LI et al., 1999; Tanaka et al., 1999). However it is Important to note a 
degree of specificity, since IKKa is required for IKK activation in response to 
RANK (receptor activator of NFkB) and the B-lymphocyte stimulator Blys/BAFF 
(B-lymphocyte stimulator/B-cell activating factor) (Cao et al., 2001; Claudio et 
al., 2002). Therefore, although certain signals can activate the kinase complex 
via IKKa, the majority of NFkB inducers target the IKKp subunit. This complex 
regulation of IKK activity by upstream interactions ultimately results in the 
phosphorylation of the IkB family proteins.
1.4.3 IkB Proteins
The IkB  family comprises of eight members: kBa, 8, p, y, s, (, R and bcl-3 
(Ghosh et al., 1998; Ray et al., 1995; Yamazaki et al., 2001). IkB ô and IkBÇ are 
the C-terminal products of p i00 and p i 05 proteolytic processing, forming p50 
and p52 respectively. The IkB s are characterised by the presence of multiple 
ankyrin repeats, protein-protein interaction domains responsible for interactions 
N F k B  via their Rel homology domain (RHD) (Lux et al., 1990). Each IkB  protein 
binds specifically to particular N F k B  subunits. For example kBa and p 
preferentially bind complexes containing p65 and c-Rel, while kBy binds to p50 
and p52 homodimers (Thompson et al., 1995; Whiteside et al., 1997) and p i00 
and p i 05 precursors complex with p50, p65 and c-Rel in the cytoplasm. kB 
members, bcl-3 and \ k B Ç  are unique however as both are primarily expressed 
within the nucleus. Bcl-3 degradation causes p52-dependent repression of 
transcription (Bours et al., 1993; Viatour et al., 2003), while kB(!; retains N F k B  
proteins in the nucleus instead of the cytoplasm (Yamazaki et al., 2001).
Of the eight kB proteins, only kBa, kBp and kBs are currently known to be 
involved in the signal-induced activation of NFkB (Figure 1.5). kBa has been
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Figure 1.5 NFkB and IkB Family Proteins
The mammalian NFkB family consists of five different memt)ers which all share 
a highly conserved Rel-homology domain (RHD). p65, c-Rel, and RelB also 
contain a transactivation domain necessary for the activation of transcription. 
p50 and p52 are cleaved from larger precursors p105 and p100 respectively 
(cleavage points indicated by T; section 1.4.4). The C-terminal products of this 
cleavage are IkBô and IkBi!; respectively which are two members of the wider 
IkB family. There are eight members in the IkB family which all contain ankyrin 
repeat regions required for interactions with NFkB (Section 1.4.3). Sites of 
phosphorylation (S) and acétylation (K) are indicated (taken from Chen and 
Greene, 2004)
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the most extensively studied due to its ability to be rapidly degraded in 
response to most NFKB-activating stimuli. It is a 37kDa protein consisting of 
three domains, a 70 amino acid N-terminus containing a signal response 
domain, a central protease-resistant 250 amino acid domain consisting of six 
ARD repeats and a final 42 amino acid C-terminus comprising of PEST-rich 
(proline, glutamic acid, serine, theronine-rich) sequences that confer rapid basal 
kB a  turnover (Brown et al,, 1997; Kroll et al., 1997; Lin et al., 1996). it has 
been suggested that the ankyrin repeats on kB a  not only prevent nuclear 
translocation of NFkB by masking its nuclear localisation sequence (NLS) but 
also inhibit the ability of NFkB to bind DNA (Beg et al., 1992; DiDonato et ai., 
1997; Henkel et al., 1992). In addition, kB a  also contains a leucine rich 
nuclear export sequence (NES) within the last ankyrin repeat which is 
recognised by the nuclear export protein CRM1, and is believed to actively 
export kBa/NFKB complexes out to the cytoplasm thereby restoring the pre­
induction state of the complexes (Arenzana-Seisdedos et al., 1997). To aid this 
restoration of the pre-induction state, transcription of kB a  is NFicB-dependent. 
Consequently, newly synthesised kB a  is able to enter the nucleus and 
sequester NFkB from KB-dependent promoters. This inhibits further NFkB 
transcription by facilitating export back into the cytoplasm via the NES on kB a 
(Arenzana-Seisdedos et al., 1995). The mechanisms of nuclear trafficking will 
be discussed in more detail in section 1.5.
The degradation of kB  proteins occurs via a process known as 
polyubiquitination. Ubiquitin is a highly conserved 76 amino acid protein that is 
added to target proteins in three enzymatic stages (Pickart, 2004). Initially the 
C-terminal Gly residue of ubiquitin is activated by a ubiquitin-activating enzyme 
(E l) in an ATP-dependent reaction. In the second step, the activated ubiquitin 
is transferred to an ubiquitin-conjugating enzyme (E2 or Ubc) on a specific Cys 
residue, forming an E2-Ub thioester. Finally, ubiquitin is attached to specific 
Lys residues on the target protein via an isopeptide bond mediated by a
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ubiquitin-ligase, E3. Ubiquitin contains seven Lys residues that can be attached 
to other ubiquitins by the above pathway to form a poiy-ubiquitin chain. Poly­
ubiquitination, typically linked via Lys 48, targets the protein for protesomal 
degradation by the 26S proteasome (Nandi et al., 2006). Site-directed 
mutagenesis of lysine residues on kBa identified K21 and K22 as the amino 
acids responsible for the covalent attachment of ubiquitin (Baldi et al., 1996; 
Rodriguez et al., 1996; Scherer et al., 1995). The formation of Lys 48- 
polyubiquitinated forms of kBa has been shown to rely on the prior 
phosphorylation of serine 32 and serine 36 as mutagenesis of these sites 
prevented phosphorylation or ubiquitination whilst the K21R/K22R mutant was 
able to undergo signal-induced phosphorylation but not ubiquitination. 
Consequently neither mutant could be degraded preventing NFkB activation 
(Rodriguez et al., 1996).
1.4.4 NFkB
N F k B  transcription factors are a family of structurally related and evolutionarily 
conserved proteins that form either homo- or hetero-dimers (Ghosh et al.,
1998). All five mammalian N F k B  subunits, Rel (c-Rel), p65 (RelA), RelB, 
N F kB -1  (p50 and its precursor p i 05) and N F k B -2  (p52 and its precursor p i00) 
contain a highly conserved 300 amino acid long N-terminal Rel homology 
domain (RHD) responsible for DNA-binding, dimérisation and association with 
the IkB  inhibitory proteins (Figure 1.5; reviewed in Ghosh et al., 1998). N F kB  
subunits can form various dimers, p65, Rel (c-Rel), and RelB contain at least 
one transcriptional activation domain in their C-terminus (Blair et al., 1994; 
Ryseck et al., 1992; Schmitz et al., 1994), and they can therefore form 
transcription-activating dimers with each other and with p50 or p52. p50 and 
p52 proteins lack the transcription activation domain, and the homodimers they 
form are mostly suppressors of gene expression (Zhong et al., 2002). However 
the classical, best-described form is composed of p50:p65 (Baeuerle and 
Baltimore, 1996; Thanos and Maniatis, 1995; Verma et al., 1995) and is found 
In virtually all cell types bound to kBa (Baeuerle and Baltimore, 1996).
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Following stimulation and subsequent degradation of kBa, NFkB is able to 
rapidly translocate to the nucleus where it binds to a KB-binding motif 
conforming to the sequence, 5'GGGACTTTCC3' (Kunsch et al., 1992; Parry 
and Mackman, 1994). It has been shown that p50 will bind to the conserved 5' 
end, while p65 binds to the less conserved 3' end (Urban and Baeuerle, 1991). 
Other types of NFkB dimers bind preferentially to different DNA sequence 
elements, contributing to the specificity of target genes regulated by this family 
of transcription factors.
Crystal structures of NFkB bound to DNA have been solved for p50, p52, p65 
homodimers and p50/p65 heterodimers and have indicated that the RFID is 
organised into three distinct sub-domains (Chen et al., 1998; Ghosh et al., 
1995; Muller et al., 1995). The 180 amino acid N-terminal folds into an Ig-like 
domain connected via a short, 100 amino acid long, linker region to a second 
Ig-iike domain of approximately 100 amino acids in length. The N-terminal Ig- 
like domain is involved in DNA recognition while the C-terminal Ig-like domain is 
involved in dimérisation. It was also found that fourteen residues from each 
subunit participate in dimer formation. The C-terminal Ig-like domain also 
contains the 13 amino acid nuclear localisation sequence (NLS) required for 
nuclear translocation (Birbach et al., 2002).
1.4.5 Regulation of NFkB by Post-translational Modifications
In addition to regulation by IkB , the localisation and transcriptional activity of 
p65 is regulated by phosphorylation-dependent acétylation (Chen et al., 2002). 
Acétylation is a common post-translational modification which was first 
associated with the regulation of histone packaging into chromatin fibres (Gray 
and Teh, 2001; Taunton et al., 1996). Acetylated histones are associated with 
transcriptionally active segments of chromatin, whereas deacetylated histones 
are present in transcriptionally inactive segments (Legube and Trouche, 2003; 
Marmorstein and Roth, 2001). Further studies indicated a range of 
transcriptionally co-activating proteins that contained histone acetyltransferase
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(HAT) activity including CBP-associated factor (PCAF), p300/CREB binding 
protein (p300/CBP), TATA-box binding protein associated factor (TAF||250) and 
steroid receptor co-activator (SRC-1) (Marmorstein and Roth, 2001). 
Subsequently proteins were also identified which contain histone deacetylase 
activity, termed ‘HDACs’, and HD AC 3 has been found to be important for p65 
deacetyiation both in vivo and in vitro (Chen et ai., 2001; Kiernan et al., 2003). 
Three main acétylation sites identified within p65 are lysines 218, 221 and 310 
(Chen et ai., 2002). The modification of these sites regulates distinct biological 
processes. For example, acétylation at K221 enhances DNA binding to p65 
and impaires its assembly with kBa, whereas acétylation of K310 is required 
for full transcriptional activity of p65 but modification of this site does not effect 
DNA binding or kB a  assembly (Chen et al., 2002). In conjunction, acétylation 
of two other sites K122 and K123, promotes post-induction removal of p65 from 
DNA and facilitates its translocation out of the nucleus (Kiernan et al., 2003). In 
contrast HDAC inhibitors (HDI) are also able to induce p65 acétylation (Chen et 
al., 2005; Xu et al., 2005) via a PI-3K/PKB dependent process (Mayo et ai.,
2003). It was recently reported by Liu et al., (2006) that treatment with the HDI, 
Suberoyianilide hydroxamic acid (SAHA), activated NFkB transcription via two 
separate mechanisms; the first via the de-repression of HDAC-1-mediated 
repression of p65, preserving the acétylation at K310 promoting NFkB 
transcription. The second mechanism involved the phosphorylation of PKB on 
8437 which transcriptionally up-regulated NFkB through its enhanced 
acétylation via an as yet undetermined mechanism.
Phosphorylation of p65 itself occurs at different phosphorylation sites, including 
3276, S529, 8536 that are targeted by several upstream kinases including 
mitogen- and stress-activated protein kinase (M8K1; 8276), protein kinase A 
catalytic subunit (PKAc: 8276), casein kinase 11 (CKIl; 8529), IKK (8536), 
protein kinase C<^  (PKCÇ; RHD) and Ca^^/caimodulin kinase IV (CaMKlV; c- 
terminus) (Vermeulen et al., 2002). Phosphorylation status is also determined 
by the activity of phosphatases such as protein phosphatase 2A (PP2A). PP2A
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is associated with p65 in un-stimulated melanocytes and can dephosphoryiate 
p65 following stimulation (Yang et al., 2001). Phosphoryiated p65 can then 
enter the nucleus where the specific phosphorylation pattern directs the 
interaction of NFkB with either p300/CBP or HDACs (Ashburner et al., 2001; 
Chen et al., 2002; Kiernan et al., 2003).
In conclusion, NFkB is an essential transcription factor required for the effective 
transcription of pro-inflammatory genes. Up-regulation of these genes 
increases surface expression of proteins which direct the recruitment of 
neutrophils, monocytes and macrophages to sites of inflammation. It responds 
to a diverse array of initial pathogenic stimuli via the integration of signals at the 
IKK complex leading to the degradation of IkB and the subsequent nuclear 
translocation of NFkB. Post-translational modifications such as phosphorylation 
and acétylation further regulate NFkB activity.
1.5 Mechanisms of Nuclear Import and Export of NFkB
The nucleus is the defining feature of the eukaryotic cell. The nuclear envelope 
divides the cell into two compartments between which there is a major 
interchange of proteins, nucleic acids and small molecules. To mediate the 
trafficking of molecules between the two compartments, the nuclear envelope 
contains nuclear pore complexes (NPCs). Small molecules are able to 
passively diffuse through these complexes whilst trafficking of molecules larger 
than 25nm in diameter is regulated by specific nuclear import and export 
systems. This section will examine the NPC followed by the nuclear import and 
export mechanisms utilised by activated NFkB.
1.5.1 Nuclear Pore Complex (NPC).
The NPC is a large 125 MDa multi-protein structure that completely spans the 
nuclear envelope, extending into both the cytoplasm and the nucleoplasm to a 
length of about 200nm (Reichelt et al., 1990; Stoffler et al., 1999). The pore 
has a total diameter of 25nm with a 9nm aqueous channel in the centre through
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which passive diffusion can occur (Bonner, 1978; Paine et al., 1975), while 
proteins larger than 25nm require active transport to facilitate their trafficking 
through the pore (Gasiorowski and Dean, 2003). The NPC is composed of 
nucleoporins (NUPs) of which there are an estimated 30-50 NUPs present 
within eukaryotic NPCs. Although many of these NUPs are functionally 
conserved from yeast to mammals (Feldherr, 1962; Reichelt et al., 1990), there 
are many which are species-specific (Reichelt et al., 1990). Several NUPs have 
been found to reside on both sides of the pore whereas others are positioned 
either at the central core or asymmetrically on one side or the other (Stoffler et 
al., 1999). A known subset of NUPs has been found to contain the amino acid 
repeats FXFG or GLFG, which are believed to mediate interactions with 
transport receptors and act as docking sites for importins (Bonner, 1978; Singh 
et al., 1999). Thus they are implicated in facilitating movement across the NPC.
1.5.2 Nuclear Import of NFkB
Three essential proteins have been discovered to mediate nuclear import: 
importin a, which recognises cargo proteins with the classical NLS (KKKK) 
(Kalderon et al., 1984; Lanford and Butel, 1984), importin-p, which binds and 
ferries the complex into the nucleus, and the small regulatory GTPase Ran. 
Specifically when then a/p/NLS cargo complex reaches the far side of the pore, 
nuclear Ran-GTP binds to importin-p and dissociates the complex, thus 
completing import (Goldfarb et al., 2004; Harel and Forbes, 2004).
1.5.2.1 Importin-a
Importin-a proteins are composed of a flexible N-terminal importin-p-binding 
(IBB) domain and a highly structured domain comprised often tandem armadillo 
(ARM) repeats (Conti et al., 1998; Fontes et al., 2000; Flerold et al., 1998). The 
helical ARM repeats assemble into a twisted, slightly arced structure, with the 
inner curve housing the cNLS-binding groove. ARM repeats 2-4 comprises the 
N-terminal NLS binding site and ARM repeats 7-9 the C-terminal NLS binding 
site. The flexible IBB domain acts as a competitive inhibitor regulating binding to
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the cNLS-binding groove by interacting either in trans with importin p, targeting 
the complex to the NPC for translocation, or in cis with the cNLS-binding 
groove. This autoinhibitory interaction is not particularly strong as cNLS cargos 
can still bind to importin-a in the absence of importin-p. It is not known whether 
importin-a interacts first with importin-p to relieve the autoinhibition of the NLS- 
binging groove and then interact with the cNLS cargo, or the cNLS cargo binds 
to the NLS-binding groove first, thus liberating the autoinhibitory IBB domain to 
interact with importin-p (Goldfarb et al., 2004). It is possible that the order of 
binding varies from event to event depending on the particular cNLS cargo and 
the effective concentrations of the relevant factors.
Of the six importin-a family members identified in humans, importin-a3 has 
been shown to bind to the cNLSs reported on p50 and p65 (Blank et al., 1991; 
Fagerlund et al., 2005; Gilmore and Temin, 1988) following TNFa-mediated 
NFkB activation (Fagerlund et al., 2005). lmportin-a3 is able to use either of its 
N- or C-terminal binding sites for binding different nucleus-targeted proteins 
(Melen et al., 2003). In a recent study it was postulated that p50 and p65 NLSs 
bound simultaneously to the different NLS binding sites of the same importin-a 
molecule possibly stabilising the complex during nuclear import (Fagerlund et 
al., 2005).
1.5.2.2 Importin-p
The concentration of importin-p within the celi has been estimated at 3jiM 
(Kutay et al., 1997). Initial mutational analysis indicated that importin-p 
consisted of three domains, an N-terminal Ran-GTP binding domain, a middle 
zone that interacts with the nuclear pore and a C-terminal importin-a binding 
domain (Chi and Adam, 1997). However following crystal structure analysis, it 
emerged that importin-p consists entirely of 19 HEAT repeats, with each HEAT 
repeat containing two a-helices, A and B, joined by a loop. In addition, the 
protein coils into a short superhelix, with extensive interaction surfaces both on
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the inside and the outside of the superhelix (Harel and Forbes, 2004). From the 
various proteins and protein fragments which have been co-crystallised with 
importin-p it has been shown that each protein utilises different binding sites 
and modes of interaction (as reviewed in Bednenko et al,, 2003; Stewart, 2003). 
It appears that the spring-like superheiical importin-p has a iarge degree of 
flexibility (Stewart, 2003) which it utilises to recognise its many partners. For 
example, in some cases several importin-p HEAT repeats open up to 
accommodate the bound protein, whilst in other cases regions of the superhelix 
wrap around the chosen partner.
Importin-p mediates the interactions with the NPC that drive translocation. 
Importin-p has been shown to bind GLFG or FXFG repeat domains of several 
nucleoporins in vitro (Kraemer et al., 1995; Radu et al., 1995; Rexach and 
Blobel, 1995). However, invivo and functional significance of these interactions 
is controversial (Kau et al., 2004). Also the interaction with the channel of the 
NPC is as yet unclear.
1.5.2.3 Ran-GTP/GDP Gradient.
Ran, the Ras-related nuclear protein (Bischoff and Ponstingi, 1991; Drivas et 
ai,, 1990) is a key component of the import reaction and belongs to a class of 
small GTP binding proteins that cycle between a GTP- and a GDP-bound state. 
Although Ran has a very low intrinsic GTP hydrolysis rate, the presence of Ran 
GTPase activating protein 1 (RanGAPI) in the cytoplasm in conjunction with 
Ran binding protein 1 (RanBPI) on the cytoplasmic face of the NPC speeds up 
this GTPase activity. This results in a much higher concentration of RanGDP 
than RanGTP in the cytoplasm. Conversion of RanGDP to RanGTP occurs by 
exchanging the entire nucleotide and is catalysed by the principle mammalian 
guanine nucleotide exchange factor RCC1 (Bischoff and Ponstingi, 1991). 
RCC1 is a nuciear, chromatin-bound protein (Ohtsubo et al., 1989) and 
therefore the RanGTP/RanGDP ratio is high within the nucleus. This gradient
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of RanGDP/RanGTP across the nuclear envelope is used to drive protein 
trafficking back and forth through the NPC.
It is generally believed that importin-p is able to associate with either RanGDP 
or RanGTP and although it is possible that Ran hydrolysis could occur 
anywhere within the cell, it is tightiy regulated by several proteins in close 
proximity to the NPC. On the cytopiasmic face of the NPC there is a 358kDa 
multi-domain protein, RanBP2 that acts as a scaffold where import and export 
complexes can assemble and disassemble. Importin-p and RanGAPI are two 
of the several proteins known to bind to RanBP2 (Matunis et al., 1998). The 
currently accepted model for nuclear import, (as reviewed in Gasiorowski and 
Dean, 2003) is that the Importin-a/p-RanGDP-NLS-cargo complex binds to 
RanBP2 on the cytoplasmic face of the NPC. The entire complex is then 
imported involving interactions with several NUPs. However the precise 
mechanism is not fully understood. Once within the nucleus, the high 
concentration of RCC1 exchanges the GDP with GTP causing the importin-a 
and cargo molecules to dissociate leaving the importin-p/RanGTP complex to 
translocate back through the NPC to the cytoplasm. A model of translocation is 
shown in Figure 1.6.
1.5.3 Nuclear Export
Nuclear export is also controlled by the RanGDP/GTP gradient along with a 
subfamily of importin-p, called exportins. The first identified exportin was 
CRM1, which has been found to recognise a leucine-rich nuciear export 
sequence (NES) (Fornerod et al., 1997). Proteins that contain a nuclear export 
sequence (NES) range from transcription factors to viral proteins (Goriich and 
Kutay, 1999; Mosammaparast and Pemberton, 2004). In contrast to the 
process observed with nuclear import, RanGTP appears to promote the 
interaction between CRM1 and NES-containing cargo proteins (Chen and 
Greene, 2003; Gasiorowski and Dean, 2003). For example, IkB  has a NES that 
is recognised by CRM1. Nuclear IkB  binds to activated N F k B , the Ik B /N F k B
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Figure 1.6 Nuclear transiocation of cNLS via Importin o/p complex
(i) Importin a (a) forms a ternary complex with importin p (p) and cargo (blue 
circles), (il) The ternary complex docks at the nuclear-pore complex (NPC) and 
(ill) translocates into the nucleus. (Iv) Binding of Ran-GTP triggers the 
dissociation of the ternary complex, (v) Importin a binds to the exportin CAS- 
Ran-GTP complex and is exported to the cytoplasm, (vl) Ran-GAP-stimulated 
hydrolysis of GTP by Ran triggers the dissociation of the exportin complex and 
releases free importin a into the cytoplasm for another transport cycle. The 
recycling of importin p to the cytoplasm, and Ran-GDP to the nucleus and its 
conversion to Ran-GTP are not shown.
assembly
Ran-GAP
cytoplasm nucleus
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complex then interacts with CRM1 and RanGTP enabling its subsequent 
trafficking through the NPC back into the cytoplasm. It has been shown that 
leptomycin B (LMB), which directly binds to CRM1 preventing its interaction with 
the NES (Fornerod et al., 1997; Fukuda et al., 1997; Kudo et al., 1998), inhibits 
the nuclear export of the IkB/NFkB complex (Huang et al., 2000).
1.6 Role of G-protein Coupled Receptors (GPCRs) in 
Inflammation
G-protein coupled receptors (GPCRs) constitute the largest family of integral 
membrane proteins involved in signal transmission and as such play a key role 
in immune and cellular responses. They can bind a diverse range of important 
inflammatory ligands including, chemokines, se reton in (5HT) and adenosine, 
making them an important target for potential anti-inflammatory therapeutics.
GPCRs are integral membrane proteins that consist of a single polypeptide 
chain containing seven transmembrane (TM) spanning hydrophobic a-helical 
regions with a hydrophilic extracellular N-terminus and an intracellular C- 
terminus which can vary in length. Despite the conservation of this original 
structure, sequence homologies between distinct GPCRs are generally 
restricted to the transmembrane domains of closely related receptor subtypes. 
Generally the ligand recognition site involves the extracellular domains of the 
receptor (both the N-terminus and the extracellular loops between the a- 
helices) and the pocket formed by the assembly of the seven TM helices, 
whereas interaction between the receptor and intracellular signalling partners 
(G-proteins) involves the intracellular loops and C-terminal tail (Gether, 2000; 
Wess, 1997; Wess, 1998). The GPCR superfamily can be further divided into 
different classes characterised by their ligand binding domains. The largest is 
Group A (rhodopsin-type receptors) and contains receptors for prostaglandins, 
prostacyclins and adenosine, along with the cell surface receptors for some 
viruses. Group B (secretin/glucagons receptors) contains receptors for distinct 
hormones and peptides (eg calcitonin, glucagon and anti-diuretic hormone).
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Group C (metabotropic glutamate receptors) was described most recently and 
includes receptors for glutamate and the Ca^ "^  ion (Wess, 1998).
1.6.1 General GPCR Signalling
GPCR activation occurs following the binding of its ligand. This results in the 
signal transduction via a conformational change within the protein structure 
responsible for coupling to and activation of the associated G-protein. It is this 
associated G-protein that activates the downstream effector molecules to 
initiate intracellular signalling.
The structure of GPCRs has been elucidated from numerous mutagenesis 
studies involving rhodopsin and p2-adrenergic receptors (PzAdAR) and the 
crystal stucture of rhodopsin (Palczewski et al., 2000). It has been shown that 
the TM domains of GPCRs are more closely packed at the intracellular surface 
than at the extracellular surface enabling ligand binding and that the N- and C- 
terminals vary in length. In most receptors, the N-terminal domain contains the 
sequence Asn-X-Ser/Ther where X is any amino acid except proline (Hubbard 
and Ivatt, 1981) which are sites for possible N-linked glycosylation. Although it 
is not known if all possible sites are functional, it has been reported that some 
are necessary for receptor expression and ligand binding activity (Liu et al., 
1993; Segaloff and Ascoli, 1993; Wess, 1998). The majority of GPCRs contain 
Cys residues in the first and second intracellular loops that are responsible for 
maintaining the tertiary structure of the protein via the formation of disulfide 
bonds as shown in rhodopsin and p2AdAR (Dixon et al., 1987; Karnik et al., 
1988). The C-terminal tail and the third intracellular loop typically contain 
numerous Ser and Thr residues that are potential phosphorylation sites for 
regulation by kinases such as GPCR kinases (GRKs) and/or second messenger 
kinases such as protein kinase A (PKA) and protein kinase C (PKC) (Dohlman 
et al., 1987; Kobilka, 1992). These residues are particularly significant for 
desensitisation of receptor signalling (Section 1.6.3.1). In addition, the third TM 
domain cytosolic region contains the highly conserved sequence Asp-Arg-Tyr
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(DRY). This sequence, in conjunction with the second intracellular loop, is 
thought to be involved in receptor-G-protein coupling.
1.6.2 Receptor and G-protein Interactions
A lot is known about the structural features of GPCRs involved in ligand 
recognition and G-protein binding. However, the mechanisms underlying 
ligand-induced activation and subsequent G-protein coupling are still relatively 
unclear. The DRY motif is a highly conserved triplet of amino acids located at 
the cytosolic region of the third TM helix and the second intracellular loop 
(Probst et al., 1992). The importance of the DRY sequence has been described 
for several GPCRs including the M l muscarinic receptor, aiB-adrenergic 
receptor (am-AdR), angiotensin lA receptor (AT iaR) and the CXCR8  receptors 
(Damaj et al., 1996; Jones et al., 1995; Ohyama et al., 1992) The Arg residue 
within the DRY motif is fully conserved amongst all class 1 GPCRs as 
mutagenesis experiments with both the M l muscarinic and am-adrenergic (aie- 
AdR) receptors resulted in impaired signal transduction properties (Jones et al., 
1995; Zhu and Toews, 1994). Interestingly, functional studies with the Ml 
muscarinic receptors have shown that a charge-conserving Arg for Lys mutation 
resulted in only a modest impairment of receptor function (Jones et al., 1995) 
which suggest that the conserved Arg residue presumably interacts with an 
anionic site on the G-protein.
1.6.3 Regulation of GPCR Function
The precise control of receptor expression and function is extremely important 
in the role that GPCRs play in inflammation. It is essential that they can 
accurately respond to rapid changes in agonist concentration. This is ensured 
by phosphorylation of specific Ser, Thr or Tyr residues by multiple protein 
kinases. The result is multiple protein-protein interactions that lead to receptor 
desensitisation, sequestration from the cell surface, recycling of the receptor 
back to the surface and in some cases down-regulation of the receptor.
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1.6.3.1 Desensitisation
Desensitisation has been defined as the process whereby a GPCR-initiated 
response reaches a plateau and then decreases despite the continued 
presence of agonist (Freedman and Lefkowitz, 1996; Krupnick and Benovic, 
1998). It can be further sub-divided into homologous and heterologous 
desensitisation. Homologous desensitisation causes the desensitisation of only 
agonist-occupied receptors, while in contrast; heterologous desensitisation 
describes the desensitisation of inactive and/or un-related GPCRs. 
Heterologous desensitisation is mediated by phosphorylation of specific 
residues by second messenger-activated kinases such as PKA and PKC, 
resulting in a decrease in the ability of the receptor to stimulate the associated 
G-protein (Benovic et al., 1985; Pitcher et al., 1992). In 1987, studies using the 
pzAdR resulted in the purification of a kinase from bovine brain responsible for 
homologous desensitisation (Benovic et al., 1987). This kinase was termed p- 
adrenergic receptor kinase (pARK) but was later renamed as G-protein coupled 
receptor kinase 2 (GRK2) (Benovic, 1991). Subsequently, there have been 
seven mammalian GRKs cloned to date, termed GRK1-7. GRKs 1 and 7 are 
solely expressed in the eye whilst GRK4 is predominantly expressed within the 
testis (Penn et al., 2000; Pitcher et al., 1998). The other GRKs are ubiquitously 
expressed suggesting an important role for these kinases in mediating 
homologous desensitisation for a wide variety of GPCRs.
1.6.3.2 Sequestration
Sequestration is the process whereby agonist stimulated GPCRs, having been 
phosphoryiated by GRKs, are removed from the cell surface. Typically this 
requires prior receptor phosphorylation and subsequent binding of an arrestin 
protein (Diviani et al., 1996; Ferguson et al., 2002; Pippig et al., 1993). Of the 
four known mammalian arrestins (arrestin 1-4) that share 45% overall identity, 
arrestins 1 and 4 are found exclusively in the eye (Murakami et al., 1993; 
Shinohara et al., 1992). Arrestins 2 and 3 (Lohse et al., 1990; Sterne-Marr et 
al., 1993) are ubiquitously expressed and therefore play a general role in
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sequestration of many GPCRs. The binding of arrestin to phosphoryiated 
GPCRs can also result in the uncoupling of activated receptors from the G- 
proteins, thereby “arresting” (switching off) GPCR intracellular signalling 
(Bunemann and Hosey, 1999).
1 .6.3.3 Down-regulation
Prolonged agonist exposure over a period of hours results in receptor down- 
regulation, defined as an overall decrease in total receptor number (Gagnon et 
al., 1998). It has been suggested from studies on the Thrombin receptor (Hein 
et al., 1994), the thyrotropin-releasing hormone receptor (TRHR; Petrou et al., 
1997) and the cholecystokinin receptor type A (CCKaR; Tarasova et al., 1997) 
that sequestered receptors traffic in an agonist-dependent manner from early 
endosomes to lysosomes where they undergo degradation.
After receptors and their ligands have been sequestered from the cell surface 
by clatherin-coated vesicles, the vesicles are uncoated and the internalised 
molecules are delivered to early sorting endosomes (Ferguson, 2001). Due to 
the acidic pH in early endosomes, the receptors and ligands dissociate and the 
receptors are either recycled back to the membrane for another round of 
agonist activation or degraded by the lysosome (Koenig and Edwardson, 1997). 
The effective regulation of receptor surface expression maintains the sensitivity 
of GPCRs to extracellular concentrations of agonist which is important in the 
activation of signal transduction pathways via G-proteins.
1.6.4 Constitutive Receptor Signalling
The concept of constitutively active GPCRs was first introduced by Costa and 
Hertz in 1989 and is now widely accepted within receptor pharmacology 
(Reviewed in de Ligt et. al., 2000, Costa and Herz, 2005). Constitutive activity 
of GPCRs is described as receptor signalling without agonist intervention. This 
exhibition of spontaneous receptor activity has lead to the observation that 
various ligands, previously considered as antagonists with no intrinsic activity,
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actually can inhibit this spontaneous activity, appearing to possess ‘negative’ 
intrinsic activity. This phenomenon has been termed inverse agonism and the 
corresponding ligands are referred to as inverse agonists (Milligan G 2003, de 
Light et al., 2000). An important consideration during the classification of 
ligands based on their (negative) intrinsic activity, is that due to the large 
influence of receptor systems and experimental conditions (whole cells versus 
membranes, stoichiometry of receptors / G-protein, signalling proteins etc.) the 
same ligand may behave as an inverse agonist, a neutral antagonist or even a 
(partial) agonist (Greasley and Ciapham, 2006).
Although virtually all GPCRs can be modified to display constitutive activity 
(Chalmers and Behan, 2002), many GPCRs display rather low levels of 
constitutive activity when expressed in recombinant systems and display greatly 
increased activity in the presence of agonist. For example, the mutation of Ala 
293 on the aib ad renoreceptor to any other amino acid increased constitutive 
activity (Kjelsberg et al., 1992) which indicates a strong evolutionary pressure to 
maintain the wide-type form of the receptor in a nearly silent state.
There have been documented differences in the extent of constitutive activity 
among GPCRs, even between sub-types of the same receptor family (Milligan 
G., 2003). The question is whether these subtle distinctions are a natural way 
of fulfilling a specific role in signalling.
1.7 G-proteins
Although recent studies have revealed the existence of G-protein-independent 
signalling through certain GPCRs (Bockaert and Pin, 1999; Hall et al., 1999; 
Heuss et al., 1999; Hur and Kim, 2002), the common biochemical feature of 
these receptors is their interaction with G-proteins and the activation of 
downstream signalling cascades through a well documented and conserved 
molecular mechanism. The binding of agonist alters the conformation of critical 
domains of the TM helix pocket, which in turn causes changes in the
42
conformation of intracellular domains of the receptor. These changes promote 
the specific association of the receptor with a variety of heterotrimeric G- 
proteins. These are composed of an a-subunit interacting with a Py-complex. 
Activation of the receptor promotes the exchange of a molecule of GDP by a 
molecule of GTP within the active site of the a-subunit. The binding of GTP 
causes the dissociation of the heterotrimeric complex, and both the GTP-bound 
a-subunit and the released py-complex are then able to interact with 
intracellular or membrane effectors of various signalling pathways. The intrinsic 
GTPase activity of the a-subunit hydrolyses GTP to GDP, restoring its initial 
inactive conformation along with its affinity for the Py-complex (Susa, 1999). 
For many receptors, the localisation of the molecular determinants of the 
receptor involved in the coupling and activation of G-proteins has been 
investigated. These studies have highlighted the role of membrane-proximal 
regions of the second and third intracellular loops and of the C-terminus of the 
receptor in driving coupling. However, no consensus linear sequence for G- 
protein interaction has yet been clearly identified (reviewed in Gether, 2000; 
Wess, 1997; Wess, 1998).
The complexity and specificity of GPCR signalling partly relies on the existence 
of numerous closely related molecular species of the G-protein subunits 
(Downes and Gautam, 1999; Morris and Malbon, 1999). Numerous a-subunits 
have been identified from various genes and are classified into four families 
(Gas, Gai/o, Gaq/n and Gai2) according to its function (Hermans, 2003).
1.7.1 Gas
The Gas family of G-proteins is defined by its ability to stimulate adenylyl 
cyclase activity leading to the generation of intracellular cAMP. Gas and Gaoif, 
the two members of this family, share 8 8 % homology (Jones and Reed, 1989) 
and are substrates for ADP-ribosylation of Arg 201 found within the GTP- 
binding site (Kassis et al., 1982). This post-translational modification inhibits 
the intrinsic GTPase activity of the G-proteins, leading to the constitutive
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activation of the initiation of cellular events that characterise the 
pathophysiology of cholera (Jones and Reed, 1989).
1.7.2 Got;
The Gai family proteins comprise, Gan, Ga.z, Gais, the retinal Ga, Gat, two 
forms of the brain-specific G a subunit Gaoi and Gaoz, along with Gaz. Defined 
by the inhibition of adenylyl cyclase activity they can also target other 
downstream signalling components including certain sodium, potassium and 
chloride channels and PLCp, (Moriarty et al., 1990). With the exception of Gaz, 
all other members of this class contain a conserved C-terminal Cys residue that 
is the site of ADP-ribosylation catalysed by a toxin from Bortadelfa pertussis. 
This causes irreversible, uncoupling of the G-protein from its activating receptor 
leaving the subunit in a permanently inactive GDP-bound state, thus preventing 
further GDP/GTP exchange by active GPCRs.
1.7.3 Gttq
The Gaq family contains five family members, G an, G a#, Gais, G a# , and Gaq. 
These closely related proteins are not substrates for either cholera toxin- or 
pertussis toxin-catalysed ADP-ribosylation. The Gaq subunits are notable 
regulators of the p-class of phosphoinositide-specific phospholipase C (PLC) 
PLCp (Rhee, 2001). Gaq and Gan are widely expressed in mammalian 
tissues, whilst in contrast the other members of the family are restricted to 
stromal and epithelial cells and are thought to activate specific members of the 
PLC(32 family that also have a similar restricted pattern of expression (Morris 
and Malbon, 1999).
1.7.4 Ga-12
This family comprises of two 44kDa proteins Ga# and G a#, both of which are 
cholera toxin and pertussis toxin resistant. Ubiquitously expressed, they couple 
GPCR activation to mutiple downstream targets including the RhoGEFs which
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activate Rho, a family of small GTP-binding proteins, and non-receptor tyrosine 
kinases such as Ras GTP-ase activating protein (Offermanns, 2003). They 
have also been reported to interact with cadherins, a class of adhesion 
molecules, causing the release of transcriptional activator p-catenin (Meigs et 
al., 2002; Meigs et al., 2001),
1.7.5 Gpy Subunits
It is widely accepted that the Gpy subunits can also target effector molecules 
that are involved in downstream receptor signalling (Wess, 1998). There have 
been 6  p-subunits and at least 12 y-subunits reported (Ciapham and Neer, 
1997). The different p-subunits share a high degree of sequence homology 
whereas the y-subunits are more structurally diverse. Gpy-subunits are 
extremely stable and can only be separated by denaturisation and as such are 
regarded as one complex in vivo. Although theoretically the numbers of p- and 
y-subunits could give rise to 72 different combinations, the reason for this 
diversity is as yet unclear as the majority of Gpy subunits have been shown to 
exert similar functional properties (Ciapham and Neer, 1997, Wess, 1998). It 
has also been reported that there is a py-binding site on GRK2 which allows for 
the regulation of GRK2 related receptor phosphorylation by promoting its 
translocation to the site of receptor-G-protein interaction and also inhibits Gpy 
signalling (Lodowski et al., 2003).
1.8 Adenosine and Inflammation
Extracellular adenosine is an ubiquitous critical regulator of homeostasis and 
plays a central role in the maintenance of the cardiovascular and central 
nervous systems. It is released by Na^-dependent transporters and is formed in 
the extracellular space by the breakdown of ATP during times of stress such as 
hypoxia (Klinger et al., 2002). Due to deamination and/or cellular uptake, 
adenosine has a limited half-life therefore hypoxia-induced increases in 
concentration only affect local adenosine receptor signalling (Klinger et al..
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2002). In hypoxic tissues, adenosine accumulates to high levels sometimes 
reaching concentration levels of 1164±415 pmol/min/g, approximately 20 times 
greater than basal levels (59±28 pmol/min/g) (Decking et al., 1997), triggering 
signalling cascades which enable the tissues to cope with both short- and long­
term effects of oxygen and nutrient deprivation (e.g. stimulating endothelial cell 
growth and angiogenesis).
There is a plethora of data linking adenosine to inflammation. Adenosine has 
been shown to inhibit phagocytosis, the generation of toxic oxygen species, and 
adhesion to endothelial surfaces (Cronstein, 1994). A study by Morabito et al. 
(1998) identified the anti-inflammatory effects of methotrexate, used in the 
treatment of rheumatoid arthritis, and sulfasalazine to include an adenosine- 
dependent mechanism. Both these therapeutic drugs act via different 
mechanisms to increase the extracellular concentration of adenosine. 
Methotrexate inhibits the enzyme aminoimidazolecarboxamino- 
adenosineribonucleotide (AlCAR) transformyiase (Allegra et al., 1985; Baggott 
et al., 1986). The resulting accumulation of AlCAR and its metabolites has a 
direct effect on at least two key enzymes, adenosine deaminase and AMP 
deaminase, with the end result of increased concentrations of adenosine and 
adenine nucleotides (Chan and Cronstein, 2002). The anti-inflammatory agent, 
sulfasalazine has been shown to promote adenosine release both in vivo and in 
vitro and that adenosine, acting at its receptors, mediates the anti-inflammatory 
effects of sulfasalazine in the murine air-pouch model of inflammation (Gadangi 
et al., 1996). Further reports have shown sulfasalazine inhibition of leukocyte 
accumulation does not have an effect on either prostaglandin synthesis or 
translocation of NFkB subunit p50 into the nucleus (Cronstein et a!., 1999).
Various knockout mice studies, utilising knockout mice in either adenosine 
deaminase or the A2a adenosine receptor, have shown that increasing available 
adenosine produced an exaggerated inflammatory response when compared 
with wild-type (Blackburn et al., 2000; Hershfield, 2005; Ohta and Sitkovsky,
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2001). This is probably due, in part, to the expression of adenosine receptors 
on the majority of cells throughout the immune system (Thiel et al., 2003).
1 .8 .1  Adenosine Receptors
Adenosine receptors (ARs) belong to the Class 1A GPCR family and are known 
as purinergic receptors as they bind the purine adenosine. There are two main 
types of purinergic receptors: Pi or adenosine receptors, and P2 receptors. P2 
receptors recognise and bind nucleotides such as ADP, ATP, UDP and UTP 
and can be sub divided into two classes. The P2x receptors are ligand-gated ion 
channels (Benham and Tsien, 1987), while the P2y receptors are GPCRs 
(Abbracchio and Burnstock, 1994; Fredholm and Altiok, 1994). The P^/ARs can 
be divided into four distinct subtypes, the AiAR, A2aAR, AzbAR and A3AR 
(Tucker and Linden, 1993).
All four of the ARs are GPCRs and as such consist of an extracellular amino- 
terminal domain linked to a cytoplasmic-terminal domain by seven 
transmembrane-spanning a-helices (Ji et al., 1998). The a-helices 2, 3 and 5 
show a large degree of sequence identity and residues within these regions are 
reported as being crucial for ligand binding and specificity. AiAR, A2aAR and 
A2bARs contain two histine residues within the TM regions which are have been 
identified via mutations to leucine to be important in ligand binding (Jacobson et 
al., 1992; Klotz et al., 1998; Olah et al., 1992).
The ARs are N-linked glycoproteins and all bar A2aAR, have Cys sites for 
palmitoylation within the carboxyl terminus (Linden, 2 0 0 1 ). Glycosylation has 
no effect on the affinity of ligands for receptors but Is believed to be involved in 
targeting freshly synthesised receptors to the plasma membrane (Linden, 
2 0 0 1 ). Multiple potential phosphorylation sites have been identified within the 
C-terminal tail of A2aAR, A2bAR and A3AR while the AiAR contains fewer 
phosphorylation sites as outlined below.
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1.8.2 AR subtypes
1.8.2.1 AiAR
The A iAR is highly expressed within most areas of the brain, heart, liver and 
testies (Fredholm et al., 2 0 0 1 ) and has been shown to signal through the Gaj/o 
G-protein pathways therefore inhibiting adenylyl cyclase activity. Activation of 
this AR has also been shown to mobilise intracellular Ca "^" following the 
activation of phospholipase C (Hansen et al., 2003) and activate PKCp in a 
MEK1 and PI3-K dependent manner (Hill et al., 2003). Once activated the 
AiAR desensitises slowly over periods of several hours to days due to a lack of 
GRK phosphorylation sites within its C-terminal tail (Palmer et al., 1996). The 
AiAR has also been reported to constitutively inhibit adenylyl cyclase when 
over-expressed in Chinese Hamster Ovary (CHO) cells (Shryock et al., 1998).
1.8.2.2 A2aAR
The A2aAR is highly expressed within most cells of the immune system, 
platelets, heart, lung and endothelium (Fredholm et al., 2001; Thiel et al., 2003). 
Classically, the A2aAR signals via the Gs family of G proteins leading to an 
activation of adenylyl cyclase and the generation of cAMP (Daly et al., 1983). 
However, it has been shown that there may be cell type-specific patterns of 
AzAAR-activated signalling. In endothelial cells, the A2aAR activates the ERK 
pathway in a p21’’®®-, rapi-, and MAP Kinase Kinase (MEK1)- dependent 
manner (Seidel et al., 1999; SexI et al., 1997).
A unique feature of the AzaAR is its long cytoplasmic C-terminal domain, 122 
amino acid residues in humans, guinea pig and dogs and 125 in rats, compared 
to the AzbAR which only consists of 36 amino acid residues. 12 out of the 122 
amino acids are serine and theronine residues and in cell experiments have 
been shown to be rapidly phosphoryiated following activation of PKC. 
However, PKC is thought to activate intermediary kinases rather than act 
directly on the receptor due to the findings that mutation of three consensus
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PKC phosphorylation sites to alanine failed to inhibit PKC-stimulated 
phosphorylation (Palmer and Stiles, 1999). In the same study it was also 
reported that phosphorylation of threonine 298 on the canine AzaAR is 
associated with the rapid desensitisation in response to agonist and multiple 
isoforms of PKC activated the downstream kinase responsible for the phorbitol 
ester PMA-mediated phosphorylation of AzaAR (Palmer and Stiles, 1999). The 
C-terminal tail is also proline rich with 11 residues in two clusters at positions -  
10 from the C-terminus and between positions 341-357, which is indicative of 
possible interactions with SH3 domains (SH- src homology). It has been 
suggested that it is involved in regulating the coupling properties of the receptor 
or may represent an anchor for a modulatory component (Kinlay et al., 2001). A 
recent study has provided a functional link between the AzaAR and the actin 
cytoskeleton (Burgueno et al., 2003). Direct interaction between a-actinin and 
AzaAR was observed suggesting that agonist-mediated clustering and 
internalisation of the AzaAR regulated by its C-terminus is dependent on an 
intact a-actinin/actin network.
The AzaAR has been shown to be constitutively active in both whole cell 
experiments and in vivo (Maenhaut et al., 1990, Lendent et al., 1992, Klinger et 
al., 2002). Transgenic mice carrying a thyroglobulin-AzAAR hybrid gene have 
been shown to efficiently express the A zaAR within the thyroid which correlated 
with increased levels of cAMP in the thyroid of transgenic animals indicating 
that the AzaAR acts in vivo as a constitutive activator of adenylyl cyclase 
(Lendent et al., 1992). In correlation with these results, studies on the C- 
terminal tail of the A zaAR, in human endothelial cells and HEK293 cells, have 
shown that truncation of the C-terminus blunted the capacity of the AzaAR to 
elevate cAMP in the absence of agonist (Klinger et al., 2002). The constitutive 
elevation of cAMP was only detectable within intact cells and the difference 
between C-terminal-truncated and full-length A zaAR was lost in membranes, 
suggesting a cellular component binds the C-terminus regulating the efficiency 
of signal transfer in intact cells.
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1.8.2.3 AzbAR
The AzbAR is expressed in the caecum, colon, lung and blood vessels 
(Fredholm et al., 2001). Coupling to Gas and Gaq, the AzbAR can not only 
increase intracellular cAMP but can also initiate Ca^^ mobilisation and 
MEK/Ras-mediated ERK activation (Gao et al., 1999). The AzbAR on vascular 
endothelial cells is also thought to contribute to the nitric oxide-dependent 
component of vasodilation mediated by Ca^^-dependent NO synthase activation 
(Linden, 2001). Although wild-type A3AR is not constitutively active, mutants 
conferring constitutive activity have been identified and utilised to identify 
ZM241385, DPCPX and MRS1706 as inverse agonists (Beukers MW et al., 
2004, Li, Q et al., 2007)
1.8.2.4 A3AR
The A3AR has been cloned from various species incuding rat, dog, sheep, 
rabbit and human (Fredholm et al., 2001; Salvatore et al., 2000) The A3 AR 
displays the greatest degree of difference between species, with the rat and 
human sharing only 72% sequence identity. This is reflected by the marked 
differences in pharmacology and local of expression. In rodents, the A3AR Is 
highly expressed on mast cells and in the testis with some expression in the 
brain (Fredholm et al., 2001). In contrast, the A3AR expression in humans and 
sheep is limited to eosinophils. It also couples to Ga, and appears to have the 
same affinity to adenosine as the AiAR. Activated A3ARS are susceptible to 
phosphorylation by GRK family of kinases (types 2, 3 and 5), resulting in rapid 
desensitisation (Palmer and Stiles, 2000). Constitutively active mutants (CAMs) 
of the human A3AR have been constructed which appear to favour adenylyl 
cyclase signalling rather than the PLC signalling pathway (Chen et al., 2001).
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1.9 Evidence of a Role of Adenosine Receptors in 
Inflammation
It is widely accepted that inflammatory tissue damage is accompanied by the 
accumulation of extracellular adenosine in inflamed areas due to its release 
from non-immune and immune cells (Berne and Rubio, 1974; Bookman et al,, 
1975; Cronstein et al., 1985; Sitkovsky, 2003; Sullivan and Parker, 1976). Also 
contributing to the accumulation of adenosine is the release of rapidly 
metabolised adenosine diphosphate (ADP) and adenosine triphosphate (ATP) 
from various cells including platelets and endothelial cells (Linden, 2001). All of 
the AR subtypes, each of which play distinct roles in inflammation, can be 
activated by adenosine generated extracellularly, particularly on endothelial 
cells. It has been shown that the last step in the extracellular breakdown of 
ATP to adenosine is controlled by the cell membrane-anchored surface enzyme 
CD73/ecto-5’-nucleotidase, predominantly associated with the vascular 
endothelium, which catalyses the extracellular converstion of 5’AMP to 
adenosine (Zernecke et al., 2006). The genetic deletion of CD73 has recently 
been associated with an impaired generation of adenosine, demonstrating its 
importance in modulating vascular tone and in limiting inflammatory responses 
by attenuating leukocyte adhesion (Koszalka et ai., 2004; Thompson et al., 
2004; Zernecke et al., 2006). Several studies suggest that the four ARs have 
both pro-and anti-inflammatory properties dependent on the model system 
studied.
1.9.1 Inflammatory Effects of AiAR Activation
The AiAR has been shown to have both pro-and anti-inflammatory effects. 
AiAR activation is reported to reduce hypersensitivity to heat and paw pressure 
in rodent models of inflammation and nerve injury (Li et al., 2003) and treatment 
with an AiAR agonist improves the symptoms of arthritis in rat models (Boyle et 
al., 2002). A protective effect of the AiAR has been suggested in studies of 
renal ischaemic-reperfusion injury in AiAR knockout mice as these mice exhibit 
increased renal injury when compared to their wild type littermates (Lee et al..
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2004). In contrast, animal models of asthma it is suggested that the AiAR is 
involved in mediating bronchospasm by a neutral mechanism which is 
independent of mast cell granulation (Meade et al., 2001). These data suggest 
that the different roles of the AiAR observed within each animal model are 
mediated by alternative signalling pathways.
1.9.2 Inflammatory Effects of AzbAR Activation
Little is known about the cell-specific expression of the AzbAR in vivo or about 
the functional significance of the A zbAR, the latter is due to a lack of specific 
agonists for this receptor. Despite these limitations, cell culture studies have 
indicated that AzbAR is expressed in immune cells, endothelial cells and aortic 
vascular smooth muscle (Yaar et al., 2005). The AzbAR has been implicated in 
several important biological events, including mediating vasodilation 
(Balwierczak et at., 1991; Martin, 1992), inhibiting growth of rat aortic smooth 
muscle cells (Dubey et al., 1996; Du bey et al., 2000) and increasing the 
production of cytokines, such as IL-6 , by vascular cells (Feoktistov et al., 2002; 
Zhong et al., 2004). It has also been reported that the AzbAR is involved in the 
pathogenesis of Alzheimers disease as A zbAR expression was found to be 
reduced in rodent models of Alzheimers disease with induced neuro­
inflammation which was prevented by treatment with a NO-releasing non­
steroidal anti-inflammatory drug (Rosi et al., 2003). Pro-inflammatory effects 
are also reported in different models of inflammation. Activation of the AzbAR  
by adenosine has been shown to increase the secretion of the pro-inflammatory 
cytokine IL-6  in in vitro studies of intestinal inflammation (Sitaraman et al., 
2001). However the direct influence of A zbAR on cytokine levels, inflammation 
and/or vascular adhesion has not yet been examined in vivo.
1.9.3 Inflammatory Effects of A3AR Activation
The A3AR has been shown to exhibit pro- and anti-inflammatory effects. In vivo 
studies of A3AR knockout mice have indicated that activation of the A3AR is 
able to inhibit LPS-induced TNFa production (Salvatore et al., 2000). This is
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supported by reports that treatment with an A3 AR agonist was shown to 
decrease inflammatory cell infiltration into the colon and reduce cytokine and 
chemokine levels in mice models of colitis (Mabley et a!., 2003). In contrast, 
A3AR activation in basophils and mast cells is able to stimulate degranulation 
and the resulting bronchospasm that leads to asthma (Nagano et al., 2000; 
Tilley et al., 2003). It has also been reported that the A3AR has a pro- 
inflammatory role as inflammation was greatly reduced in A3 AR knockout mice 
when compared to their wild type littermates (Wu et al., 2002). However due to 
the species-specific differences in the pharmacology of the A3AR between 
rodents and humans, it is unclear whether these data can be relied upon to 
reflect the signalling responses in humans.
1.9.4 Anti-inflammatory Effects of AzaAR Activation
In contrast to the other ARs, multiple in vivo and in vitro studies show a potent 
anti-inflammatory effect of the AzaAR, It was reported In 1989 that AzaAR 
activation could inhibit superoxide release from guinea pig and human 
eosinophils stimulated with opsonised zyosan (Yukawa et al., 1989). Further 
studies by Salmon and Cronstein, (1990), reported that the A zaAR selective 
agonist NECA could inhibit Fey R-mediated phagocytosis and superoxide 
generation in polymorphonuclear leukocytes (PMN) whereas the AR agonist 8 - 
p-sulphenyltheophylline blocked this effect. It has also been reported that a 
decrease in the adhesion of fMLP-induced PMN to endothelial cells was 
detected using concentrations of adenosine and NECA sufficient to inhibit the 
generation of reactive oxygen species (ROS) (Cronstein et al., 1992). Studies 
in neutophils have indicated that this reduction was due to the inhibition of aiviPz 
integrin expression (Wollner et al., 1993).
As mentioned earlier, the anti-inflammatory effect of the folate antagonist 
methotrexate is also adenosine dependent (Chan and Cronstein, 2002). It has 
been shown that injection of low concentrations of methotrexate can reduce 
leukocyte accumulation in carrageen-inflamed air pouches. This was found to
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be due to the accumulated presence of adenosine following up-regulation of the 
adenosine transporter, in splenocytes (Cronstein, 1994). During the same 
study it was also found that inhibition of adenosine kinase could reduce 
leukocyte accumulation, an effect that was completely reversed by co-injection 
of adenosine deaminase.
The development of A2aAR gene-deficient mice has provided the most valuable 
tool in studying the anti-inflammatory effects of the AsaAR and have established 
the critical role of these receptors in several models of immune-mediated tissue 
damage in vivo (Ledent et al., 1997; Ohta and Sitkovsky, 2001). The absence 
of A2aARs on immune cells means that the accumulation of extracellular 
adenosine in inflamed areas is not able to trigger the production of intracellular 
cAMP, allowing the uninhibited and uniterupted activities of activated immune 
cells and for continued tissue damage (Sitkovsky et al., 2004). It has also been 
reported that the A2aAR has a role in wound healing as mice lacking the A2aAR 
form less dense granular tissue and fewer blood vessels during wound repair 
and surprisingly accumulate fewer leukocytes in response to inflammatory 
stimuli (Montesinos et al., 2002).
Due to these findings, the development of selective A2aAR agonist is of great 
interest and many groups have successfully synthesised such compounds and 
demonstrated their anti-inflammatory potential (Lappas et al., 2005). Most 
A2aAR selective agonists are 2-substitutions of the non-selective AR agonist 
NECA and include CGS21680 (Hutchison et al., 1989), HENECA (Cristalii et al., 
1992), ATL-146e (Sullivan et al., 2001) and MRE-0470 (Glover et al., 2001). 
The selective activation of the A2aAR has been shown to have significant 
protective effects in several models of inflammation causing a decrease in 
neutrophil transmigration into the cerebrospinal fluid in patients with endotoxin 
stimulated meningitis and attenuate the inflammation induced increase in the 
blood-brain barrier permeability (Sullivan et al., 1999), inhibition of oxygen 
radical production (Thiel et al., 2003) and inhibition of cytokine production such
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as TNFa (Majumdar and Aggarwal, 2003). In addition, ATL-146e reduces joint 
destruction caused by septic arthosis and CGS 21680 can regulate HIV-1 
transactivation regulating protein (Tat)-induced inflammatory responses (Cohen 
et al., 2004; Fotheringham et al., 2004).
The consistent anti-inflammatory role for A2aAR signalling in a variety of 
different models of inflammation indicates a possible common mechanism of 
action. Various studies have shown that A2aAR activation can inhibit the 
expression of pro-inflammatory cytokines (Bouma et al., 1996; Majumdar and 
Aggarwal, 2003) suggesting that this inhibition may occur at the level of 
transcription via a decreased accumulation of nuclear NFkB (Sands et al., 
2004). The aim of this project was to determine where in the NFkB signalling 
pathway the A2aAR was exerting its effects and also compare the effects of 
A2aAR on certain NFkB regulated proteins involved in inflammation. The 
dissections of the pathways involved could lead to more specific drug design 
that may benefit a wide range of pro-inflammatory diseases.
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Chapter 2 
Materials and Methods
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2.1 Chemicals and Suppliers
All reagents were of the highest grade commercially available and obtained 
from the following suppliers:
Abeam Ltd., Cambridge
Rabbit Anti-CREB (cat # ab3419), Rabbit Anti-Sp1 (cat # ab13370-50), Anti- 
glyceraldehyde-3-phosphate dehydrogenase (GAPDH ) (cat # ab8243)
Amersham Biosciences AB, SE-751 84, Uppsala, Sweden.
Glutathione-Sepharose beads™ 4B
Alexis Biochemicals, San Diego, CA92121/ÜSA
Rabbit Anti-COX-2 (cat #210-712-1), Mouse Anti-COX-1 (cat #804-030-0500)
Assay Designs, 800 Technology Drive, Ann Arbour, Ml 48108/USA
Correiate-EIA™ 6 -keto-prostaglandin Fia Enzyme Immunoassay Kit (cat # 900- 
004), Correlate-EIA™ prostaglandin E2 Enzyme Immunoassay Kit (cat # 900- 
001)
BioRad Laboratories Ltd, Maylands Avenue, Hemel Hemstead
Protein assay dye reagent concentrate
BDH Laboratory Supplies, Poole BH15 1TD
Ammonium persulphate (APS), acetic acid, isopropylalcohoi, methanol, 
potassium chloride, potassium hydroxide, sodium chloride
Cambrex BioScience Wokingham Ltd., BioWhittaker House, Workinghom, 
Berkshire
Endothelial Basal Media-2 ™, Singlequots™ (foetal bovine serum (FB8 ), 
hydrocortisone, fibroblast growth factor-B (hFGF-B), vascular endothelial growth
57
factor (VEGF), insulin-like growth factor-1 (IGF-1), ascorbic acid, epidermal 
growth factor (hEGF), gentamicin sulphate and amphotericin-B (GA-1000) and 
heparin), human umbilical vein endothelial cells (HUVEGs), SeaPlaque ® 
agarose, phosphate-free Dulbecco’s modified Eagle’s medium (DMEM), cell 
culture grade phosphate-buffered saline (PBS)
Calbiochem-Novabiochem (UK) Ltd., Nottingham
Forskolin, 4-(4-Fluorophenyl)-2-(4-methylsulfinylphenyl)-5-(4-pyridyl)1H-
imidazole (SB203580), pyrrolidinedithiocarbamate (PDTC), bisindolylmalemide 
1 (BIM), emitine dihydrochloride, rolipram, 1,4-Diamino-2,3-dicyano-1,4-b/s(2- 
aminophenylthio)butadiene (U0126)
Cell Signalling Technology, Beverley, MA, U.S.A.
Mouse anti phospho-kB-a (Ser 32/36) (cat # 9246), rabbit anti-MEK 1/2 (cat # 
9122)
Duchefa Biochemie, Haarlem, Netherlands
Yeast extract, tryptone, microagar
Finnzymes Oy, Keilaranta 16 A, 02150 Espoo Finland
DyNAmo™ SYBR® green qPCR kit
Fisher Scientific, Loughborough, Leicestershire
4-2-hydroxyethl-1-piperazineethanesulphonic acid (HEPES), sodium dodecyl 
sulphate (SDS), ethylenediaminotetra-acetic acid (EDTA), dimethyl sulphoxide 
(DMSO), glacial acetic acid, ethidium bromide solution, glycine, ethanoi, 
concentrated hydrochloric acid, sodium hydroxide, Tris (hydroxymethyl)- 
aminomethane (TRIS) base, sodium carbonate, sodium hydrogen carbonate, 
sodium di-hydrogen ortho-phosphate, di-sodium hydrogen ortho-phosphate, 
boric acid, chloroform, sucrose
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GIBCO BRU Life Technologies, Paisley
Lipofectamine, OptiMEM
Inverclyde Biologicals, Strathclyde Business Park, Bellshill, Lanarkshire, 
UK
Protran nitrocellulose Schleicher and Schuell membrane (0.2pim pore size)
Melford laboratories, Chelsworth, Ipswich, Suffolk, UK
Dithiothreitoi (DTT), isopropyl-p-D-thiogalactopyranoside (IPTG)
Molecular Probes, Invitrogen Ltd, Inchinnan Business Park, Paisley, UK
Alexa Fluor® 594 goat anti rabbit IgG (cat # A-11037)
New England Biolabs Inc., Beverley, MA U.S.A
Pre-stained protein molecular weight markers (ranging from 6.5-175kD), 
restriction enzymes Pmel, Pad
Novagen, Merck Biosciences LTD. Nottingham NG9 2JR, UK
Gene Juice
Perkin-Elmer Life and Analytical Sciences, Via Tiepolo, Monza, Italy
Enhanced chemiluminescence (ECL) reagents
Pierce, Rockford, IL, U.S.A.
Western Blot Stripping Solution, Slide-A-Lyzer ® Dialysis Cassette (0.5-3ml 
capacity)
Promega, Southhampton UK
Promega ™ Wizard Plus SV DMA mini-prep kit, AMV reverse transcriptase, 
ribonuclease inhibitor, oligo dT 15 primer, Taq DMA polymerase, T4 Ligase
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Qiagen, Crawley, West Sussex.
DNA plasmid maxi-prep kit
R&D systems, INC.
Sheep anti-human VCAM-1 (cat # AF809)
Reidel-de Haen, Seezle, Germany
Glycerol, calcium chloride
Roche Diagnostics GmbH, 68298 Mannheim, Germany
DIG Gel Shift Kit, 2“^  ^Generation, Nylon membranes - positively charged
Santa Cruz Biotechnology, California, USA
Rabbit anti-lxB-a (S-21; cat # sc371. Sheep anti-Cdc42 (cat # sc6083), NFkB 
consensus oligonucleotide (cat # sc2505), mouse anti-Lyn (H-6 ) (cat # sc7274), 
rabbit anti-hcBs (cat# sc7155), rabbit anti-NFicB p65 (cat# sc109)
Serotec, Kindiington, Oxford, UK
Mouse anti human CD62E/GD62P (E-selectin) (cat # MCA883)
Sigma-Aldrich Company Ltd., Poole, Dorset
Leptomycin B, recombinant human interferon-y (IFNy), human tumour necrosis 
factor-a (TNFa), Escherichia coli 0111 :B4 lipopolysaccharide (LPS) Triton X- 
100, Tween-20, soybean trypsin inhibitor, benzamidine, bovine serum albumin 
(BSA), 30% (w/v) acrylamide / 0.8% (w/v) bis-acrylamide, horseradish 
peroxidase (HRP)-conjugated anti-mouse IgG, horseradish peroxidase (HRP)- 
conjugated anti-rabbit IgG, horseradish peroxidase (HRP)-conjugated anti­
sheep IgG, horseradish peroxidase (HRP)-conjugated anti-goat IgG, thimerosal, 
bromophenol blue, agarose, ampicillin, paraformaldhyde, bichinchonic acid di­
sodium salt (BCA), N,N,N',N'-tetramethylethylenediamine (TEMED), 
phenlymethylsulphonyl fluoride (PMSF), foetal bovine serum (FBS), cell culture
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grade trypsin, endothelial grade trypsin, (0.5g/L), penicillin/streptomycin, L- 
Glutamine, 3,3'5,5'-tetramethylbenzidine (TMB), sodium fluoride, sodium 
periodate, sodium potassium tartrate, deoxycholic acid (sodium salt), poly-D- 
lysine, Trizol Reagent, lysosyme, sodium orthovanadate, NP-40, diethyl 
pyrocarbonate (DEPG), phenol:chloroform:isoamyl alcohol (25:24:1;v/v/v), 
ethylene giycol-bis (2-aminoethylether)-N,N,N',N'-tetraacetic acid (EGTA), 
brilliant blue G
Stratagene, Gebouw California, 1101 CB Amsterdam, The Netherlands
BJ5183-AD-1 electroporation-competent bacterial cells
Thermo Electron GmbH, D89077 Dim, Germany
Oligonucleotide primers (see Table 2.3.1 for details)
pGEX/importin a1, 3, 5 and 7 constructs (Fagerlund et al., 2005) were gifted 
from Dr Riku Fagerlund, Dept, of Viral Diseases and Immunology, National 
Public Health Institute, Helsinki, Finland.
Arkalone P was kindly gifted from Dr Ian Salt, Division of Biochemistry and 
Molecular Biology, IBLS, University of Glasgow, UK.
Sheep anti-p50/p105 polyclonal antibody (Hay and Nicholson, 1993) was kindly 
gifted from Prof. RT Hay, Division of Gene Regulation and Expression, School 
of Life Sciences, University of Dundee, UK.
Dried skimmed milk powder was obtained from a variety of commercial sources.
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2.2 Cell Culture and Transfection Methods
2.2.1 Cell Maintenance
All cell types were grown at 37°C In a humidified atmosphere containing 5% 
(v/v) CO2.
HUVEGs were maintained in endothelial basal medium supplemented with 2% 
(v/v) foetal bovine serum, 0.04% (v/v) hydrocortisone, 0.4% (v/v) fibroblast 
growth facto r-B (hFGF-B), 0.1% (v/v) vascular endothelial growth factor 
(VEGF), 0.1% (v/v) insulin-like growth factor-1 (IGF-1), 0.1% (v/v) ascorbic acid, 
0.1% (v/v) epidermal growth factor (hEGF), 0.1% (v/v) gentamicin sulphate and 
amphotericin-B (GA-1000), and 0.1% (v/v) heparin. Gells were routinely sub­
cultured only until passage 6, as HUVEGs have been shown in cell culture 
conditions to become less responsive over time to cytokines thereby changing 
the regulation of expression of different cellular proteins such as adhesion 
molecules (Muller et al., 2002). When confluent, cells were washed in 2 x 20ml 
sterile PBS (phosphate-buffered saline) and then treated briefly with 2ml 
endothelial grade trypsin in order to detach the cells. The trypsin was then 
neutralised with 10ml of spent media and the contents transferred to a 50ml 
centrifuge tube. Gells were centrifuged for 5 min at 200 x g and the supernatant 
was discarded. The cell pellet was gently resuspended in medium at a dilution 
factor suitable to establish a cell density which could be reliably counted using a 
standard haemocytometer (typically 1:10). Wells were then seeded at an 
appropriate level according to the analysis performed as indicated in the figure 
legends. Typically a 6-well plate would be seeded with 4x 1 0^  cells /well and a 
10cm dish would be seeded with 8x10"^ cells, ready for infection the following 
day. A minimum of 1 x 10"^  cells was used to maintain the cell line in a fresh 
150cm^ tissue culture flask to which 11ml of fresh medium was added.
Human embryonic kidney 293 cells (HEK293) were maintained in DMEM 
supplemented with 10% (v/v) FBS, ImM L-glutamine, 100 un its/m I penicillin and
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100pg/ml streptomycin. Confluent monolayers were washed in 2 x 20ml sterile 
PBS and then treated with 1ml trypsin. Cells were then returned to the 
incubator for a few minutes before the flask was disrupted to dislodge the cells. 
Cells were then typically diluted 1:8, 7ml of which was used in experimental 
analysis and of which 1ml was used to maintain the cells to which 9ml of fresh 
medium was added.
2.3 Molecular Biology
2.3.1 Preparation of antibiotic agar plates
LB agar (1% (w/v) bactotryptone, 0.5% (w/v) yeast extract, 1% (w/v) sodium 
chloride, 1.5% (w/v) agar) was prepared, autoclaved and allowed to cool before 
the addition of ampicillin antibiotic at the final concentration of 50jig/ml. The 
liquid LB agar was then poured into 90mm-diameter Petri dishes, allowed to 
solidify, then left to sweat overnight at room temperature to rid the plates of 
excess moisture. Plates were then stored at 4°C for a maximum of 2 weeks 
until required.
2.3.2 Transformation of competent E.coli (XL1 Blue and BL21 strains)
Approximately 30-50ng of plasmid DNA was added to a plastic 13ml Falcon 
round-bottomed tube on ice. Once thawed 50)il /tube of competent E.coli was 
immediately added and the mix incubated on ice for 30min. The tubes were 
heat shocked at 45°C for 45sec then immediately returned to ice. 0.5ml of LB 
per tube was added and the tubes shaken at 37°C for 1 hour. 0.1ml of the 
transformation mix was then plated out onto LB-Amp plates (see section 2.3.1) 
and incubated overnight at 37°C.
2.3.3 Preparation of plasmid DNA
Transformed colonies picked from agar plates using sterile pipette tips, were 
used to inoculate 10ml of LB broth supplemented with 50pg/ml ampicillin, and 
grown in a shaking incubator at 37°C overnight. Plasmid DNA was then
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isolated using the Promega Wizard plus SV miniprep purification system as per 
the manufacturer’s instructions. For larger quantities of plasmid DNA, the initial 
10ml culture was then used to inoculate a 500ml culture containing ampicillin 
and grown overnight. Plasmid DNA was isolated using the Qiagen Maxi Kit 
system as directed by the manufacturer’s instructions. The concentration of 
double stranded DNA obtained was calculated based on the assumption that 1 
absorbance unit (A260) is equivalent to 50|ag/ml of double stranded DNA. An 
absorbance ratio (Aaeo/ A280) greater than or equal to 1 indicated good quality 
DNA that was free of contamination with protein.
2.3.4 Digestion of plasmid DNA
1-2p,g of purified plasmid DNA was digested in a sterile microfuge tube 
containing the appropriate enzyme buffer and 2-4 units of enzyme as per the 
manufacturer’s instructions. In certain cases it was necessary, due to 
incompatible buffer restrictions, to purify the linearised plasmid DNA from the 
first digestion, before digestion with the second enzyme and buffer. This was 
achieved by phenol extraction and ethanol precipitation. The volume of 
digested DNA was made up to 150pl with endonuclease free H2O. In the fume 
hood, 50pl phenohchloroform was added, the microfuge tubes were well shaken 
and incubated at room temperature for 5 min. The microfuge tubes were well 
shaken prior to centrifugation at 13,000g for 5 min at room temperature. The 
aqueous upper layer was carefully pipetted into a fresh microfuge tube and 
centrifuged for a further 5 min at 13,000g at room temperature. The 
supernatant was transferred to a fresh microfuge tube and 1/10 volume of 3M 
sodium acetate and 3 volumes of ice-cold absolute ethanol were added to the 
sample. Following 30 min incubation on ice, samples were centrifuged at 
13,000g for 30 min at 4°C and the supernatant removed. The DNA pellet was 
washed once in 50pl of 70% (v/v) ethanol, centrifuged at 13,000g for 5 min at 
4'^C and air-dried. Restriction fragments were resolved on a 1% (w/v) agarose 
gel containing 2.5pg/ml ethidium bromide run at 75mV for 20-30 min in TAE 
buffer pH 8.0 (40mM Tris-acetate, ImM EDTA, and 0.1% (v/v) glacial acetic
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acid). Samples of the restriction fragments were resolved on a 1% (w/v) 
agarose gel containing 2.5pg/ml ethidium bromide run at 75 mV for 20-30 min in 
TAE buffer (40mM Tris-acetate, 1mM EDTA, and 0.1% (v/v) glacial acetic acid).
2.3.5 Preparation of RNA
10cm dishes were seeded with HUVEGs at a density of 8 x 10^ cells/dish and 
were treated the next day as indicated in the figure legends. Following 
treatment, the dishes were placed on ice and the cell monolayer washed twice 
with ice-cold PBS after which all PBS was drained off. The cells were then 
harvested by re-suspension into 1ml Trizol and stored in a cryovial at -80°C 
overnight. Samples were defrosted at room temperature and briefly pulsed to 
prevent phenol splashes. 0.2ml of chloroform was added and the samples were 
shaken vigorously by hand for 15 seconds. Following an incubation at room 
temperature for 3min, the samples where then centrifuged at 12000g for 15min 
to separate the RNA, DNA and protein fractions. The upper aqueous phase 
was carefully pipetted into a fresh microfuge tube and the RNA precipitated by 
mixing with 0.5ml isopropylalcohoi and incubation at room temperature for 
lOmin. Samples were then centrifuged at 12000g, room temperature for lOmin, 
the supernatant was discarded and the pellet was washed with 75% (v;v) 
ethanol and vortexed. Samples were then centrifuged at 12000g, room 
temperature for 5min. The supernatant was discarded and the pellet left to air- 
dry for 5-10min. Once dry the pellet was resuspended in SOpI RNAse free 
water and incubated for 10min at 60°C to ensure the RNA was completely 
dissolved. The concentration of RNA obtained was calculated based on the 
assumption that 1 absorbance unit (A260) is equivalent to 40jig/ml of RNA. An 
absorbance ratio (A260/ A280) equal to 1.8 indicated RNA free from protein and 
DNA contamination. RNA was stored at -80°G until analysis.
2.3.6 Reverse transcription
First strand cDNA was synthesised from RNA (section 2.3.6) using AMV 
reverse transcriptase. 2pg RNA was made up to 15j.il with DEPG-treated water
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and 300ng of oligo dTis primer. Samples were heated at 70°C for 3 minutes 
and then immediately placed on ice to cool. A mixture of 5x reverse 
transcriptase buffer (supplied with kit) and dNTPs was made and added to each 
reaction to give final concentrations of 50mM Tris-HCL (pH 8.3 @ 25°C), 40mM 
KCL, 8.75mM MgCL, 10mM DTT, 0.1 mg.ml acetylated BSA and 1mM of each 
dNTP. 20U Ribonuclease inhibitor and 50U AMV reverse transcriptase were 
then added, the samples mixed by pipetting and incubated at 42°C for 3hrs. 
The cDNA generated was stored at -20°C until PCR analysis was performed.
2.3.7 qRT-PCR of prepared cDNA
Real-time PCR was carried out using DNA Engine Opticon 3™ system (MJ 
Research Inc.). Prior to this, standard PCR has been carried out to confirm that 
primers caused amplification of only one product of the correct size (human 
COX-2 amplicon size of 290bp and human GAPDH amplicon size of 150bp;). 
cDNA equilivant to 200ng total RNA was amplified using DyNAmo™ SYBR® 
green qPCR kit (Finnzymes). The kit provides a 2x master mix comprising 
modified Thermus brockianus DNA polymerase, SYBR Green 1 fluorescent 
dye-optimised PCR buffer, 5mM MgCL and dNTP mix. Data were analysed 
using the Opticon analysis software.
For each run, a PCR master mix was prepared, which included primers for the 
gene of interest (final concentration of IpM for both GAPDH and COX-2; Table 
2.3.7.1) with the master mix from the DyNAmo ™ SYBR® green kit. This was 
pipetted into a 96-well plate (20pl per well) and appropriately diluted cDNA 
samples (5|il) were added to give a final volume of 25(il. All samples were run 
in quadruplicate and standards in duplicate. The Opticon was preheated to 
95°C to minimise the risk of primer-dimer formation, and a denaturing step 
followed of lOmin at 95°C. Each cycle consisted of the following: an 
amplification step of 95'^C for 10 seconds, followed by 60°C for 2Qsec, an 
extension step of 72°C for 20 seconds, a step to ensure primer dimers were
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melted at 72°C for 20 seconds, followed by a fluorescence reading. This was 
repeated a further 39 times, to give a total of 40 cycles. Melting curves were 
constructed by taking readings every 0.2°C from 65°C to OS'^ C. The cooling 
step consisted of the plate being held at 4°C until the end of the run.
2.3.7.1 COX-2 and GAPDH primer details
Target Protein Sequence (5’ -  3') Primer
position
COX-2 (forward) GCC CAG CAC TTC ACG CAT CAG 659-679
COX-2 (reverse) AGA CCA GGC ACC AGA CCA 
ACC
AAG 925-948
GAPDH GAA GGT GAA GTG CGG AGT C 1245-1260
(forward)
GAPDH GAA GAT GGT GAT GGG ATT TC 1445-1464
(reverse)
To determine efficiency of the PCR reaction and to enable relative quantification 
of genes, a standard curve was performed. For each analysis, a standard curve 
was constructed using serial log dilutions of cDNA from within the experiment 
and the sequence of interest was plotted so that cycle number correlated with 
the amount of product formed after each cycle. The first standard was made 
from 5|il of cDNA from the sample that was expected to have the highest quality 
of the gene of interest present (e.g. HUVECs stimulated with 10ng/ml TNFa for 
10hrs). The relative COX-2 mRNA expression was normalised to GAPDH 
mRNA expression, which was also quantified by real-time PCR as described for 
COX-2.
2.3.8 Propagation and purification of human A2A adenosine receptor 
adenovirus
In order to express myc-tagged human A2aAR in HUVECs, an adenoviral gene 
transfer approach was used. This is because it achieved much greater
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expression when compared with commercially available transfection reagents, 
electroporation or calcium phosphate-mediated transfection methods (Teifel et 
al., 1997). The propagation and purification of the Ad-A2AAR/GFP and Ad-GFP 
were carried out in accordance with the protocols of Nicklin et al. (2001) using 
the Ad Easy system described by (Fie et al., 1998).
Lab stocks of the pAdTrackCMV/mycA2AAR shuttle construct (Sands et al., 
2004) was cut at the Pmel site within the vector which exposed the inverted 
terminal repeats, and co-transformed with the viral backbone construct 
pAdEasyl into E.coli rec+ strain BJ5183 by electroporation (2kV, 25jiF, 200Q). 
Recombination-positive clones identified by growth on ampicillin plates were 
screened by digestion with Pmel yielding a large (~30kb) fragment and a 
smaller (3-4.5Kb) fragment. These colonies were then expanded and the cDNA 
isolated. The plasmid cDNA was then linearised with Pad and 4.5pg was 
transfected using 15jil of GeneJuice onto low-passage HEK293 cells in 25cm^ 
tissue culture flasks. The presence of the gene encoding GFP in a separate 
open reading frame allows monitoring of viral expression by fluorescence 
microscopy. 6 days post infection, cells were removed from the flask and 
collected in a sterile centrifuge tube and pelleted by centrifugation at 200 x g for 
5 min at room temperature. The pellet was resuspended in 1.5ml of cold sterile 
PBS and transferred to a cryovial. The cells were then disrupted by four 
freeze/thaw cycles in a dry ice/methanol bath. Cleared lysate from this was 
then used to infect two T-150 flasks of 50-60% confluent HEK293 cells, grown 
in DMEM medium. Virus particles from these cells were prepared three days 
later as before, and used to infect a larger scale culture of 20 x T-150 flasks of 
FIEK293 cells. From this large scale preparation, virus was isolated as per the 
method of Nicklin and Baker (2001). Briefly, dislodged cells were pooled and 
pelleted by a brief centrifugation at 250g for 10 min at room temperature. The 
supernatant was then transferred to sterile vials for future infection. The pellet 
was resuspended in 1.5ml of sterile PBS and subjected to four freeze/thaw 
cycles in order to lyse the cells and release the virus particles. The preparation
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was then added to a discontinuous caesium chloride gradient set up in a 13ml 
sterile ultracentrifuge tube, in order to separate intact virus particles from other 
cellular debris and empty viral capsids. Turbulence caused by friction under 
braking would disrupt the separated adenoviral layer so the samples were 
subject to centrifugation at 100,000g for 90min at 8°C with zero deceleration. 
The opaque adenovirus band was then isolated by syringe extraction and 
added into a Slide-A-Lyser that allowed efficient overnight dialysis at 4°C in 1 L 
of dialysis buffer (51.2jiM  Tris, lOpM EDTA, 15mM NaCI) which was changed 
three times. The dialysed adenovirus was then diluted in a 1:1 (v/v) ratio with 
sterile virus storage buffer (lOmM Tris-HCI (pH8), lOOmM sodium chloride, 
0.1% (w/v) BSA, 10% (w/v) glycerol) and stored at -80“C in 40pl aliquots.
2.3.9 Preparation of GST-lmportin a 3-immobilised Sepharose beads
10ml of LB Amp broth (LB broth supplemented with 50jig/ml ampicillin) was 
inoculated from a glycerol stock of BL21 E.coli transformed with pGEX importin 
a-3, which was then grown overnight, shaking at 37°G. This starter culture was 
then used to inoculate 400ml LBAmp, which was grown shaking at 200rpm for 5 
hours (or until OD6oo=0.3 or greater) at 21 °C. The cells were then induced by 
addition of IPTG to a final concentration of ImM, then grown shaking at 200rpm 
for 4 hours at 21 °C. The bacteria were then harvested by centrifugation at 
6700g for 15 minutes, the supernatant discarded, cells resuspended in 20ml 
Lysis Buffer (50mM HEPES, pH7.4, 150mM NaCI, 5mM EDTA and 1% (v/v) 
Triton-X-100) and incubated at room temperature for SOmins. The sample was 
then probe sonicated to ensure efficient cell lysis and then centrifuged at 
27000g for 30 minutes to pellet insoluble material. The cleared lysate was then 
added to 0.6ml 50% (v/v) glutathione-Sepharose bead suspension and placed 
on a rotating wheel at 4'^C for 1 hour to allow the fusion protein to bind. The 
beads were then washed three times with 10ml PBS, following the final wash, 
resuspended in 50% (v/v) glycerol in PBS supplemented with protease 
inhibitors (O.ImM PMSF, lOjig/jil soybean trypsin inhibitor and 10jig/|il
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benzamidine) and stored at -20°C. The same procedure was utilised for the 
preparation of GST-immobilised Sepharose beads which was used as a control.
2.3.10 SDS protein assay for immobilised GST Fusion proteins on 
Sepharose Beads.
20jil of prepared bead suspension was pippeted into a microfuge tube, briefly 
centrifuged for 20 sec at 4°C and supernatant removed using a 1ml syringe. 
The protein was eluted from the beads by the addition of 20|iil of 2% SDS 
sample buffer and incubated at 37°C for 30min. Sample was briefly centrifuged 
at room temperature and the protein containing supernatant was removed via a 
Hamilton syringe into a fresh microfuge tube. Standard concentrations of BSA 
ranging from 0.2-2jig and 5jil and 10|il of eluted protein was analysed by SDS- 
PAGE using a 10% (w/v) resolving gel. The gel was stained with Coomassie 
stain (3mM Coomassie Brilliant Blue G, 45% (v/v) methanol, 10% (v/v) acetic 
acid) for 1hr and washed overnight in destain (50% (v/v) methanol, 5% (v/v) 
acetic acid). The stained gel was then scanned and the density of the protein 
bands were used to determine a straight line from which the concentration of 
protein immobilised on GST-Sepharose beads could be determined.
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2.4 Laboratory Techniques
2.4.1 Protein concentration determination using the bicinchoninic acid 
(BCA) protein assay.
Duplicate 0.01ml samples of known BSA standards in the range 0-2 mg/m I and 
unkown protein samples were added to a 96-well plate. 0.1ml BCA solution 
(1% (w/v) 4,4 dicarboxy-2,2 biquinoline disodium salt, 2% (w/v) sodium 
hydroxide, 0.95% (w/v) sodium bicarbonate pH 11.25, 0.08% (w/v) copper (II) 
sulphate) was then added to each well. Protein concentration-specific reduction 
of Cu^^ to Cu^^ allows the bicinchoninic acid sodium salt to bind the Cu^ "" ion 
forming an intense purple colour allowing measurement of the absorbance at 
492nm. Colour was therefore allowed to develop at room temperature for 
30min and the absorbance of the standards was used to determine a straight 
line from which unknown protein concentrations could be calculated (Smith et 
al., 1985).
2.4.2 Protein concentration determination using Bradford’s reagent
Duplicate 0.01ml of known BSA standards in the range of 0-2mg/ml and 
unknown protein samples were added to a 96-well plate. 0.01ml of Bradford’s 
reagent was then added to each well. Binding of protein to the dye component 
of the Bradford reagent. Brilliant Blue G, causes a shift in the absorption spectra 
of the dye from 465nm to 595nm. Colour was therefore allowed to develop for 
10-20 min and the ODeoo of the standards and samples was measured. The 
absorbance of the standards was used to determine a straight line from which 
unknown protein concentrations could be calculated.
2.4.3 Discontinuous SDS-PAGE and immunobiotting
Samples prepared for SDS-PAGE were equalised for protein using the 
bicinchonic acid assay described in Section 2.4.1. Pre-strained protein markers 
(Invitrogen Rainbow Markers, range 6.5-175kDa) in sample buffer (50mM Tris 
(pH 6.8), 10% (v/v) glycerol, 12% (w/v) SDS, 0.0001% (w/v) of bromophenol
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blue) were prepared in the electrophoresis to determine protein molecular 
mass. 30|Lil of sample, equalised for protein and volume, was then subjected to 
discontinuous SDS-PAGE using a 6 cm 10% (w/v) polyacrylamide resolving gel 
(10% (w/v) acrylamide, 0.3% (w/v) bisacrylamide, 0.4M Tris (pH 8.8), 0.1% 
SDS, 3% (v/v) glycerol, 0.01% (w/v) ammonium persulphate and 0.001% (v/v) 
TEMED) and a 2cm 3% (w/v) stacking gel (3% (w/v) acrylamide, 0.1% (w/v) 
bisacrylamide, 0.1 M Tris (pH 6.8), 0.1% SDS, 0.01% (w/v) ammonium 
persulphate and 0.001% (v/v) TEMED). Electrophoresis was carried out using 
BioRad Mini-Protean III gel electrophoresis systems in running buffer (27.4mM 
Tris, 0.19M glycine, 0.1% (w/v) SDS) at 150 V until the bromophenol blue dye 
front reached the end of the gel. Proteins were then transferred 
electrophoretically onto a nitrocellulose membrane at 400mA for 45 min in 
transfer buffer (24.7 mM Tris, 0.19M glycine in 20% (v/v) methanol). The 
nitrocellulose membrane was then removed, trimmed and briefly washed in 
PBS before incubating for Ih r at room temperature in Blotto (5% (w/v) skimmed 
milk, 0.1% (v/v) Tween-20 in PBS) to block non-specific binding of antibody. 
The membrane was then briefly washed in PBS before being transferred to a 
plastic bag containing 2ml of the relevant primary antibody diluted in Blotto as 
indicated in the Figure Legends. This was incubated at 4°C overnight on a 
rotating platform. The membranes were then rinsed briefly in PBS before being 
washed three times in Blotto for 10 min. Membranes were then washed again 
briefly in PBS before being transferred to a bag containing 2ml of the 
appropriate HRP-conjugated secondary antibody in Blotto. This was then 
incubated for Ih r on a rotating platform at room temperature. The membrane 
was then washed three times for lOmin in Blotto and then washed a further 
twice in PBS for lOmin, Membranes were then exposed to an enhanced 
chemiluminescence procedure. HRP-specific oxidative degeneration of the 
substrate from the bound secondary antibody causes emission of light at 
428nm, detected by Kodak X-OMAT blue X-ray film to visualise immunoreactive 
proteins. Occasionally a higher stringency Blotto was required to minimise non­
specific reactivity and provide clear visualisation of specific immunoreactive
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proteins. In this case Blotto/Triton (5% (w/v) skimmed milk, 0.2% (v/v) Triton X- 
100 in PBS) was used to incubate the primary antibody and subsequent 
washes and High Detergent Blotto (10% (v/v) Blotto 1.02% (v/v) Triton X-100 
and 0.1% (w/v) SDS in PBS) was used to dilute the secondary antibody.
2.4.4 Determination of cell surface protein expression by enzyme-linked 
immunoabsorbant assay (ELISA).
2 X lO'  ^ HUVECs/well were seeded in a 96-well plate. The following day, cells 
were treated with the appropriate concentrations of cytokine/lipopolysaccharide 
(LPS) for the time indicated in the Figure Legends. The assay was stopped by 
transferring the plate to ice and cells were washed gently three times with 200|il 
PBS. Cells were then fixed with 0.1ml of 4% (w/v) paraformaldehyde in 5% 
sucrose (w/v) in PBS (pH 7.2), covered and incubated overnight at 4°C. The 
following day, cells were washed gently three times with 200jil PBS and then 
incubated for 1hr at room temperature in 0.1% (w/v) BSA in PBS in order to 
block non-specific antibody binding sites. Cells were then washed gently three 
times with 200jil PBS before incubation with appropriate primary antibody at 
1:1000 dilution in PBS/0.1% (w/v) BSA for 2hr at room temperature. To assess 
non-specific binding, an antibody raised in the same species as the specific 
antibody was also used at 1:1000 dilution, (E-selectin -  Lyn (H-6), VCAM-1 -  
Cdc42) in wells treated in parallel. Cells were then gently washed three times 
with 200jil PBS before the addition of the appropriate HRP-conjugated 
secondary antibody at 1:1000 dilution in PBS/0.1% (w/v) BSA for Ih r at room 
temperature. Cells were then gently washed five times with 200jiil PBS, before 
the addition of lOOpl 3,3'5,5'-tetramethylbenzidine (TMB). The colour was 
allowed to develop for 5-15min at room temperature and the Aeoo determined 
using a plate reader.
2.4.5 Separation of Cytosolic and Nuclear fractions from treated HUVECs
1x10® cells were seeded out into 10cm dishes and then treated as described in 
the Figure Legends. Following cell treatments, the dishes were placed on ice.
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the cell monolayers were gently washed three times with ice-cold PBS, and 
scraped into 1ml PBS before transfer to a microfuge tube. The cell suspension 
was centrifuged at 14 x g for 4 min at 4°C and the supernatant removed. The 
pellet was resuspended in 400|il of Buffer A (lOmM HEPES, lOmM KCI, O.ImM 
EDTA, O.ImM EDTA ImM DTT, pH7.9 with KOH) and allowed to swell on ice 
for 15mins. 25|il of 10% (v/v) NP40 was then added and the mix vortexed. The 
microfuge tube was then pulse centrifuged in the micro centrifuge for lOsec and 
the cytosolic fraction (supernatant) carefully removed and stored in a chilled 
microfuge tube at -80°C. The pellet was washed four times with 400pl of Buffer 
A. Following the fourth wash, the pellet was resuspended in SOjil Buffer B 
(20mM HEPES, 450mM NaCI, 1mM EDTA, 1mM EGTA, ImM DTT, pH7.9 with 
NaOH), vortexed and incubated with shaking on ice for 15 min. The microfuge 
tube was then centrifuged at 10,000g for 15min at 4°C. The nuclear fraction 
(supernatant) was then transferred to a sterile chilled micofuge tube and stored 
at -80°C.
2.4.6 Electromobility Shift Assay (EMSA)
Nuclear fractions of treated HUVECs (section 2.4.5) were assayed for protein 
concentration using a Bradford Assay (as section 2.4.2) as the DTT present in 
Buffer B interferes with the BCA assay.
A double-stranded DNA probe (20ng/pl) containing the NFkB consensus 
sequence GGG GAC TTT CCC was used to detect any induced NFkB 
transcription factors. This procedure was undertaken utilising DIG Gel Shift Kit, 
(2"^ Generation) as per manufacturer’s instructions (Roche). In brief, lOOng of 
NFkB consensus sequence oligo was labelled, aliquoted and stored at -20°C. 
Nuclear fractions were equalised for protein content in a total volume of 5pl and 
bound to 8ng of the labelled probe. The samples were run on a non-denaturing 
6% (w/v) PAGE gel in 0.5 X Tris-borate-EDTA (TBE) buffer (44.5mM Tris, 
44.5mM boric acid, ImM EDTA, pH8.0), then transferred to a positively charged 
Nylon membrane, at 400mA for 45 minutes in 0.5 X TBE buffer. The membrane
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was then fixed by irradiation with UV light, blocked with kit blocking solution, 
probed with 75mU/ml anti-digoxigenin- alkaline phosphatase (Fab fragments 
congujated to AP) and the bands visualised by chemiluminescence detection.
2.4.7 Incident-light Fluorescence Microscopy
2x10® cells were seeded onto coverslips and then treated as described in the 
Figure Legends. Following cell treatments, cell monolayers were washed three 
times in 1.5ml PBS and then fixed in 1.5ml of 4% (w/v) paraformaldehyde in 5% 
(w/v) sucrose/PBS for lOmin. Cells were then washed in 1.5ml PBS and 
blocked in blocking solution (3% (w/v) skimmed milk, 0.15% (v/v) Triton X-100 
in PBS). The primary anti-MEKI/2 antibody was used at a 1:100 dilution in 
blocking solution and the Alexa 594-conjugated anti-mouse IgG was used at 
1:400 dilution in blocking solution. lOOp-l of antibody solution was then spotted 
onto Nescofilm and the coverslip placed cells down onto the antibody solution 
and incubated for 1hr at room temperature. Cells were then washed three 
times in PBS and then placed onto lOOpl of Alexa 594-conjugated secondary 
antibody on Nescofilm and incubated for 1 hr at room temperature. The 
coverslips were then washed three times in PBS prior to being thoroughly air 
dried and mounted onto microscope slides with 40% (v/v) glycerol in PBS.
Cells were observed using a Zeiss Axiovert 40 CFL microscope with HBO 50 
illuminator (Zeiss, Oberkochen, Germany) using a Zeiss Plan- x 20 lens. GFP 
was detected via 515-540nm band pass filter. Alexa-594 conjugated antibodies 
were excited at 542nm and detected with a long pass band filter at 590nm. The 
images were adjusted with Zeiss LSM software.
2.4.8 Determination of Prostaglandin concentration by enzyme-linked 
immunoabsorbant assay (ELiSA).
Prostaglandin E2 and prostacyclin concentration levels in spent media were 
determined by Correlate-EIA™ Enzyme Immunoassay Kit. Prostacyclin has a 
short half life of 60 minutes so it is typically monitored by measurement of 6-
75
keto-PGFia which is produced by non-enzymic hydration of prostacylin and has 
been shown to be stable (Ylikorkala and Makila, 1985). 2 x 10® HUVECs 
cells/well were seeded out into 1 2 -well plates and treated as described in the 
Figure Legends. Following cell treatment, the plates were placed on ice and 
the spent media removed to microfuge tubes and stored at -80°C. Samples 
were defrosted on ice and all ELISA reagents allowed to equilibrate to room 
temperature. The ELISAs were carried out as per manufactur’s instructions, 
using lOOjil of samples in duplicate and the plate read at A405 on a plate reader. 
The background reading from the lysates and the buffers were subtracted from 
the standards and test sample readings. From these readings a standard curve 
was produced using GraphPad Prism, from which the concentrations of 
Prostaglandin E2 or 6 -keto-prostaglandin Fi« were determined. These 
concentrations were then normalised to the control TNFa reading which was set 
at 100% and analysed using GraphPad Prism.
2.4.9 GST Pulldown Assay to detect importin a3-p65 interaction
8x10® HUVECs were seeded out into 10cm dishes which were then treated the 
following day as described in the figure legends. Following cell treatment, the 
dishes were placed on ice, the spent media removed and the cells washed 
twice with 10ml ice-cold PBS. The dishes were drained and the cells harvested 
in 250jil Lysis Buffer (50mM HEPES, pH7.4, 150mM NaCI, 5mM EDTA and 1% 
Triton-X-100) supplemented with 100)iM sodium orthovanadate and protease 
inhibitors (O.ImM PMSF, lOpg/jil soybean trypsin inhibitor and 10|ig/|Lil 
benzamidine) and transferred to a microfuge tube. The samples were placed 
on a rotating wheel at 4°C for 1 hr to ensure total lysis of the cells and then 
centrifuged at 20000g for 15 min. The soluble supernatant was transferred to a 
fresh microfuge tube and a BCA assay carried out to determine the protein 
concentration of the samples, (see Section 2.4.1). The samples were 
equalised for protein concentration and ~200jil was added to 5|Lig of GST- 
importin aS immobilised to glutathione-Sepharose beads and incubated on a
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rotating wheel at 4°C for 2hrs. The GST complexes were isolated by brief 
centrifugation and the supernatant discarded. The beads were then washed 
three times with 1mi lysis buffer. Bound proteins were eluted from the beads by 
the addition of 40jil electrophoresis sample buffer and incubation at 65°C for 15 
minutes. The eluate and lysates were analysed by SDS-PAGE using 10% (w/v) 
resolving gels, transferred to nitrocellulose membranes. Membranes were 
stained with ponceau strain to ensure equal levels of GST-fusion protein had 
been used during the pull-down. Membranes were then blocked with Blotto 
supplemented with 0.1% (v/v) Tween-20 (section 2.4.3). ImportinaS-bound p65 
was detected by immunobiotting with the appropriate primary antibody as 
described in the appropriate figure legends.
2.4.10 HUVEC membrane preparation and ^^ ®I-ZM241385 saturation 
binding
All procedures were on ice unless stated otherwise. Confluent 10 cm dishes of 
HUVECs were washed three times with cold PBS prior to scraping into 5 
ml/dish PBS. Following centrifugation at 200g for 2 min, the isolated ceil pellet 
was resuspended in 1 ml lysis buffer (10 mM sodium Hepes, pH 7.5, 5 mM 
EDTA) and lysed by 20 up-and-down strokes of a glass Dounce homogeniser. 
The membrane pellet was isolated by centrifugation at 48,000g for 15 min and 
initially resuspended in 0.2 ml binding buffer (50 mM sodium Hepes, pH 6.8, 10 
mM magnesium chloride). Following the removal of duplicate lOpI aliquots for 
protein determination, the membrane suspension was diluted to a final volume 
of 4 ml with binding buffer supplemented with 1 unit/ml adenosine deaminase 
prior to further homogenisation and immediate use in binding assays.
Binding studies were performed in duplicate in a 0.25 ml final volume containing 
0.15 ml membrane suspension, 50 |il ^^®I-ZM241385 (ranging from 0.25 to 4-8 
nM final concentrations, prepared and purified by high performance liquid 
chromatography to a specific activity of 2200 Ci/mmol by Dr Tim Palmer as 
described in Palmer et al., (1995) and 50 pi of either distilled deionised water or 
NECA at a final concentration of 50 pM (to define non-specific binding).
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Incubations were carried out with shaking for 1 hr at 37°C by which time 
equilibrium had been reached. Bound radioligand was isolated by rapid 
vacuum filtration over 0.3 % (v/v) polyethylimine-soaked glass fibre filters 
followed by three 3 ml washes with ice-cold binding buffer supplemented with 
0.03 %(w/v) CHAPS detergent to minimise non-specific binding. Following 
quantitation of filter-bound radioactivity using a gamma-counter, saturation 
curves were generated by fitting data to a one site hyperbola using Graphpad 
Prism software and from which Kd and Bmax values were derived.
2.4.11 Statistical Analysis
Statistical analysis was carried out using Student’s t-test using GraphPad Instat 
3 as indicated in the Figure Legends. Significance was assessed as p<0.05.
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Chapter 3
Effect of A2aAR gene transfer on the induction of 
infiammatory markers in HUVECs
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3.1 introduction
There is an obvious requirement to control prolonged or inappropriate 
inflammatory responses which contribute to the pathogenesis of many pro- 
inflammatory diseases such as ischemia-reperfusion injury (Sullivan et al.,
2000) and atherosclerosis (Greaves and Channon, 2002). Regulated 
interactions between endothelial cells and leukocytes are fundamental to the 
inflammatory response as they trigger further downstream events including 
cytokine, chemokine and growth factor release, surface expression of adhesion 
molecules and expression of other pro-inflammatory proteins such as COX-2 
(Section 1.2).
COX-2 is an inducible pro-inflammatory marker that catalyses the synthesis of 
the prostaglandin endoperoxide, PGH2. This is the rate determining step in the 
production of prostaglandins that regulates vascular tone and tissue protection 
(Wu et al., 2005). Induced by pro-inflammatory stimuli including TNFa, LPS 
and IFNy (Tanabe and Tohnai, 2002), COX-2 over-expression is associated 
with several inflammatory diseases including atherosclerosis, rheumatoid 
arthritis and sepsis (Crofford et al., 2000; Turini and DuBois, 2002; Zhang et 
al., 1997). In these cases inflammation is not resolved, thereby creating a 
severe pro-inflammatory state. The standard treatment for patients with pro- 
inflammatory diseases used to be via the pain relievers known as nonsteroidal 
anti-inflammatory drugs (NSAIDs). Flowever most NSAIDs are considered 
non-selective due to their action of blocking both COX enzymes, resulting in 
irritation of the upper gastrointestinal tract due to COX-1 inhibition. The result 
of this was that selective COX-2 inhibitors were developed and about five years 
ago were approved for treatment (Mitchell and Warner, 2006). Flowever in 
September 2004, Merck withdrew its COX-2 inhibitor Vioxx from the market 
following reports that selective COX-2 inhibitors were associated with an 
increased risk of myocardial infarction in susceptible patients (Bombardier et 
al., 2000; Caughey et ai., 2001; Mitchell and Warner, 2006). A study by
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Caughey et al., (2001) reported that induction of COX-2 in the endothelium 
resulted in increased synthesis of PGI2 but not TXA2, favouring an anti­
thrombotic state. This implies that up-regulation of COX-2 in the endothelium 
may represent an important protective mechanism against vascular injury or 
insult. Therefore, understanding the cellular mechanisms regulating mediators 
of leukocyte interaction and COX-2 induction would provide an insight into 
possible future drug targets.
It is well documented that the A2A adenosine receptor (A2aAR) has an anti­
inflammatory effect not only in numerous pharmacological studies (Linden,
2001) but also through A2AAR-knockout mice studies in vivo (Gomez and 
Sitkovsky, 2003; Ohta and Sitkovsky, 2001). Previous work undertaken in our 
lab has shown that A2AAR-mediated inhibition of Nuclear Factor kB (NFkB) 
activation is a critical aspect of its anti-inflammatory signalling properties and 
that the molecular basis of this inhibition is cell type-specific (Sands et al., 
2004), although the precise mechanism that underlies this important property is 
not yet fully understood. As discussed in the introduction, endothelial cells line 
the entire cardiovascular system and are involved in the pathology of many 
disease states that involve platelet activation or leukocyte infiltration into 
underlying tissue. Immortalised endothelial cell lines are commonly used to 
examine endothelial/leukocyte interactions and negate the variability 
associated with primary endothelial cells. It is widely accepted that a 
heterogeneity of endothelial function (Yang et al., 1991) and phenotype (Page 
et al., 1992) exists depending on the vascular bed of origin. One of the major 
documented differences between endothelial cells, as far as inflammatory 
processes are concerned, relates to responses to cytokines. Human umbilical 
vein endothelial cells (HUVECs) were used as a model of inflammation in vitro 
in our studies as they are relatively tractable compared to other human 
endothelial cell types whilst still able to respond similarly to ECs from other 
vascular beds to cytokine exposure (Lidlngton et al., 1999). However while 
tractable, it is difficult to introduce cDNA into primary endothelial cells which
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could be problematic as poor transfection efficiencies could lead to a masking 
of any inhibitory effects of A2aAR expression. With transfection efficiencies of 
as low as 2-10% commonly generated with standard transfection methods 
(Teifel et al., 1997), a replication-deficient recombinant adenovirus encoding a 
myc-His-tagged human A2aAR was used to ensure consistently high levels of 
A2aAR transfection (see Results).
We have previously demonstrated that in HUVECs, A2aAR gene transfer 
suppresses NFkB activation in response to stimuli such as TNFa and LPS by 
reducing the nuclear accumulation of p50/p65 heterodimers (Sands et al., 
2004). To fully assess any functional significance of this phenomenon, the 
effects of A2aAR gene transfer in HUVECs on the accumulation of three 
important gene products whose induction is controlled at least in part by NFkB 
was compared. These are. A) COX-2, the rate limiting enzyme in the formation 
of prostaglandins in response to pro-inflammatory stimuli (Smith et al., 1996b; 
Wu, 1995), B) the type 1 glycoprotein E-selectin, which is involved in the rolling 
phase of leukocyte recruitment and C) the immunoglobulin-like adhesion 
molecule, vascular cell adhesion molecule-1 (VCAM-1), which binds firmly to 
tt4Pi integrin expressed on infiltrating leukocytes to arrest leukocyte on 
activated ECs prior to their translocation into the underlying tissue.
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3.2 Results
Before investigating the effect of A2aAR gene transfer on the accumulation of 
NFKB-regulated pro-inflammatory proteins, the effect of various NFicB-activating 
pro-inflammatory stimuli on protein induction was examined. LPS and TNFa 
are known to activate NFkB via different cell surface receptors (see Sections
1.3.1 and 1.3.3). To compare the ability of each stimulus to induce COX-2, 
confluent monolayers of HUVECs were treated with LPS, TNFa and IFNy either 
on its own or in combination for 24hrs. Cell lysates were then subjected to 
SDS-PAGE followed by immunoblotting with anti-COX-2 antibody as described 
in section 2.4.3. Figure 3.1 shows that significant COX-2 expression was 
induced solely by TNFa and that the presence of IFNy did not alter TNFa- 
mediated expression. It is reported that the other cyclooxygenase isoform, 
COX-1 is constitutively expressed in HUVECs (Caughey et al., 2001). Thus 
COX-1 levels are stable regardless of any pro-inflammatory stimulation and can 
be used as an appropriate loading control. In summary, it is clearly shown that 
the greatest COX-2 induction is achieved in the presence of TNFa and 
therefore subsequent experiments were undertaken using this cytokine.
To identify the concentration of TNFa which provided the greatest induction, 
confluent monolayers of HUVECs were treated with increasing concentrations 
of TNFa from 10pg/ml to lOng/ml for 24hrs. Cell lysates were subjected to 
SDS-PAGE followed by immunoblotting with anti-COX-2 antibody as described 
in section 2.4.3. it can be seen in Figure 3.2, that significant TNFa-mediated 
COX-2 induction was detectable at 0.1ng/ml TNFa increasing to a maximum 
response observed following treatment with lOng/ml TNFa. As COX-2 
induction did not saturate with the concentrations of TNFa used, it was not 
possible to calculate an accurate EC50 from these data. Thus for maximal 
TNFa-mediated COX-2 induction, a concentration of 10ng/ml was utilised in 
subsequent experiments.
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Figure 3.1 Effect of various ligands on COX-2 induction
4x10^ HUVECs/well were seeded into a 6 well plate. 24hrs after seeding, cells 
were stimulated with different pro-inflammatory stimuli (1pg/ml LPS, 10ng/ml 
TNFa, 10units/ml IFNy, 1 |ig/ml LPS + 10units/ml IFNy, 10ng/ml TNFa+ 
10units/ml IFNy) for 24hrs. Cells were harvested, equalised for protein 
concentration and assessed for COX-2 and then COX-1 induction by SDS- 
PAGE and immunoblotting as described in section 2.4.3 
The graph show combined results from 3 experiments, where as the blot is 
representative of one experiment.
*** = p<0.001 when compared to vehicle
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Figure 3.2 Effect of increasing concentrations of TNFa on COX-2 
Induction
4x10^ HUVECs / well were seeded into a 6 well plate. 24hrs after seeding, cells 
were stimulated with the indicated concentrations of TNFa for 24hrs. The cells 
were then harvested, equalised for protein concentrations and assessed for 
COX-2 and then COX-1 induction by SDS-PAGE and immunoblotting as 
described in section 2.4.3
Panel A shows representative blots of one experiment whilst panel B shows the 
combined results from n=3 experiments.
Statistical significance observed * = P<0.5, *** = P<0.001 when compared to 
vehicle.
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The effect of inhibitors and stimuli on any cell can differ at various time points 
studied. Thus, to determine which time point resulted in optimal induction, 
confluent monolayer of HUVECs were stimulated with 10ng/ml TNFa at various 
time-points over a 48hr period. Cell lysates were subjected to SDS-PAGE 
followed by immunoblotting with anti-COX-2 antibody. Figure 3.3 shows that a 
statistically significant increase in TNFa-mediated levels of COX-2 induction 
was detectable after 12hrs, reaching a maximum at 24hrs and although levels 
decreased after 48hrs they were still found to be significant.
It has already been shown that the A2aAR decreases NFkB accumulation in the 
nucleus (Sands et al., 2004). The COX-2 promoter has been shown to contain 
several potential transcription regulatory elements, including an NF-IL6 motif, 
two NFkB sites and a CRE motif (Chun and Surh, 2004). To determine which 
signalling pathways were involved in COX-2 induction, confluent monolayers of 
HUVECs were pre-treated with the following signalling inhibitors for 30mins. 
SB203580, a p38 MARK inhibitor (Lee et al., 1994), U0126, an inhibitor of 
MEK1 or 2, the upstream activators of ERK 1 or 2 (DeSilva et al., 1998), 
pyrrolidinedithiocarbamate (PDTC) an inhibitor of NFkB activation (Pan et al., 
1995), N-acetyl-L-cysteine (NacCys) as a control for the antioxidant properties 
of PDTC (Tsai et al., 1996) and bisindolylmalemide 1 (BIM) a PKC inhibitor 
(Kiss et al., 1995). Following pre-treatment, the cells were then stimulated with 
lOng/ml TNFa for 24hrs and the cell lysates subjected to SDS-PAGE and 
immunoblotting with anti-COX-2 antibody. As shown in Figure 3.4, only pre­
treatment with SB203580 resulted in a reduction of TNFa-mediated COX-2 
induction suggesting that at 24hr COX-2 induction is solely regulated by the p38 
MAPK pathway. This was unexpected as COX-2 is known to be regulated by 
NFkB (Deng et al., 2003). NFkB is a transcription factor, therefore it might be 
expected that regulation of transcription would occur earlier than 24hrs. Thus, 
to identify whether NFkB is involved at an earlier time point the experiment was 
repeated but stimulating with TNFa for only 8hrs (Figure 3.5). This showed that 
at this earlier time-point there is a statistically significant decrease in
86
Figure 3.3 Time-course of COX-2 Induction in response to maximal
concentration of TNFa
4x10^ HUVECs/ well were seeded into a 6 well plate. 24hrs after seeding, cells 
were stimulated with 10ng/ml TNFa at the shown time points from 48hrs. Cells 
were then harvested, lysed and assessed for COX-2 and then COX-1 induction 
by SDS-PAGE and immunoblotting as described in section 2.4.3 
Panel A shows representative blots of one experiment whilst panel B shows the 
combined results from n=3 experiments.
Statistical significance observed ** = P<0.01, *** = P<0.001 when compared to 
vehicle.
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Figure 3.4 Effect of signalling inhibitors on TNFa induced COX-2 
induction after 24 hrs
4x10^ HUVECs / well were seeded into 2x 6 well plates, 24hrs after seeding, 
the cells were pre-treated with either vehicle, 10^M SB203580 (p38 MAPK 
inhibitor), lOO^iM U0126 (ERK inhibitor), 100pM PDTC (NFkB inhibitor), 100pM 
NAcCys (PDTC control), SjiM BIM (PKC inhibitor) for 30mins then stimulated ± 
10ng/ml TNFa for 24hrs. Cells were harvested, lysed, equalised for protein 
concentration and assessed for COX-2 and then COX-1 induction by SDS- 
PAGE and immunoblotting as described in section 2.4.3.
The graph shows the combined results from 3 experiments, whilst the blots are 
representative of one experiment.
*** = p<0.001 when compared to vehicle +TNFa
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Figure 3.5 Effect of signalling inhibitors on TNFa induced COX-2 
induction after 8 hrs
4x10® HUVECs / well were seeded into 2x 6 well plates, 24hrs after seeding, 
the cells were pre-treated with either vehicle, 10pM SB203580 (p38 MAPK 
inhibitor), lOO^iM U0126 (ERK inhibitor), 100pM PDTC (NFkB inhibitor), 100pM 
NAcCys (PDTC control), 5|iM BIM (PKC inhibitor) for 30mins then stimulated ± 
lOng/ml TNFa for 8hrs. Cells were harvested, lysed, equalised for protein 
concentration and assessed for COX-2 and then COX-1 induction by SDS- 
PAGE and immunoblotting as described in section 2.4.3.
The graph shows the combined results from 3 experiments, whilst the blots are 
representative of one experiment.
** = p<0.01, * = P<0.05 when compared to vehicle + TNFa
1 2 5
u_zh - <D 100-
2  Q. 75-
C  0)oo  CM 50
o
25
NAcCy BIMvehicle SB203580 U0126 PDTC
1 One/m I TNFa
r
COX-2 — ► 
COX-1 — ►
+ + + + +
89
COX-2 induction in the presence of PDTC, as well as in the presence of 
SB203580. The graph indicates that PKC could also be involved but this 
reduction proved to be statistically insignificant. Thus, TNFa-mediated COX-2 
induction is regulated largely by two pathways; at 8hrs by NFkB and p38 MAPK 
pathways but only by the p38 MAPK pathway at later time-points.
Other pro-inflammatory markers regulated by N F k B are specific adhesion 
molecules required for leukocyte trafficking. To identify whether A2aAR gene 
transfer exerts any significant effect on other k B regulated genes, two of these 
adhesion molecules, E-selectin and VCAM-1, were analysed. As E-selectin is a 
cell surface protein the effects of the various pro-inflammatory stimuli (LPS, 
TNFa and IFNy) were examined via cell surface ELISA as described in section
2.4.4. It can be seen in Figure 3.6 that LPS stimulation caused a significant 
increase in E-selectin induction but TNFa stimulation caused an even greater 
increase. The presence of IFNy either on its own or in the presence of either 
LPS or TNFa does not appear to have any significant effect on induction. 
Previous work undertaken by the lab had already characterised the optimum 
conditions of TNFa-mediated E-selectin induction (4hr stimulation with 10ng/ml 
TNFa; A. F. Martin, unpublished results).
Like COX-2, the E-selectin promoter consists of various transcription promoter 
elements including three -k B sites and a GRE/ATF-like domain (Collins et al., 
1995). To determine whether any response observed was due to a k B effect, 
confluent monolayers of HUVECs were pre-treated for 30mins with the same 
panel of signalling inhibitors as in Figure 3.4-3.S. The cells were then 
stimulated with TNFa for 4hrs and subjected to ELISA with anti-E-selectin 
antibodies as described in 2.4.4. As shown in Figure 3.7, only treatment with 
the N F k B inhibitor PDTC produced any significant reduction in E-selectin 
induction. Therefore, TNFa-mediated E-selectin induction is solely N F k B - 
dependent. Like E-selectin, VCAM-1 is a cell surface adhesion molecule
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Figure 3.6 Effect of different pro-inflammatory stimuli on E-Selectin
induction
4x10* HUVECs/ well were seeded into a 96 well plate. 24hrs after seeding, 
cells were stimulated with different pro-inflammatory stimuli (Ipg/ml LPS, 
lOng/ml TNFa, 10u nits/m I IFNy, Ipg/ml LPS + lOunits/ml IFNy, lOng/ml TNFa+ 
10units/ml IFNy) for 4hrs. Cells were assessed for E-selectin induction via cell 
surface ELISA as described in section 2.4.4.
The graph shows combined specific binding results for 3 experiments.
* = P<0.05, *** = P<0.001 when compared with vehicle
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Figure 3.7 Effect of signalling inhibitors on TNFa induced E-Selectin
induction
4x10* HUVECs / well were seeded into a 96 well plate, 24hrs after seeding, 
cells were pre-treated with either vehicle, lOpM SB203580 (p38 MAPK 
inhibitor), lOOpM U0126 (ERK inhibitor), lOOpM PDTC (NFkB inhibitor), lOOpM 
NAcCys (PDTC control) for 30mins then stimulated ± lOng/ml TNFa for 4hrs. 
Cells were assessed for E-Selectin induction via cell surface ELISA as 
described in section 2.4.4.
The graph shows combined specific binding results for 3 experiments.
** P<0.01 when compared to vehicle + TNFa
du. o0)coQ.
%
200-,
150-
5  c  1 0 0 -cq  Ü  u  o
o l
^  l iJ
50-
0
TNFa lOng/ml
* *
I
vehicle SB203580 U0126 PDTC NAcCvs
92
involved in arresting leukocytes on activated ECs prior to their migration through 
the endothelium. Therefore VCAM-1 induction in HUVECs was also examined 
via cell surface ELISA. To compare the effects of various pro-inflammatory 
stimuli on VCAM-1 induction, confluent monolayers of HUVECs were treated 
with LPS, TNFa and IFNy either on its own or in combination. Figure 3.8 shows 
that significant VCAM-1 induction is observed with TNFa and to a lesser extent 
with LPS. Interestingly, IFNy produced no significant response on its own and 
had no effect on LPS-mediated induction. Although in the presence of TNFa it 
appears to suppress the TNFa-mediated induction by nearly 30%, this was 
found not to be statistically significant. Thus, since it produced the greatest 
effect, TNFa-mediated VCAM-1 induction was characterised in future 
experiments.
To ensure the optimum TNFa concentration was utilised for VCAM-1 induction, 
confluent monolayers of HUVECs were stimulated for 4hrs with increasing 
concentrations of TNFa (10'^ng/ml-10ng/ml). A significant Increase in VCAM-1 
induction was first observed with 0.1 ng/ml TNFa this continued to increase with 
each concentration until a maximum was reached at 10ng/ml, as shown in 
Figure 3.9. In further experiments the concentration lOng/ml TNFa was used 
as it caused the optimal VCAM-1 induction. To determine the stimulation time 
with TNFa required for optimal VCAM-1 induction, confluent monolayers of 
HUVECs were stimulated with lOng/ml TNFa at various time-points over a 24hr 
period and VCAM-1 induction examined via ELISA as described in section
2.3.4. As seen in Figure 3.10, statistically significant VCAM-1 induction was 
first observed from 2hrs and increased in a time-dependent manner reaching 
maximal levels at 8hrs and was sustained for at least 24hrs.
Induction of VCAM-1 in HUVECs has been shown to have some k B 
dependence (lademarco et al., 1992). To determine if any other signalling 
pathways are involved in TNFa-mediated VCAM-1 induction, confluent
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Figure 3.8 Effect of different pro-inflammatory stimuli on VCAM-1
induction
4x10* HUVECs/ well were seeded into a 96 well plate, 24hrs after seeding, cells 
were stimulated with different pro-inflammatory stimuli (1pg/ml LPS, lOng/ml 
TNFa, 10units/ml IFNy, Ipg/ml LPS + 10units/ml IFNy, lOng/ml TNFa+ 
10units/ml IFNy) for 6hrs. Cells were assessed for VCAM-1 induction via cell 
surface ELISA as described in section 2.4.4.
The graph shows combined specific binding results for 3 experiments.
*** P<0.001, ** P<0.01, * P<0.05 when compared to vehicle
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Figure 3.9 Effect of increasing concentrations of TNFa on VCAM-1
Induction
4x10^ HUVECs / well were seeded into a 96 well plate, 24hrs after seeding, 
cells were stimulated with the indicated concentrations of TNFa for 4hrs. Cells 
were assessed for VCAM-1 induction via cell surface ELISA as described in 
section 2.4.4.
The graph shows combined specific binding results for 3 experiments.
Statistical significance of P<0.001 (***) is observed and sustained from 
0.01 ng/ml TNFa
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Figure 3.10 Time-course of VCAM-1 induction in response to 
maximum concentration of TNFa
4x10^ HUVECs / well were seeded into a 96 well plate. 24hrs after seeding, 
cells were stimulated with 10ng/ml TNFa at the shown time points from 24 hrs. 
Cells were assessed for VCAM-1 induction via cell surface ELISA as described 
in section 2.4.4.
The graph shows combined specific binding results for 3 experiments.
Statistical significance is observed as * = P<0.05 at 2hrs and *** = P<0.001 from 
4hrs.
80- 
>
60-
I  oy  c  40 ->  3
EE 20 -
0 10 155 20 25 30
Exposure to  TNFa (hrs)
96
monolayers were pretreated for SOmins with the same panel of signalling 
inhibitors as used previously (Figures 3.4, 3.5 and 3.7). 4hr TNFa-mediated 
VCAM-1 induction was examined via ELISA as described in section 2.3.4. 
Figure 3.11 shows only a slight non-significant decrease in VCAM-1 induction in 
the presence of NFkB inhibitor, PDTC and also the PKC inhibitor, BIM. This is 
interesting as VCAM-1 is supposedly a classic kB regulated gene (Ahmed et al., 
1998; lademarco et al., 1992; Lee et al., 2006; Neish et al., 1995). To ensure 
that the ELISA had not reached saturation, absorbance readings were taken at 
various times, and the same trend was observed for these readings (data not 
presented).
It was necessary to ensure adequate A2aAR expression levels were achieved 
via adenoviral gene transfer before utilising these characterisation data to 
examine the effect of the A2aAR on TNFa-mediated induction. As mentioned 
earlier, adenoviral gene transfer was necessary due to the passage-dependent 
loss of endogenous A2aAR expression observed in HUVECs. Confluent 
monolayers of HUVECs were infected with 125pfu/cell of either AdA2AAR or 
control virus AdGFP, which was shown in preliminary experiments to be the 
optimal MOI required to achieve consistent A2aAR expression. Infected cells 
were identified under fluorescence at 510nm, by the presence of green 
fluorescent protein (GFP). Figure 3.12 shows A2aAR gene transfer in HUVECs 
under phase and fluorescent light with the infection efficiency determined to be 
-75%. GFP gene transfer was found to have an infection efficiency of -75%. 
To ensure that the AdA2AAR was functional, saturation binding analysis using 
the specific A2aAR antagonist ^^^l-ZM241385, was undertaken as described in 
section 2.3.10. Figure 3.13 shows that AdA2AAR gene transfer facilitates the 
expression of functional A2aAR.
Having determined the effectiveness of A2aAR gene transfer in HUVECs, its 
effect on NFKB-regulated COX-2 induction was investigated. Control (Ad GFP) 
and AdA2AAR infected HUVECs were treated with lOng/ml TNFa for 8 hrs (kB-
97
Figure 3.11 Effect of signalling inhibitors on TNFa induced VCAM-1
induction.
4x10* HUVECs /well were seeded into a 96 well plate. 24hrs after seeding, 
cells were pre-treated with either vehicle, lOpM SB203580 (p38 MAPK 
inhibitor), lOOpM U0126 (ERK inhibitor), lOOpM PDTC (NFkB inhibitor), lOOpM 
NAcCys (PDTC control) for 30mins then stimulated ± lOng/ml TNFa for 6 hrs. 
Cells were assessed for VCAM-1 induction via cell surface ELISA as described 
in section 2.4.4
The graph shows combined specific binding results for 3 experiments.
No statistical significance was observed between values.
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Figure 3.12 A2aAR gene transfer into HUVECS via adenoviral 
infection
4x10® HUVECs /well were seeded into 2 x 6  well plates. 24hrs after seeding, 
cells were infected with 125pfu/cell of recombinant Ad myc-His A2aAR or Ad 
GFP. 48hrs post infection, cells were examined for the presence of GFP via 
fluorescence microscopy.
Panel A shows AdA2^AR infected HUVECs via fluorescence and phase 
microscopy.
Panel B shows AdGFP infected HUVECs via fluorescence and phase 
microscopy.
A AüA2aAR
B Ad GFP
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Figure 3.13 Specific binding of A2aAR to selective antagonist 
radioligand '^ ’ i-ZM241385
8x10  ^HUVECs /well were seeded into 2 x 10cm dishes. 24hrs after seeding, 
cells were infected with 125pfu/cell of recombinant Ad myc-His AzaAR or Ad 
GFP. 48hrs post infection, cells membranes were prepared and subjected to 
saturation binding analysis using the A2aAR selective antagonist radioligand 
^^®I-ZM241385 as described in section 2.4.10.
Panel A is representative of three experiments.
Panel B shows equivalent amounts of the indicated cell lysates fractionated by 
SDS-PAGE and immunoblotted using anti-myc antibody 9E10.
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regulated COX-2 induction detectable at this time; Figure 3.5) in the presence 
and absence of a maximally effective concentration of A2AAR-selective agonist 
CGS21680 (Jarvis et al., 1989). Cell lysates were then subjected to SDS- 
PAGE and immunoblotting with anti-COX-2 antibody. Figure 3.14 indicates that 
AdA2AAR causes a significant reduction in TNFa-mediated COX-2 induction 
compared to control GFP-expressing cells. Surprisingly, addition of A2aAR- 
selective agonist CGS21680 and TNFa to A2AAR-expressing HUVECs actually 
potentiated the effect of TNFa alone. To initially determine whether these 
effects could be attributed to regulation of COX-2 by N F k B, Ad GFP- and 
AdA2AAR-infected HUVECs were treated as Figure 3.14 for 24hrs, a time-point 
at which N F k B had previously been shown not to regulate COX-2 induction 
(Figure 3.4). Figure 3.15 shows that no significant change in COX-2 induction 
was observed in the A2aAR expressing cells when compared to the GFP- 
expressing control cells. This suggests that the observed effects (Figure 3.14) 
in A2AAR-expressing HUVECs are mediated at least in part by N F k B regulation.
The A2aAR is predominately coupled to Gs, leading to the activation of adenylyl 
cyclase and elevation of intracellular cAMP (Olah, 1997). Thus, to investigate 
whether the changes in COX-2 induction could be reproduced by increasing 
intracellular cAMP, control uninfected HUVECs were pre-treated for 30mins with 
either rolipram (phosphodiesterase (PDE) 4-selective inhibitor; Zhu et al., 1998), 
forskolin (direct adenylyl cyclase catalytic activator; de Souza et al., 1983), or 
A2AAR-selective agonist CGS21680 and then stimulated with a submaximal 
concentration of TNFa (1 ng/ml). Cell lysates were then subjected to SDS- 
PAGE and immunoblotting with anti-COX-2 antibody. Figure 3.16 indicates that 
forskolin either on its own or in conjunction with rolipram potentiates TNFa- 
mediated COX-2 induction. To identify whether increasing cAMP was sufficient 
to induce COX-2 in the absence of TNFa, HUVECs were treated with a 
combination of rolipram and forskolin at various time-points over a 48hr period. 
Rolipram and forskolin treatment appears to cause a transient increase in COX- 
2 induction, as shown in Figure 3.17, with initial induction
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Figure 3.14 Effect of Ad Ag^AR Gene Transfer on COX-2 induction 
by TNFa
4x10® HUVECs /well were seeded into 2 x 6  well plates. 24hrs after seeding, 
cells were infected with 125pfu/cell of recombinant Ad myc-His A2aAR or Ad 
GFP. 48hrs post infection, cells were treated with ± 5pM CGS21680 (A2aAR- 
selective agonist), ±10ng/ml TNFa for 8 hrs. Cells were harvested, lysed, 
equalised for protein concentration and assessed for COX-2 and then COX-1 
induction by SDS-PAGE and immunoblotting as described in section 2.4.3.
The graph shows the combined results for 3 experiments and the blots are 
representative of one experiment.
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Figure 3.15 Effect of Ad Ag^AR Gene Transfer on COX-2 Induction 
by TNFa
4x10^ HUVECs /well were seeded into 2 x 6  well plates. 24hrs after seeding, 
cells were infected with 125pfu/cell of recombinant Ad myc-His A2aAR or Ad 
GFP. 48hrs post infection, cells were treated with ± 5pM CGS21680 (A2aAR- 
selective agonist), ±1 ng/ml TNFa for 24hrs. Cells were harvested, lysed, 
equalised for protein concentration and assessed for COX-2 and then COX-1 
induction by SDS-PAGE and immunoblotting as described in section 2.4.3.
The graph shows the combined results for 3 experiments and the blots are 
representative of one experiment.
No statistical significance observed
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Figure 3.16 Effects of cAMP elevating agents on COX-2 induction in 
the presence of TNFa
4x10® HUVECs / well were seeded into 2 x 6 well plate. 24hrs after seeding, 
cells were pretreated for 30mins with vehicle, lOpM rolipram (PDE inhibitor), 
10|iM forskolin (adenyl cyclase activator), lOpM rolipram +10pM forskolin, 5pM 
CGS21680, then stimulated with a sub maximal concentration of TNFa (Ing/ml) 
for 24hrs. Cells were harvested, lysed, equalised for protein concentration and 
assessed for COX-2 and then COX-1 induction by SDS-PAGE and 
immunoblotting as described in section 2.4.3.
The graph shows combined results for 3 experiments and the blots are 
representative of one experiment.
*** = p<Q.GQl, * = P<Q.Q5 when compared with vehicle + TNFa
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Figure 3.17 Time course of the effect of rolipram and forskolin on 
COX-2 induction in the absence of TNFa
4x10^ HUVECs / well were seeded into a 6  well plate. 24hrs after seeding, cells 
were treated with combination of 10|iM rolipram and 10pM forskolin at 0, 4, 8 , 
10, 24 and 48hrs. Cells were harvested, lysed, equalised for protein 
concentration and assessed for COX-2 and then COX-1 induction by SDS- 
PAGE and immunoblotting as described in section 2.4.3. The graph shows 
combined results for 3 experiments and the blots are representative of one 
experiment.
Statistical significance is observed as * = P<0.05 at 8 hrs and 24hrs and ** = 
P<0.01 at 12 hrs.
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observed at 4hrs, maximal response observed at 10hrs and returned to basal 
levels after 48hrs. Thus increasing intracellular cAMP levels is sufficient to 
promote COX-2 induction.
There are two possible methods by which the A2aAR is able to achieve this. 
Firstly that the A2aAR activates two downstream pathways whereby transient 
A2aAR expression is able to inhibit p65 nuclear accumulation and active A2aAR 
signalling increases intracellular cAMP resulting in an upregulation of CREB 
target proteins. The second possibility is that there is a threshold of cAMP 
concentration. Below this cAMP concentration threshold, the effect of the 
A2aAR is inhibitory causing an inhibition of COX-2 induction whereas above this 
threshold the effect of the A2aAR is stimulatory causing a potentiation of COX-2 
induction due to the upregulation of CREB. To identify if there is a threshold 
concentration of cAMP at which COX-2 induction was potentiated in the 
presence of TNFa, HUVECs were pre-treated with differing concentrations of 
forskolin and then stimulated with TNFa for 8 hrs. Consistent with this 
hypothesis, it was observed that low concentrations (0 .1  pM) of forskolin 
suppressed COX-2 Induction whilst at higher concentrations enhanced COX-2 
induction (Figure 3.18). Thus, low intracellular cAMP levels inhibited COX-2 
induction while high cAMP levels resulted in a strong COX-2 induction that is 
able to counteract the inhibitory effect on NFkB.
To determine whether the same complex pattern of regulation was observed 
with other KB-regulated genes, comparative analysis of E-selectin by cell 
surface ELISA revealed that while induction was suppressed by A2aAR, the 
suppression was more pronounced in the presence of CGS21680 (Figure 3.19). 
This correlated with the effects of treating control uninfected cells with cAMP- 
elevating stimuli (Figure 3.20) which inhibited TNFa-mediated E-selectin 
induction. Thus, it can be concluded that TNFa-mediated E-selectin induction 
is solely dependent on NFkB activation and is further inhibited by cAMP under 
these conditions.
106
Figure 3.18 Effect of Forskolin Dose Response on COX-2 induction
4x10^ HUVECs / well were seeded into 6  well plate. 24hrs after seeding,cells 
were pretreated for 30mins with vehicle or with concentrations of forskolin 
(adenylyl cyclase activator;) ranging from 1 0 '^° to 1 0 ‘®, then stimulated with 
TNFa (10ng/ml) for 8 hrs. Cells were harvested, equalised for protein 
concentration and assessed for COX-2 and then COX-1 induction by SDS- 
PAGE and immunoblotting as described in section 2.4.3.
The graph shows combined results for 3 experiments and the blots are 
representative of one experiment.
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Figure 3.19 Effect of Ad Ag^AR gene transfer on E-Selectin
Induction by TNFa.
2x10^ HUVECs / well were seeded into 96 well pate. 24hrs after seeding, cells 
were infected with 125pfu/cell of recombinant Ad myc-His A2aAR or Ad GPP. 
48hrs post infection, cells were treated with ± 5pM CGS21680 (AgA-selective 
agonist), ±10ng/ml TNFa for 4hrs. Cells were assessed for E-Selectin induction 
via cell surface ELISA as described in section 2.4.4.
The graph shows combined specific binding results for 3 experiments.
Statistical significance is observed as * = P<0.05.
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Figure 3.20 Effects of cAMP elevating agents on E-Selectin
induction by TNFa
4x10* HUVECs / well were seeded into 96 well plate. 24hr after seeding, cells 
were pretreated for SOmins with vehicle, lOpM rolipram (PDE inhibitor), lOpM 
forskolin (adenylyl cyclase activator), 1G|aM rolipram +10pM forskolin, 5pM 
CGS21680, then stimulated with a sub maximal concentration of TNFa (Ing/ml) 
for 4hrs. Cells were assessed for E-Selectin induction via cell surface ELISA as 
described in section 2.4.4.
The graph shows combined specific binding results for 3 experiments.
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In the case of VCAM-1 the results were distinct from those of E-selectin and 
COX-2. A2aAR gene transfer had no effect on TNFa-mediated VCAM-1 
induction in the presence or absence of CGS21680 (Figure 3.21). Also in 
control cells, sub-maximal TNFa-mediated VCAM-1 induction was not affected 
positively or negatively by cAMP-elevating stimuli (Figure 3.22). Although it has 
been reported that VCAM-1 induction can be reduced via increased cAMP 
levels via the A2aAR (Bouma et al., 1996) this was not reproducible in our 
hands.
COX-2 is the rate-determining enzyme for the production of biologically active 
prostanoids (Caughey et al., 2001). To determine whether the potentiation in 
COX-2 induction, observed in A2aAR expressing cells in the presence of 
CGS21680 and TNFa, caused any downstream effect on COX-2-regulated 
prostaglandin E2 and prostacyclin concentrations, conditioned media from 
treated samples samples were examined via ELISA as described in section
2.4.8. There was no difference in prostaglandin E2 generation in TNFa- 
stimulated A2AAR-expressing cells when compared with control GFP-expressing 
cells. However, the presence of CGS21680 and TNFa caused a significant 
increase in prostaglandin E2 generation (Figure 3.23) in A2AAR-expressing cells 
when compared to TNFa-stimulated A2AAR-expressing cells or control GFP- 
expressing cells. Samples of the same conditioned medium were also assayed 
for prostacyclin via the presence of the stable prostacyclin breakdown product, 
6 -keto-prostaglandin Fia (6 -keto-PGFia). As shown in Figure 3.24, a slight 
reduction in 6 -keto-PGFia generation was observed in TNFa-stimulated A2aAR 
expressing HUVECs when compared to control cells whilst combined treatment 
with CGS21680 and TNFa caused an increase in 6 -keto-PGFia production in 
both A2AAR-expressing cells and control cells. However this increase was only 
statistically significant in the A2AAR-expressing cells when compared to TNFa- 
stimulation alone. These data correlates with the increase in COX-2 induction 
following the same treatment in A2AAR-expressing cells which correlated with
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Figure 3.21 Effect of AjaAR gene transfer on TNFa-stimulated
VCAM-1 induction
2x10* HUVECs / well were seeded into 96 well pate. 24hrs after seeding, cells 
were infected with 125pfu/cell of recombinant Ad myc-His A2aAR or Ad GPP. 
48hrs post infection, cells were treated with ± 5pM CGS21680 (A2A-selective 
agonist), ±10ng/ml TNFa for 6 hrs. Cells were assessed for VCAM-1 induction 
via cell surface ELISA as described in section 2.4.4.
The graph shows combined specific binding results for 3 experiments.
No statistical significance was observed between values.
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Figure 3.22 Effects of cAMP elevating agents on VCAM-1 induction 
in the presence of TNFa
4x10^ HUVECs / well were seeded into 96 well plate. 24hrs after seeding, cells 
were pretreated for SOmins with vehicle, 1GpM rolipram (PDE inhibitor), 10|iM 
forskolin (adenylyl cyclase activator), 10pM rolipram + 1Q|aM forskolin, 5pM 
CGS21680, then stimulated with a sub maximal concentration of TNFa (1ng/ml) 
for Shrs. Cells were assessed for VCAM-1 induction via cell surface ELISA as 
described in section 2.4.4.
The graph shows combined specific binding results for 3 experiments.
No statistical significance was observed between values.
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Figure 3.23 Effect of Ad Ag^AR gene transfer on Prostaglandin E2
accumulation
2x10^HUVECs / well were seeded into 2 x 24 well plate. 24hrs after seeding, 
cells were infected with 125pfu/cell of recombinant Ad myc-His A2aAR or Ad 
GFP. 48hr post infection, cells were treated with ± 5^iM CGS21680 (A2A- 
selective agonist), ±10ng/ml TNFa for 8 hrs. Spent medium was collected and 
analysed for prostaglandin E2 concentration via ELISA as described in section
2.4.8.
The graph represents data from three experiments
Statistical significance of P<0.05 (*) observed between indicated values.
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cells were infected with 125pfu/cell of recombinant Ad myc-His A2aAR or Ad 
GFP. 48hr post infection, cells were treated with ± 5pM CGS21680 (A2A- 
selective agonist), ± lOng/ml TNFa for 8 hrs. Spent medium was collected and 
analysed for 6 -keto-prostaglandin F i„ concentration via ELISA as described in 
section 2.4.8.
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COX-2 mediating the production of prostaglandin E2 and prostacyclin from 
arachidonic acid.
To identify whether cAMP elevating agents could also increase prostaglandin E2 
and prostacyclin production, control cells were treated with cAMP elevating 
agents over a 24hr time-period. Figure 3.25 shows an approximate 50% 
increase in prostaglandin E2 production following 8 hr TNFa treatment which is 
sustained until 24hrs. Figure 3.26 shows that this trend was also observed in 6 - 
keto-PGFia production. However the increase in both 6 -keto-PGFia and 
prostaglandin E2 production proved to not to be statistically significant. It must 
be noted that although these experiments were undertaken in triplicate all 
samples were analysed on the same ELISA plate and significance may be 
observed if repeated.
The regulation of mRNA stability is an important factor in modulating gene 
expression, in particular for transiently expressed genes that require tightly 
controlled mRNA levels. For different cytokines such as TNFa (Caput et al., 
1986) and mRNAs of inducible enzymes such as COX-2 (Dean et al., 2002), 
modulating the decay rate involves adenylate uridylate-rich elements (AREs) 
which often consist of one or more copies in the 3’-untranslated region (3’UTR) 
(Chen and Shyu, 1995). COX-2 mRNA has been shown to be stabilised by 
specific inflammatory stimuli which target the ARE through the p38 mitogen- 
activated protein kinase (MAPK) signalling pathway (Dean et al., 1999; Ridley et 
al., 1998) (Kumar et al., 2003). This provides an explanation for the inhibition of 
COX-2 induction observed following pre-treatment with p38 MAP kinase 
inhibitor SB203580 in Figure 3.4 and 3.5. To identify any possible role A2aAR 
gene transfer has on COX-2 mRNA levels which would explain the observed 
changes in COX-2 protein levels, quantitative PCR analysis of COX-2 mRNA 
levels was performed as described in Section 2.3.7. Identification of the optimal 
time-point for examining the effects of A2aAR gene transfer was undertaken by 
a 24hr time-course of TNFa stimulation in control cells. RNA was extracted and
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Figure 3.25 Effect of Forskolin and Rolipram treatments on
Prostaglandin E2 generation
2x10 HUVECs / well were seeded into 2 x 24 well plate. 24hrs after seeding, 
cells were treated with combination of lOpM rolipram +1 0 pl\/l forskolin at 0 , 8 , 
10 and 24hrs. Spent medium was collected and analysed for prostaglandin E2 
concentration via ELISA as described in section 2.4.8.
The graph represents data from three experiments run on one ELISA plate.
No statistical significance observed
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Figure 3.26 Effect of Forskolin and Rolipram treatments on 6-keto-
prostaglandin Fia generation
2x10^HUVECs / well were seeded into 2 x 24 well plate. 24hrs after seeding, 
cells were treated with combination of 10p.M rolipram +10|j,M forskolin at 0, 8 , 
10 and 24hrs. Spent medium was collected and analysed for 6 -keto- 
prostaglandin Fia concentration via ELISA as described in section 2.4.8.
The graph represents data from three experiments 
No statistical significance observed
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cDNA generated using random primers which was then examined by q-RT-PCR 
using cox- 2  and the housekeeping gene, gapdh primers as described in section
2.3.8. Initial examination suggested that the optimal accumulation of COX-2 
mRNA occurred following 6 hr of TNFa treatment, therefore this time-point was 
chosen to examine if A2AAR-gene transfer has any effect on COX-2 mRNA 
levels. Control and A2aAR expressing cells were treated ± TNFa and ± 
CGS21680 for 6 hrs, RNA extraction and examination by qRT-PCR as sections 
2.3 6  - 2.3.8. However consistency between reaction triplicates and reaction 
plates could not be attained. To determine whether this inconsistency was due 
to primer-dimer formation or the amplification of introns, PCR was undertaken 
with the cox-2 and gapdh primers using either genomic DNA or cDNA 
generated from TN Fa-treated HUVECS as a template. Figure 3.27 shows that 
neither the cox-2 primers or gapdh primers produced PCR product from 
genomic DNA nor generated any primer-dimer formation. This suggests that 
the observed inconsistencies with the qRT-PCR cannot be explained by 
inconsistencies with the primers. Examination of the experimental technique 
provided no further answers for the inconsistencies between triplicates as the 
PCR mixture was obtained from two master-mixes.
3.3 Discussion
The A2aAR has been identified as a protective anti-inflammatory receptor 
protein not only by numerous pharmacological studies (Linden, 2001) but also 
from characterisation of inflammatory responses in mice in which both copies of 
the A2aAR gene have been deleted (Ohta and Sitkovsky, 2001). Previous work 
undertaken in our lab has shown that increasing A2aAR gene expression 
suppresses the induction of TNFa-mediated E-selectin induction by more than 
70% in HUVECs (Sands et al., 2004). This was shown to occur by A2aAR gene 
expression suppressing NFkB activation in response to stimuli such as TNFa 
and LPS by reducing the nuclear accumulation of p50/p65 heterodimers (Sands 
et al., 2004). To assess in greater detail potential functional consequences of
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Figure 3.27 Examination of PCR primers for qRT-PCR
8x 10® HUVECs was seeded out into 1 x 10cm plates. 24hrs after seeding 
cells were treated with lOng TNFa for 6 hrs. Cells were harvested into 1ml tri 
reagent and RNA extracted as described in section 2.3.6. 2ng RNA was then 
used to generate cDNA as described in section 2.3.6. Ing of cDNA and Ing of 
genomic DNA was then used as templates in PCR reactions with cox-2 or 
gapdh primers and Tag polymerase. The PCR program was run as section 
2.3.7. 5ul of PCR product was then run on a 2% agarose gel with Ikb markers. 
cox-2  primers-
Lane 1 Ikb Marker, Lane 2 genomic DNA, Lane 3 cDNA, Lane 4 cDNA + 
DMSO
gapdh primers -
Lane 1 empty. Lane 2 Ikb Marker, Lane 3 genomic DNA, Lane 4 cDNA
12 3 4
cox-2
GAPDH
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this phenomenon, we have compared the effects of A2aAR gene transfer in 
HUVECs on the accumulation of three important EC gene products known to be 
controlled at least in part by NFkB: COX-2, E-selectin and VCAM-1.
Characterisation of COX-2 induction in response to TNFa revealed that while 
sustained induction (24hr) was solely dependent on activation of p38 MAP 
kinase, earlier time-points at which induction was first detectable (8 hr) were also 
sensitive to inhibition of the N F k B pathway. These findings are consistent with 
what is currently known about the promoter region of the human COX-2 gene 
(Figure 3.28) which has been shown to contain several potential transcription 
regulatory elements, including an NF-IL6  motif, two AP-2 sites, three Spl sites, 
two N F k B sites, a cAMP response element (CRE) motif and an E-box (Tanabe 
and Tohnai, 2002). There are many consensus c/s-elements in the 5’-flanking 
region regulating the transcription of the COX-2 gene. However only a limited 
number of elements, namely the CRE site, NF-1L6 motif, N F k B site and the E- 
box are known to be involved in the regulation of COX-2 gene expression 
(Tanabe and Tohnai, 2002). The CRE site has been identified as one of the 
most essential regulatory elements in the COX-2 promoter region. Homo-or 
hetero-dimers of c-fos, c-jun, AT F family members and the cAMP response 
element binding protein (CREB) can bind to this element and activate COX-2 
expression (Inoue et al., 1995; Nakabeppu et al., 1988; Rauscher et al., 1988; 
van Dam et al., 1993). Inoue et al. (1995) reported that destruction of both the 
CRE and NF-IL6  regulatory elements markedly reduced COX-2 expression by 
75% in human endothelial cells following treatment with LPS. However 
destruction of either the NF-IL6  motif or the CRE caused 40% and 10% 
reductions respectively (Inoue et al., 1995). TNFa induces activation and 
binding of N F k B to two separate k B enhancer elements on the core promoter 
region and mutation of either enhancer element greatly reduces the TNFa- 
stimulated transcriptional activity (Saunders et al., 2001), suggesting that CRE 
element is regulated by a different mechanism. This is consistent with what we
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Figure 3.28 Schematic o f cox-2 promoter
Regulatory elements in the human COX-2 promoter indicating points of 
interaction by p38 MAPK inhibitor, SB203580, ERK inhibitor, U0126 and NFkB 
inhibitor PDTC.
COX-2
U0126 SB203580
PDTC
^  COX-2 mRNA
NF-IL6RE CRE k B
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have also shown, namely the COX-2 induction by TNFa depends at least in part 
on NFkB activation and binding.
At 8hrs, A2aAR gene transfer alone was sufficient to reduce TNFa-stimulated 
COX-2 induction compared with control cells. Surprisingly, the addition of the 
A2aAR selective agonist CGS21680 to A2AAR~expressing HUVECs actually 
reversed the effect seen with receptor alone. A2aAR activation elevates 
intracellular cAMP levels in HUVECs via interaction with Gs and stimulation of 
adenylyl cyclase (Klinger et al., 2002). Therefore exposing A2AAR-expressing 
HUVECs to CGS21680 will increase the intracellular levels of cAMP. To 
determine if the potentiation of COX-2 Induction observed in TNFa-stimulated 
A2aAR expressing HUVECs was due to increasing levels of cAMP, control 
HUVECs were pre-treated with various cAMP elevating agents; PDE inhibitor 
(rolipram), adenylyl cyclase stimulator (forskolin) and CGS21680, before 
treatment with submaximal concentration of TNFa. We observed a five-fold 
increase in COX-2 Induction following combined pre-treatment with both PDE 
Inhibitor and adenylyl cyclase stimulator when compared to TNFa alone. This 
suggests that increasing concentrations of cAMP can explain the potentiation of 
COX-2 induction observed in A2AAR-expressing HUVECs. However, 
preliminary experiments suggested that in the presence of TNFa, exposure to 
different concentrations of forskolin demonstrated that cAMP elevation exerted 
different effects depending upon the concentration used. Low levels of cAMP 
inhibited COX-2 induction by Inhibiting NFkB while high cAMP levels overcame 
this increasing COX-2 induction. These data suggests that the effects of A2aAR 
expression with or without agonist on TNFa-mediated COX-2 induction can be 
accounted for completely by corresponding changes in cAMP. Work 
undertaken to identify If this cAMP-mediated increase in COX-2 induction was 
via PKA or EPAC pathways proved to be unsuccessful. Inhibitor experiments 
utilising PKA inhibitor, H89 and EPAC activator, 8- (4- Chlorophenylthio)- 2'- O- 
methyladenoslne- 3', 5'- cyclic monophosphate (8-pCPT-2'-0-Me-cAMP; 
(Kraemer et al., 2001) proved inconclusive as treatment of HUVECs with H89
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alone caused COX-2 Induction whereas treatment with 8-pCPT-2'-0-Me-cAMP 
failed to induce COX-2 (results not shown).
Comparative analysis with E-selectin revealed that induction of this gene was 
more straightforward, being sensitive to N F k B inhibition alone with no 
contribution of any other signalling pathway being detectable. This is in contrast 
to previous studies which have shown that the cAMP response 
element/activating transcription factor element CRE/ATF-like domain within the 
E-selectin promoter (Figure 3.29) can be occupied by a variety of members of 
the ATF family of transcription factors, including ATF-2 ATF-a ATF-3 and c-jun 
(De Luca et al., 1994; Kaszubska et al., 1993). Although the nature of ATF 
family members bound to this element in TN Fa-activated endothelial cells is 
uncertain, ATF-2 appears to be essential for E-selectin induction in that ATF-2 
homozygous null mice are defective in E-selectin induction (Reimold et al., 
1996). The activation of ATF-2 occurs by phosphorylation via activation of the 
JNK and p38 MAP kinases. Although both the N F k B and p38 MAP kinase 
pathways are activated simultaneously, there are notable differences in the 
duration of activation. Nuclear translocation of N F k B in endothelial cells treated 
with TNFa occurs by 15min and persists over many hours when TNFa is 
continuously present (Read et al., 1997). E-selectin transcription requires 
continuous presence of the activating cytokine and the continuous presence of 
N F k B in the nucleus (van Dam et al., 1993; Whelan et al., 1991). Although 
activation of JNK/p38 MAP kinases and the subsequent phosphorylation of 
ATF-2 and c-jun also occur within 15 minutes of TNFa stimulation, in contrast to 
N F k B, both JNK and p38 kinase activity and phosphorylation are transient 
events, (Read et al., 1997) suggesting that once transcription is initiated, 
sustained phosphorylation of ATF-2 and c-JUN may no longer be required 
which could explain why we did not observe a decrease in E-selectln induction 
when the cells were pre-treated with the p38 MAP kinase Inhibitor (Figure 3.7).
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Figure 3.29 Schematic of E~selectin promoter
Regulatory elements In the human E-selectin promoter indicating points of 
interaction by p38 MAPK inhibitor, SB203580 and NFkB inhibitor PDTC.
PDTC
kB AP-1 kB kB
E-Selectin
SB203580
PDTC E-Selectin mRNA
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AzaAR gene transfer suppressed TNFa-mediated E-selectin induction, but not 
significantly more than was observed in control cells. In contrast to the data 
observed with COX-2 induction, combined treatment with TNFa and CGS21680 
in A2AAR-expressing HUVECs showed a further reduction in E-selectin 
induction when compared to TNFa alone. However this was not a significant 
decrease when compared to control cells treated with TNFa and CGS21680. 
Also elevating cAMP levels in control cells showed a significant reduction of 
TNFa-mediated E-selectin induction when pre-treated with forskolin. The 
reduction in E-selectin induction in response to TNFa and cAMP elevating 
agents is consistent with findings by Ghersa et al. (1994) where they reported 
that increasing cAMP via forskolin treatment inhibited E-selectin induction.
Although it has been shown that VCAM-1 induction is solely mediated by N F k B 
with the VCAM-1 promoter containing two k B binding sites (lademarco et ai.,
1992), our results showed that TNFa-mediated induction of VCAM-1 in 
HUVECs was unaffected by either A2aAR gene transfer or pre-treatment of 
control cells with cAMP-elevating agents. This is in contrast with other reported 
findings where VCAM-1 is inhibited by increasing levels of intracellular cAMP 
although this was a IL-1-mediated effect (Ghersa et al., 1994). It can be 
concluded from Figure 3.7, 3.19 and 3.20 that the inhibitors and cAMP elevating 
agents were effective. Possible explanations could be that NFKB-regulated 
VCAM-1 induction occurs at an earlier time-point as observed with TNFa- 
mediated COX-2 induction, or VCAM-1 induction may be regulated by more 
than one signalling pathway and inhibition of one is not sufficient to suppress 
induction.
T o g e th e r th e s e  d a ta  a rg u e  that the  ability  o f A 2aA R  to m o d u la te  express ion  
patterns  o f d efin ed  K B -sensitive  g e n e s  in H U V E C s  is d e p e n d e n t  on the  
p ro m o te r o f tho se  g en e s . T ranscrip tion  o f g en es  w hich a re  p red o m in an tly  k B -  
d e p e n d e n t such as  E -se lectin , is inhibited in A 2A A R -express ing  ceils  and
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increasing cAMP levels by stimulating adenylyl cyclase further inhibits induction 
of these proteins. On COX-2 where transcription is controlled by NFkB, NF-IL6  
and CRE binding sites, the effect of the A2aAR is far more complex. Our results 
indicate that at basal or slightly increased levels of intracellular cAMP the A2aAR 
inhibits COX-2 induction by inhibition of NFkB nuclear translocation, whereas at 
increased levels of intracellular cAMP this is counteracted by the cAMP- 
dependent activation of CREB, causing a significant increase in COX-2 
induction compared to control cells. The negative effect of the A2aAR 
increasing cAMP is also consistent with the decrease in E-selectin induction, 
which is soley a KB-regulated event in our hands.
Examination of A2aAR gene transfer on TNFa-mediated prostaglandin E2 
generation revealed that in treatment of A2AAR-expressing cells with TNFa and 
CGS21680 resulted in a significant potentiation of prostaglandin E2 generation 
when compared to control cells. These findings are consistent with the 
observed potentiation of COX-2 induction following the same treatment. 
However in contrast to the trend observed with COX-2 induction combined 
treatment with TNFa and CGS21680 in control cells resulted in a potentiation 
rather than a reduction of prostaglandin E2 generation. This trend was also 
observed following identical examination of 6 -keto-prostaglandin Fia. These 
data suggest that an inhibition of COX-2 following treatment with TNFa and an 
A2aAR agonist does not necessarily equate to a reduction in the downstream 
prostanoids. Increasing cAMP concentration by treatment with rolipram and 
forskolin over a 24hr time-course although increasing generation of 
prostaglandin E2 or 6 -keto-prostaglandin Fia by around 50% did not result in a 
significant increase. However it is important to note that although each sample 
as well as each experiment was run in triplicate, all the samples were analysed 
on the same ELISA plate. Therefore further analysis would need to be 
undertaken.
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Analysis of COX-2 mRNA by quantitative PCR proved to be inconclusive. 
There were some problems optimising and obtaining consistent triplicates of 
samples which were unable to be rectified because of time and financial 
constraints. These problems were not due to primer derived problems as it was 
shown that the primers utilised produced one PCR-product from cDNA only. 
Therefore further work will need to be undertaken to clarify these preliminary 
findings.
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Chapter 4
Suppression of NFkB nuclear import in vascular 
endothelial cells following A2aAR gene transfer.
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4.1 Introduction
The A2A adenosine receptor (A2aAR) is a critical non-redundant suppressor of 
inflammatory responses in vivo. While the receptor is known to elevate 
intracellular cyclic AMP (cAMP) levels, the molecular mechanisms underlying its 
inhibitory effect on defined inflammatory signalling pathways remain obscure.
The results in Chapter 3 suggest that A2aAR expression can inhibit the 
activation of the nuclear factor k B (N F k B ). A s discussed in detail in sections 
1 .4  and 1.5, N F k B is held in an inactive state in the cytoplasm of unstimulated 
cells by one or more members of the Ik B family of inhibitor proteins which serve 
to mask the NLSs present on the p50 and p65 subunits (Ghosh and Karin, 
2002). The degradation of Ik B following targeted phosphorylation and poly- 
ubiquitination exposes the NLSs of p50 and p65 subunits of N F k B. The dimers 
are then able to translocate to the nucleus where they activate N F k B- 
responsive genes following binding to specific k B response elements and 
recruitment of transcriptional co-activatiors (Li and Verma, 2002; Li and Stark, 
2002).
Eukaryotic cells are compartmentalised by the nuclear envelope into the 
cytoplasm and the nucleus. As discussed in section 1.5 the nuclear envelope 
contains nuclear pore complexes (NPCs), which mediate the molecular traffic 
between the two compartments. The nuclecytoplasmic traffic of large 
molecules (>25nm in diameter) is regulated by specific nuclear import and 
export systems. Proteins that contain classical NLSs are imported into the 
nucleus by importin a/(3 heterodimers. Importin-a binds to NLS containing 
proteins, and importin-p is responsible for the docking of the importin cargo 
complex to the cytoplasmic side of the NPC followed by translocation of the 
complex through the NPC. A classical NLS consists of a stretch of basic amino 
acids, arginines and lysines (Dingwall and Laskey, 1991). NFkB subunits p50
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and p65 have been identified as containing classical NLSs (Blank et al., 1991; 
Gilmore and Temin, 1988). All importin-a molecules contain a large central 
motif that consists of 10 tandemly repeated armadillo (ARM) motifs. These 
ARM motifs mediate the interactions with the NLS-containing cargo protein as 
ARM repeats 2-4 comprise the N-terminal NLS binding site and ARM repeats 7- 
9 the C-terminal NLS binding site (Conti et al., 1998; Fontes et al., 2000; Melen 
et al., 2003). Of the six a importin family members identified in humans, 
importin-a3 and -a4 preferentially transport TNFa-activated NFkB (Fagerlund et 
al., 2005).
As discussed in section 1.9.2.2, the A2aAR has been shown to be constitutively 
active. Preliminary experiments treating TNFa-stimulated A2AAR-expressing 
HUVECs with adenosine deaminate showed no significant difference in A2aAR 
signalling, therefore the cells are not generating lots of adenosine. Although the 
global classic AR antagonist ZM241385 is able to prevent agonist binding but is 
not an effective A2aAR inverse agonist. As there is yet no effective inverse 
agonist for the A2aAR currently available, the experiments dicussed in this 
chapter were undertaken examining the signalling of the A2aAR in unstimulated 
cells.
It has previously been demonstrated in HUVECs that A2aAR gene transfer 
causes a decrease in the nuclear accumulation of p65 (Sands et al., 2004). To 
identify at what point in the NFkB signalling pathway the A2aAR is exerting its 
inhibitory effect in endothelial cells the following experiments were undertaken.
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4.2 Results
Previous work carried out by our lab indicated that A2aAR gene expression in 
HUVECs and C6  glioma cells caused a decrease in nuclear p65 accumulation 
in the presence of pro-inflammatory stimuli such as tumour necrosis factor-a 
(TNFa) and lipopolysaccharide (LPS). Confocal experiments in HUVECs 
suggest that A2AAR-expressing cells inhibit the TN Fa-mediated nuclear 
translocation of p65 (Sands et al., 2004). However one of the limitations of 
confocal experiments is that only a small number of cells can be examined, 
therefore to determine whether the inhibition of nuclear p65 accumulation is 
significant, subcellular fractionation experiments were undertaken. A2aAR- 
expressing HUVECS were stimulated with 10ng/ml TNFa for various time- 
points and the cytosolic and nuclear fractions separated as described in section 
2.4.5 of Materials and Methods. Nuclear fractions were then equalised for 
protein concentration and subjected to SDS-PAGE and immunoblotting with 
anti-p65 antibody and anti-SP1 antibody (a predominately nuclear protein which 
acts as a loading control). It can be seen in Figure 4.1 panel A that A2aAR gene 
transfer causes a decrease in nuclear p65 at all the time-points examined 
compared to control cells. Panel B shows that in control cells there is a 
significant increase in nuclear p65 accumulation following treatment with TNFa 
for 15min. This is further increased at 30min, but following 60min stimulation 
with TNFa there is a decrease in nuclear p65 which could be explained by the 
resynthesis of kB a  enabling NFkB to shuttle back out of the nucleus into the 
cytoplasm (Verma et al., 1995). In A2AAR-expressing cells the trend is similar 
but the level of p65 accumulation is severely inhibited over the entire time- 
course. As the quantity of SP1 detected remains constant in both control and 
A2AAR-expressing cells it can be concluded that the inhibition of p65 
accumulation in A2AAR-expressing cells is not due to an overall decrease in 
nuclear protein concentration.
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Figure 4.1 Effect of Aj^AR gene transfer on nuclear accumulation
of p65 by TNFa
8x10® HUVECs/ dish were seeded into 12 x 10cm dishes. 24hrs after seeding, 
cells were infected with 125pfu/cell of recombinant Ad myc-His A2aAR or Ad 
GPP. 48hrs post infection, cells were treated with lOng/ml TNFa for the times 
shown. Cells were harvested, lysed and nuclear and cytosolic fractions 
separated as descnbed in section 2.4.5. The nuclear fraction was then 
equalised for protein concentration and assessed for p65 and SRI expression 
by SDS-PAGE and immunoblotting as described in section 2.4.3.
Panel A shows the separation of nuclear (N) and cytosolic (C) fractions 
Panel B represents one of 3 experiments
Panel C shows a line graph of 3 experiments for the amount of nuclear p65 
**=P<0.01, *=P<0.05 when compared to vehicle
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To identify whether this decrease in nuclear p65 accumulation by A2aAR is due 
to newly synthesised IkB binding the activated NFkB and translocating the 
complex back out to the cytosol, AzAAR-expressing cells were treated with 
TNFa over a 2hr time-period. Whole cell lysates were then subjected to SDS- 
PAGE and immunoblotting using anti-kBa or anti-kBs antibodies. As can be 
seen from the representative blot and cumulative line graph in Figure 4.2, IkBœ 
is present in control GFP-expressing and AzAAR-expressing cells prior to TNFa 
stimulation. After 15 min stimulation with TNFa, kB a  is no longer detectable 
although evidence of kB a  resynthesis is observed after 60min stimulation with 
TNFa. There was no significant difference observed between GFP- and AzaAR 
expressing cells. A similar trend was observed with TN Fa-mediated 
degradation of kBs (Figure 4.3), however as kBs is not a kB regulated gene 
there is no evidence of kBs resynthesis. These data indicates that the A zaA R  
inhibition of nuclear p65 accumulation cannot be explained by reduced 
phosphorylation-mediated degradation of kB  proteins. Therefore the effect of 
the A zaA R  must occur downstream of this step.
This leaves two possibilities for the decrease in nuclear p65 accumulation, 
either due to a reduced importin-mediated nuclear import of p50/p65 and/or an 
acceleration of CRM 1-driven export of p50/p65-lKBa complexes from the 
nucleus back into the cytoplasm.
To discriminate between these two possibilities the Streptomyces metabolite 
Leptomycin B (LMB; Nishi et al., 1994) was utilised. LMB covalently binds to 
the Cys528 residue on CRM-1 preventing it from binding to the NES of kB a  in 
the NFkB/IkB complex (Huang et al., 2000). Initially, to ensure that the 
concentration of LMB was sufficient to prevent nuclear export, uninfected 
HUVECs was treated with LMB for 24hrs and stained for MEK1/2. MEK 
contains a NES which ensures that it is predominately found within the cytosol 
(Fukuda et al., 1996). However, as shown in Figure 4.4, lOng/ml LMB is
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Figure 4.2 Effect of Ag^AR gene transfer on k B a  degradation by
TNFa
4x10® HUVECs/well were seeded Into a 6 well plate. 24hrs after seeding, cells 
were infected with 125pfu/cell of recombinant Ad myc-His A2aAR or Ad GFP. 
48hrs post infection, cells were treated with lOng/ml TNFa at the time points 
indicated. Cells were harvested, lysed and equalised for protein concentration 
and assessed for IkB a, and p65 induction by SDS-PAGE and immunoblotting 
as described in section 2.4.3.
Panel A is representative of one experiment
Panel B shows the combined results of 3 experiments for the production of IkBa 
***= p<Q.001, **= P<0.01, *= P<0.05 when compared with the 0 time-point. 
However there is no significant difference between control and AzaAR 
expressing cells.
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Figure 4.3 Effect o f Ag^AR gene transfer on IkBe degradation by
TNFa
4x10® HUVECs/well were seeded into a 6 well plate. 24hrs after seeding, cells 
were infected with 125pfu/cell of recombinant Ad myc-His A2aAR or Ad GFP. 
48hrs post infection, cells were treated with lOng/ml TNFa at the time points 
indicated. Cells were harvested, lysed and equalised for protein concentration 
and assessed for kB e, and p65 induction by SDS-PAGE and immunoblotting 
as described in section 2.4.3.
Panel A is representative of one experiment
Panel 8 shows the combined results of 3 experiments for the production of IkBe 
***= p<0.001, **= P<0.01, *= P<0.05 when compared with the 0 time-point. 
However there is no significant difference between control and A2aAR 
expressing cells.
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Figure 4.4 Effect of LMB on the subcellular compartmentallsatlon 
of MEK1/2 In HUVECs
4x10®HUVECs were seeded out onto poly-L-Lysine-coated cover slips in a 6 
well plate. 24hrs after seeding the cells were treated with lOng/ml LMB for 30 
mins. Following treatment the cells were washed and fixed in 
paraformaldehyde. Cells were then semi-permeabilised and incubated with 
anti-MEK1/2 antibody (1:200 dilution) for 1 hour at room temperature. Cells 
were then rinsed and incubated with the Alexa 594-conjugated secondary 
antibody (1:400 dilution) for Ihr at room temperature. Following several rinses, 
coverslips were mounted onto microscope slides and analysed using a 
fluorescence microscope as indicated in section 2.4.7. Images were taken at 
40X magnification.
Pictures are representative of 4 experiments
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lOng/ml LMB
100 fjtn
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sufficient to block CRIVI1-mediated nuclear export of MEK1, sequestering it 
within the nucleus. If A2aAR gene transfer accelerated CRM-1-mediated export, 
it would be expected that pre-treatment with LMB would cause an accumulation 
of the NFkB/IkB complex within the nucleus. Control GFP-expressing and 
A2AAR-expressing cells were pre-treated ± LMB and ± TNFa. In Figure 4.5, it 
can be seen that LMB did not have any significant effect on the inhibitory effect 
of A2aAR gene transfer on TNFa-stimulated nuclear p65 accumulation. Thus, 
suggesting that the A2aAR exerts its inhibitory effect via blocking nuclear import 
rather than accelerating export.
As mentioned earlier, kBa is a kB  target gene (Sun et al., 1993) and as such 
plays a role in turning off the kB  response. It is believed that newly synthesised 
kBa enters the nucleus where it binds to the activated NFkB and the NES on 
kBa enables the complex to be translocated back into the cytosol. To 
determine whether the inhibition of the nuclear accumulation of p65 in A2aAR- 
expressing cells does not involve the interaction of a kB  target gene, control 
GFP-expressing and A2AAR-expressing cells were pre-treated with a 
concentration of emetine (a protein synthesis inhibitor) sufficient to block kBa 
resynthesis (Figure 4.6) which is required for p50/p65 nuclear export. Figure 
4.7 shows that pre-treatment with emetine also failed to attenuate the inhibitory 
effects of A2aAR gene transfer on the nuclear accumulation of NFkB as 
determined by EMSA analysis to assess kB  binding to target DNA.
Many proteins contain cNLS, so it is important to determine whether A2aAR 
gene transfer effects the nuclear import of all proteins which utilise the importin 
transport system or if it is specific to NFkB translocation. Activating 
transcription factor (ATF) is found predominately within the nucleus and is 
activated upon phosphorylation by phosphorylated p38. Inactive p38 is found in 
the cytosol where activation by upstream mediators causes it to be 
phosphorylated enabling it to be translocated to the nucleus via the importin
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Figure 4.5 Effect of Aj^AR gene transfer on TNFa-stimulated 
nuclear accumulation of p65 following pre-treatment 
with LMB
8x10®HUVECs/ dish were seeded into 8  x 10cm dishes. 24hrs after seeding, 
cells were infected with 125pfu/cell of recombinant Ad/myc-His A2aAR or Ad 
GFP. 48hr post infection, cells were pre- treated with lOng/ml LMB for 30 
minutes and then treated ± lOng/ml TNFa for 15 min. Cells were harvested in 
PBS and the nuclear and cytosolic fractions separated. Nuclear fractions were 
equalised for protein concentration and assessed for p65 accumulation by SDS- 
PAGE and immunoblotting as described in section 2.4.3.
Panel A is a representative blot of three experiments.Panel B shows a line 
graph of the cumulative results of 3 experiments.
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Figure 4.6 Effect o f Emitine on k B a  resynthesis following TNFa
stimulation
4x10® HUVECs were seeded Into a 6 well plate. 24hrs after seeding out cells 
were pre-treated with lOOpM emitine for 30 min, then treated with lOng/ml 
TNFa for the times shown. Cells were harvested, lysed, equalised for protein 
concentration and assessed for kBa and p65 by SDS-PAGE and 
immunoblotting as described in section 2.4.3.
Panel A shows a representative blot of 3 experiments.
Panel B shows a line graph of the cumulative results of 3 experiments
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Figure 4.7 Effect of A2aAR gene transfer on TN Fa-mediated nuclear 
accumulation of p65 following pre-treatment with emitine
8x10® HUVECs/ dish were seeded into 8  x 10cm dishes. 24hrs after seeding, 
cells were infected with 125pfu/cell of recombinant Ad/myc-His A2aAR or Ad 
GFP. 48hrs post infection, cells were pre-treated ± lOpM emitine for SOmins 
and then treated with 10ng/ml TNFa for a further 30 mins. Cells were then 
harvested in PBS and the cytosolic and nuclear fractions separated as 
described in section 2.4.5 of Materials and Methods. Protein concentrations of 
nuclear fractions were determined and equal protein concentrations of samples 
were analysed by EMSA as described in section 2.4.6 of Materials and 
Methods.
*= P<0.05 there is a significant reduction in p65 in A2AAR-expressing cells 
compared to the control, but there is no significant difference between cells 
treated with emitine and TNFa and those only treated with TNFa.
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transport system where it is able to phosphorylate ATF (Read et al., 1997). 
Examination of TNFa-stimulated control GFP-expressing and A2AAR-expressing 
HUVECs by SDS-PAGE and immunoblotting with anti-pATF, anti-p38 and anti- 
total p38 antibodies, identified that there was no significant difference between 
control GFP-expressing and A2AAR-expressing HUVECs. A2aAR gene transfer 
did not prevent phosphorylated p38 translocation into the nucleus enabling it to 
phosphorylate the nuclear protein, ATF (Figure 4.8). Therefore, suggesting that 
the inhibition of nuclear p65 accumulation by A2aAR gene transfer is specific to 
p65 translocation and not a global effect of all nuclear imported proteins.
Work undertaken by Fagerlund et al., (2005) showed that the classical NLS on 
both p50 and p65 NFkB subunits, preferentially binds to importin-a3. To 
determine if A2aAR gene transfer inhibited p65/importin-a3 binding the following 
experiments were undertaken. 5pg of GST- and GST-importin-a3-immobilised 
Sepharose beads were added to control cells following treatment with TNFa 
over a Ih r time-period. Figure 4.9 shows that there was no interaction between 
GST-importin-a3 and p65 prior to TNFa treatment. Following 15min of TNFa 
treatment, there is a significant interaction between p65 and GST-importin-a3 
which decreases overtime but still shows significant binding. The interaction is 
specific since it was shown to occur between importin-a3 and not GST alone as 
p65 was not detected within these samples. The use of Ponceau 8  stain shows 
that equal quantities of protein was loaded onto the gel. When examined in 
A2AAR-expressing HUVECs, it was observed that at this concentration of GST- 
importin-a3 there was no significant effect on the ability of importin-a3/p65 to 
bind when compared to control GFP-expressing cells (Figure 4.10).
4.3 Discussion
It has been reported in several cell types, including HeLa and cultured 
endothelial cells, adenosine-mediated inhibition of NFkB can be observed
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Figure 4.8 Effect o f Ag^AR gene transfer on phosphorylated p38
and phosphorylated ATF-2
4x10  ^HUVECs were seeded Into a 6 well plate. 24hrs after seeding, cells were 
Infected with 125pfu/cell of recombinant Ad/myc-Hls A2aAR or Ad GFP. 48hrs 
post Infection, cells were treated with 10ng/ml TNFa for the times Indicated. 
Cells were harvested, lysed, equalised for protein concentration and assessed 
for phospho-ATF-2, phospho-p38 and total p38 levels by SDS-PAGE and 
Immunoblotting as described In section 2.4.3.
Panel A Is a representative blott of three experiments 
Panel B Is a line graph of phospho-ATF-2 expression 
Panel C Is a line graph of phospho-p38 expression
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Figure 4.9 Effect of TNFa on p65-GST- Importin a-3 interaction in 
vitro
8x10  ^HUVECs/ dish were seeded into 8 x 10cm dishes. 24hrs after seeding, 
cells were treated with lOng/ml TNFa for the times indicated. Cells were then 
harvested, lysed, equalised for protein concentration and incubated with 5pg 
GST-importin a-3-imobilised or GST-immobilised Sepharose beads for 2hrs at 
4°C as described in section 2.4.9. The beads were then washed and bound 
protein eluted in 12% SDS sample buffer for 15 mins at 65 °C. Eluate and cell 
lysates were assessed for p65 content by SDS-PAGE and immunoblotting as 
described in section 2.4.3.
Panel A shows representative blots from one experiment 
Panel B shows a line graph of cumulative results of 3 experiments for p65 
bound to GST-importin a-3 beads 
**= P<0.1 and *= P<0.5 
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Figure 4.10 Effect of Ag^AR gene transfer on importin a-3 /p65
interaction in vitro
8x10 HUVECs/ dish were seeded into 8 x 10cm dish. 24hrs after seeding, cells 
were infected with 125pfu/cell of recombinant Ad/myc-His A2aAR or Ad GFP. 
48hrs post infection, cells were treated with 10ng/ml TNFa for the times 
indicated. Cells were harvested, equalised for protein concentration and 
incubated with 5pg GST-importin a-3 beads for 2hrs at 4°C as described in 
section 2.4.9. The beads were then washed and bound protein eluted in 12% 
SDS sample buffer for 15 mins at 65 °C. Eluate and cell lysates were assessed 
for p65 content by SDS-PAGE and immunoblotting as described in section 
2.4.3.
Panel A shows representative blots from one experiment
Panel B shows a line graph of the cumulative results of 3 experiments for p65
bound to GST-importin a-3 beads
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(Majumdar and Aggarwal, 2003). Pharmacological analysis ruled out the 
contribution of Ai and AgARs, but did not address the specific involvement of 
A2a or A2bARs in each of the cell types under investigation. Work presented by 
Sands et al., (2004) indicated that it was the A2aAR subtype which was largely 
responsible for the inhibition of NFkB. Majumdar and Aggarwal (2003) also 
noted that adenosine specifically inhibited TNFa-induced NFkB activation and 
nuclear translocation in the absence of any effect on Ik B degradation.
Our results demonstrate that in A2AAR-expressing HUVECs there is an 
inhibition of NFkB activation and nuclear translocation. Consistent with the 
findings of Majumdar and Aggarwal (2003) this effect appears to occur 
downstream of IkB degradation. Therefore the effect of the AzaAR inhibiting 
NFkB nuclear accumulation must be due to either reduced nuclear import of 
p50/p65 and/or accelerated CRM-1-mediated export of kBa/NFKB complexes 
out of the nucleus (Arenzana-Seisdedos et al., 1997).
However, as our results showed that there was not a significant increase in 
TNFa-mediated nuclear p65 in LMB pre-treated A2AAR-expressing cells when 
compared to those not treated with LMB. This suggests that AzaAR gene 
transfer reduced nuclear import by an as yet undetermined method. Consistent 
with these findings were our observations that pre-treatment with the protein 
synthesis inhibitor emitine, at a concentration which inhibited kB a  resynthesis 
in control cells, did not significantly increase the TNFa-mediated nuclear p65 in 
AzAAR-expressing cells. However it should be noted that there were some 
difficulties using the EMSA method described in section 2.4.6 and it would be 
prudent to repeat this experiment using a hot EMSA method.
p38 is a predominately cytosolic protein, when phosophorylated it translocates 
to the nucleus where it subsequently phosophorylates the nuclear protein ATF 
(Read et al., 1997). Our results indicate that the effect of AzaAR gene transfer 
on nuclear p65 accumulation specific to p65 as there was no observed
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decrease in phosphorylated p38 and phosphorylated ATF in AzaAR expressing 
cells when compared to control cells, ruling out a global effect.
NFkB translocates to the nucleus via the nuclear pore complex (NPC) in a 
complex with the importin a/(3 heterodimer as discussed in Section 1.8. It has 
been shown that the NLS’s on both p65 and p50 preferentially bind to importin- 
a3 (Fagerlund et al., 2005). Our results show that p65 does indeed bind to 
importin-a3, however there is no difference in binding between A zaA R -  
expressing cells and control cells. This was unexpected as it was hypothesised 
from our other observations that the A zaA R  was inhibiting nuclear import of p65 
via the importin-a3.
Importin-a subunits contain an importin-p binding (IBB) domain at its N-terminal 
which serves a dual role. It binds to importin-B to target the complex to the 
NPC for nuclear translocation (Gorlich et al., 1996; Weis et al., 1996) but it also 
contains an auto-inhibitory sequence that mimics a classical NLS (cNLS) such 
as those on p65 and p50. This regulates binding of cNLS cargo to the ARM 
domain of importin-a. (Fanara et al., 2000; Moroianu et al., 1996) The auto- 
inhibitory sequence apparently interacts with the NLS-binding pocket when 
importin-a is not bound to importin-p. (Kobe, 1999) This interaction is not 
exceptionally strong as cNLS cargos can still bind to importin-a in the absence 
of importin-p although at a lower affinity. The order of binding of importln-a to 
its cNLS cargo and importin-p is not full understood and is suggested that it 
varies depending on the particular cNLS cargo (Goldfarb et al., 2004). Either 
way the relationship of importin-a/p and its cNLS cargo has to be bipolar, 
forming tight complexes in the cytoplasm then switching to an extremely low 
affinity state in the nucleus to release the cNLS cargo.
if the A zaA R  is not inhibiting the binding of p65 to importin-a3 there are other 
areas in the nuclear import pathway that the A zaA R  could be effecting. One
146
possibility is that the AzaAR could be preventing the binding of p65/importin-a3 
to Importin-p therefore preventing the complex from being targeted for nuclear 
translocation. This could be examined by using Sepharose bound GST- 
importin-p, as this should pull-down the importin-a3 complex. Integrating p65 
into co-immuno-precipitation experiments would also be useful in identifying 
whether importin-a3/p complexes could be pulled-down in AzAAR-expressing 
cells. However as the order of binding is not fully understood if importin-a binds 
to importin-p before to the cNLS, further experiments would need to be 
undertaken.
Due to the nature of the pull-down experiments importin-a3 is present in excess 
and the AzaAR may be inhibiting binding to the importin-a subunit but this 
inhibition could not be observed. To clarify this, further pull-down experiments 
would need to be undertaken utilising decreasing concentrations of the GST- 
importin-a3 bound Sepharose beads. Western blotting could also be utilised to 
determine if there is a decrease in free importin-a in the cytoplasm as it has 
been reported that CAS, the export receptor for importin-a (Katay et al., 1997), 
when in excess, could lead to constitutive binding with importin-a and RanGTP, 
depleting cytoplasmic stores of free importin-a and thus inhibiting nuclear 
import (Kau et al., 2004). CAS is phosphorylated by MEK1 and treatment with 
MEK1 inhibitors can alter the nuclear/cytoplasmic distribution of CAS (Scherf et 
al., 1998).
Another possibility is that the A zaAR causes a post-translational modification of 
the activated NFkB, such as site-specific phosphorylation, acétylation or 
ubiquitination. It has been reported that to achieve a maximal transcriptional 
response, the p65 subunit of NFkB must undergo post-translational 
modifications including phosphorylation (Chen and Greene, 2004). One of the 
key phosphorylation events involves that action of the catalytic subunit of PKA 
(PKAc), which modifies Ser276 within the RHD of p65. This phosphorylation
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event occurs within the cytosol and regulates the DNA-binding and 
oligomerisation properties of NFkB (Ganchi et al., 1993; Mosialos and Gilmore,
1993). Although the majority of phosphorylation and acétylation events exert a 
positive effect on the transcriptional activity of NFkB (Chen and Greene, 2004), 
it is possible that a post-translational modification could prevent NFKB/importin 
binding and subsequent translocation into the nucleus. One method that could 
be utilised to identify any modification would be via 2 -dimentional 
electrophoresis gels. Any modification would result in a difference in charge 
and size which could be identified when the gels were compared. This method 
was attempted but due to time and optimisation constraints it was not possible 
to obtain any reproducible results. Therefore further work would need to be 
undertaken.
Taken together these data argue the ability of AzaAR to inhibit TNFa-mediated 
nuclear accumulation of p65 in endothelial cells is due to a reduced ability of 
p50/p65 dimers to undergo importin-mediated nuclear import. However, further 
work is required to determine where in the importin nuclear import pathway the 
A zaA R  is exerting its effect.
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Chapter 5 
Final Discussion f'
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Inappropriate or prolonged inflammation contributes to the pathogenesis of 
many diseases including atherosclerosis, rheumatoid arthritis, sepsis, heart 
disease and cancer (D'Cruz, 1998; Greaves and Channon, 2002; Gueler et al., 
2004; Karouzakis et al., 2006; Kinlay et al., 2001; Zimmerman et al., 1999). 
Fundamental to the inflammatory response is the interaction between 
endothelial cells and leukocytes. These interactions trigger further downstream 
signalling events including cytokine, chemokine and growth factor release, 
surface expression of adhesion molecules and expression of other pro- 
inflammatory proteins (Section 1.2). It is widely accepted that adenosine is a 
potent inhibitor of inflammatory processes and that the AzaAR plays an 
important role as a suppressor of inflammation (Lappas et al., 2005). Therefore 
understanding the mechanisms behind the suppression of inflammation would 
be beneficial in providing future drug targets for chronic inflammatory diseases. 
It has been reported that AzaAR gene transfer suppresses p65 nuclear 
translocation and subsequently N F k B activation in response to pro- 
inflammatory stimuli such as TNFa and LPS (Sands et al., 2004). Results 
presented in this thesis have demonstrated that AzAAR-expressing cells exhibit 
an inhibitory effect on TNFa-mediated protein induction of primarily k B - 
dependent target genes. However activation of the A zaA R  causes potentiation 
of protein induction on target genes which require both k B and other elements 
for optimal gene transcription. Additional data also shows that the inhibitory 
effect of the A zaA R  on nuclear accumulation of p65 occurs by inhibiting the 
nuclear import of N F k B.
In Chapter 3, it was shown that TNFa-mediated E-selectin induction was 
significantly inhibited in AzAAR-expressing HUVECs and that activation of the 
A zaA R  resulted in the further inhibition of E-selectin induction. It has been 
reported that although E-selectin gene transcription requires activation of ATF-2 
(Reimold et al., 1996) and NFkB, once transcription is initiated ATF-2 is no 
longer required (Read et al., 1997). This is consistent with our findings that the 
inhibition of TNFa-mediated E-selectin induction in AzAAR-expressing HUVECs
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was found to be solely due to the inhibition of NFkB (Sands et al., 2004). This 
could explain the observed A zaA R  activation resulting in a decrease in 
leukocyte-mediated inflammatory responses (Kelly et al., 2003)
VCAM-1 induction has previously been reported to be a solely k B regulated 
gene due to the two k B binding sites present at -7 7  and -6 3  of the VCAM gene 
(lademarco et al., 1992). In contrast to these findings, our data failed to show 
significant inhibition of TNFa-mediated VCAM-1 induction following pre­
treatment with the NFkB inhibitor PDTC. In addition, neither AzaAR gene 
transfer nor pre-treatment with elevating cAMP agents had any effect on TNFa- 
mediated VCAM-1 induction which is in contrast to the findings of Ghersa et al. 
(1994) where elevating intracellular cAMP concentrations inhibited IL-6- 
mediated VCAM-1 induction. Further analysis is required to completely 
understand the mechanisms involved in VCAM-1 induction. One possibility is 
that there was a loss of VCAM-1 from the cell surface during the ELISA 
protocol. This could be examined by western blot analysis. Other possibilities 
are that NFKB-regulation of VCAM-1 induction occurs at an earlier time-point 
than the one examined or there are other signalling pathways involved in 
VCAM-1 induction. Chromatin immunoprécipitation (CHIP) analysis of the 
VCAM-1 promoter region could provide some insight into whether other 
signalling pathways are involved. CHIP analysis enables the rapid identification 
of the precise binding sites of specific DNA binding proteins including 
transcription factors and histones within large streatches of target DNA.
In HUVECs, A zaA R  gene transfer had a dual regulation of TNFa-mediated 
COX-2 induction. In AzAAR-expressing cells TNFa-mediated COX-2 induction 
was inhibited however In the presence of AzAAR-selective agonist CGS21680, 
TNFa-mediated COX-2 induction was significantly potentiated. Further analysis 
utilising the cAMP elevating agents rolipram and forskolin, suggested that the 
effects of AzaAR expression with or without agonist on TNFa-mediated COX-2 
induction could be accounted for completely by corresponding changes in
151
cAMP. These findings are consistent with the report by Schroer et al. (2002), 
which indicated that elevation of cAMP by either PGIz, PGEz or forskolin 
amplifies COX-2 promoter activity by increasing CREB binding to the CRE 
element, although they were unable to detect an increase in COX-2 protein 
levels. Preliminary attempts to identify if the cAMP-mediated increase in COX-2 
induction was via PKA or EPAC pathways have proved inconclusive. This was 
in part due to PKA inhibitor, H89-mediated COX-2 induction in the absence of 
TNFa and the failure of EPAC activator, 8-pCPT-2'-0-l\/Ie-cAMP to induce COX- 
2. Determining the role of cAMP on the potentiation of COX-2 induction could 
be undertaken by utilising siRNA to knockdown CREB or identification of the 
proteins bound to the COX-2 promoter in AzAAR-expressing cells by promoter 
immunoprécipitation or CHIP analysis. With regards to our data, CHIP analysis 
could be used to identify the transcription factor bound to the COX-2 promoter.
The up-regulation of COX-2 is associated with a number of disease states 
including myocardial infarction, arthritis, urogenital disease and cancer (Turini 
and Du Bois, 2002). These data indicate that expression of the A zaA R  would 
result in constitutive down regulation of COX-2 induction which in these disease 
states would be beneficial. However, as it has been shown that activation of the 
A zaA R  results in a significant potentiation of COX-2 induciton, tissues that 
express high levels of A zaA R  would, if activated by a local increase in 
adenosine, result in an increase in COX-2 metabolites. As the A zaA R  is 
expressed within blood vessels, leukocytes, the spleen and thymus, an increase 
in local adenosine concentrations could have implications in disease in these 
tissues. The recent findings that NSAID COX-2 inhibitors have been found be 
associated with an increased risk of myocardial infarction in susceptible patients 
(Bombardier et al., 2000; Caughey et al., 2001; Mitchell and Warner, 2006) 
means that elucidating the mechanism of COX-2 induction would provide 
valuable insight into the global effects these inhibitors can cause and enable 
more selective drug targets to be identified.
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In Chapter 4 it was reported that AzaAR inhibited nuclear accumulation of p65 
was due to an inhibition of nuclear import rather than accelerated nuclear 
export. Other groups have previously reported that the effect of the A zaA R  to 
inhibit N F k B nuclear accumulation occurs downstream of Ik B degradation and 
must be due to either reduced nuclear import of p50/p65 and/or accelerated 
CRM-1-mediated export of Ik Bœ/N F k B complexes out of the nucleus 
(Arenzana-Seisdedos et al., 1997; Majumdar and Aggarwal, 2003). The 
inability of CRM-1 treatment to rescue the AzAAR-mediated inhibition of p65 
nuclear accumulation ultimately means that the effect of the AzaAR has to be 
inhibiting nuclear import. The translocation of N F k B into the nucleus requires 
the interaction of importin-a, importin-p/RanGTP and the NPC (Fagerlund et al., 
2005; Goldfarb et al., 2004). However, AzAAR-expressing cells did not show 
any inhibition in p65/importina-3 interaction in GST-pulldown experiments. One 
possibility is that the concentration of GST-importina-3 was in excess which 
could be masking any AzAAR-mediated changes in p65/importin-a3 binding. To 
address this, pulldown experiments utilising varying concentrations of GST- 
importin-a3 bound Sepharose beads could be undertaken. In addition co- 
immunoprecipitation experiments could be undertaken to identify if A zaA R -  
expression results in a decrease in p65/importin-a3 interaction. Another 
consideration is that an excess of the nuclear export protein CAS can lead to 
the constitutive binding of imortin-a and RanGTP resulting in a decrease in 
cytoplasmic stores of free importin-a (Kau et al., 2004). Western blot analysis 
could be utilised to identify any decreases in cytoplasmic importin-a. It is 
possible that A zaA R  does not effect p65/importin-a binding, but it may effect the 
interaction of p65/importin-a with importin-p and/or the NPC. Co- 
immunoprecipitation experiments would thus be useful to identify if there is an 
inhibition in importin-a/-p binding. It is important to note that the exact order of 
binding between the NLS-containing protein, importin-a and importin-p is not 
fully understood which may impede the understanding of A zaA R  inhibition of the 
nuclear import of N F k B.
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It is known that NFkB is subjected to regulation by post-translational 
modifications such as site-specific phosphorylation, acétylation or ubiquitination 
(Chen et al., 2005; Greene and Chen, 2004). 2-dimensional gel electrophoresis 
was attempted to identify if the A2aAR mediated changes in the pattern of p65 
post-translational modification. Unfortunately due to time constraints it was not 
possible to obtain any reproducible results. Optimisation of this process could 
lead to the identification of a post-translational modification of NFkB in A2aAR- 
expressing cells. There are other methods which can be utilised to identify the 
type of possible post-translational modification. Possible post-translational 
modifications include phosphorylation, ubiquitination and acétylation. As any 
possible modification of p65 is preventing nuclear translocation, acétylation, 
which occurs predominately within the nucleus, will not be discussed here.
TNFa-mediated activation of p65 requires site-specific phosphorylation prior to 
nuclear import (Section 1.34). There are a few methods which could be 
undertaken to determine whether A2AAR-expression results in a change in site- 
specific phosphylation of p65 that inhibits nuclear import. A change in the 
phosphorylation pattern of p65 in A2AAR-expressing cells could be identified by 
metabolic labelling experiments followed by immunoprécipitation of p65 or
2-dimensional gel electrophoresis. If this is successful the sequence can be 
examined for consensus phosphorylation sites and site-directed mutagenesis 
can be undertaken to identify the role, if any, of these sites in the inhibition of 
N F k B nuclear import. Another possibility is that accessory proteins such as 
Pin-1 or 14-3-3, which are recruited to specific phosphorylated sites on p65, 
prevent interaction with the nuclear import machinery. Pin-1 is a proline 
isomerase that binds and isomerases specific phosphorylated Ser or Thr 
residues that precede proline in certain proteins. It has been reported that Pin-1 
directly binds to the phosphoyiated Thr254-Pro motif on N F k B which is exposed 
upon Ik B degradation, causing a conformational change (Ryo et al., 2003). It is 
possible that the binding of a Pin-like protein which causes a conformational
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change in NFkB assists the A2AAR-mediated inhibition of NFkB nuclear import. 
To identify if phosphorylation of p65 results in changes in p65/importin-a 
binding, pulldown experiments utilising GST-Pin-1 could be undertaken. 14-3-3 
are Ser/Thr binding proteins are established as a large family (over 100 
members identified) of dimeric proteins that can modulate protein interactions 
required for intracellular trafficking and transcription (Aitken, 2006). In most 
cases the binding occurs through a consensus motif within the target protein, 
which contains a phosphorylated Ser or Thr residue (Muslin et ai., 1996), 
although some cases have been reported where phosphorylation of 14-3-3 
proteins themselves may modulate interaction (Aitken, 2006). It has been 
reported that PKB-mediated phosphorylation of Thr157 on the cyclin-dependent 
kinase (CDK) inhibitor p27 promotes the binding of 14-3-3. Thr157 is within the 
importina-3 specific NLS binding site of p27 and the binding of 14-3-3 to this 
site prevents p27/importin a-3 interactions, resulting in the inhibition of nuclear 
import (Sekimoto et al., 2004). As p65 also binds to importin a-3, it is possible 
14-3-3 could also be responsible for the A2AAR-mediated inhibition of p65 
nuclear import. This could be identified by GST-14-3-3 pulldown experiments, 
however as there are over 100 members of the 14-3-3 family It would be 
beneficial to identify whether 14-3-3 binds to p65 by immunoprecipitating p65 
from TNFa-stimulated A2AAR-expressing FlUVECs and identify any 
phosphorylated 14-3-3 binding motifs by western blot.
There are recent reports that NFkB signalling pathways are subject to 
ubiquitination (Chen, 2005). Along with the traditional role of ubiquitin, targeting 
IkB via Lys 48 polyubiquitination for protesomal degradation (section 1.4.3), 
polyubiquitin chains linked by Lys 63 have recently been found to regulate DNA 
repair and protein-kinase activation through a degradation-independent 
mechanism (Chen, 2005). Our data indicates that A2AAR-expressing cells do 
not inhibit p65 by targeting it for degradation in the proteasome through 
ubiquitin Lys 48 linkage, although it is possible that polyubiquitination can occur 
via another Lys residue. Possible methods for identification of ubiquitination
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include treatment of A2AAR-expressing cells with a proteosome inhibitor and 
then analysing p65 by immunoblotting. If p65 is polyubiquitinated then a ladder 
effect should be observed on the blot at 8 kDa intervals. However this is not 
always effective as the specific antibodies may not recognise the ubiquitinated 
protein. Another method would be to immunoprecipitate the target protein and 
then probe by western blot using an anti-ubiquitin antibody. Lys 63-linked 
polyubiquitination is known to be associated with protein/protein interactions 
(Vong et al., 2005). To identify whether p65 is Lys63 polyubiquitinated or only 
monoubiquitinated, either L63/Arg or all Lys/Arg mutants could be generated. 
These could then be transfected into cells and p65 immunoprecipitated 
following TNFa stimulation. If p65 is Lys63 polyubiquitinated then it would not 
be detected in L63/Arg mutants, however if p65 is monoubiquitinated then p65 
would be detected in Lys/Arg mutants.
While it is important to analyse the precise role of A2aAR regulation of NFkB 
activation with respect to inflammation, NFkB has also emerged as a critical 
regulator of tumourogenesis and cancer (Garg and Aggarwal, 2002; Perkins, 
2004). This can partly be explained by its ability to regulate the expression of a 
number of genes which are involved in the regulation of apoptosis and tumour 
progression (Garg and Aggarwal, 2002). Inhibition of NFkB by A2aAR activation 
could also be able to sensitise cells to apoptosis and promote tumour growth. 
Sensitisation to apoptosis would be of great benefit in treating tumours, 
although it could also lead to undesirable side effects such as the premature 
apoptosis of immune cells leading to an immunocompromised situation. 
However it is important to note that NFkB has been reported to actively repress 
anti-apoptotic gene expression when activated by UV-C and chemotherapeutic
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Although this thesis has focused on the p50/p65 heterodimer of NFkB it would 
be interesting to see if the A2AAR-mediated inhibition of NFkB nuclear import 
occurs with the other NFkB dimers as some combinations are known to repress 
transcription (p50/p50 homodimers; Zhong et al., 2002)
-.V::
drugs such as daunorubicin (Campbell et al., 2006). This inhibition which is 
mediated by the association of p65 with HDAG, therefore indicates that NFkB 
has the ability to act as both a transcriptional activator or suppressor dependent 
upon the signalling pathway of induction (Campbell et al., 2004)
in conclusion, A2aAR inhibits the nuclear accumulation of NFkB by specifically 
inhibiting nuclear import, resulting in the inhibition of icB-regulated E-selectin 
induction. This is not the case for the target gene COX-2 which is regulated by 
both k B and CRE elements. The A2aAR appears to have a dual role in the 
regulation of COX-2. Low concentrations of cAMP results in the inhibition of 
COX-2 induction whereas increasing intracellular cAMP concentrations by 
signalling from activated A2aARs, results in the potentiation of COX-2 induction 
and subsequent up-regulation of COX-2 metabolites.
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